Reaffirming the role of SGLT2 inhibitors in slowing fibrotic progression in MASLD: Correspondence to editorial on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction- Jonggi Choi, Raymond T. Chung Clinical and Molecular Hepatology.2026; 32(3): e369. CrossRef
Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xingyu Yao Clinical and Molecular Hepatology.2026; 32(2): e267. CrossRef
Correspondence to editorial on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e219. CrossRef
Correspondence to editorial 2 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Rui Huang, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(1): e85. CrossRef
Longitudinal Changes in Lipid Profile After Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals Oana Koppandi, Bogdan Miutescu, Iulia Ratiu, Alexandru Popa, Camelia Nica, Eyad Gadour, Bogdan Dan Totolici, Raluca Lupusoru, Ana Maria Ghiuchici, Eftimie Miutescu Healthcare.2026; 14(4): 486. CrossRef
Microbial exposure and host responses to infection reshape the disease trajectory of MASLD Yunqi Zhang, Qingqing Xun, Shuyu Liu, Bo Zhuang, Meiyue Zang, Chengwei Tan, Yu Cui, Ruiji Li, Qianqian Zhang Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C” Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang Clinical and Molecular Hepatology.2025; 31(2): e203. CrossRef
Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C” Chen-Hua Liu, Yu-Ping Chang Clinical and Molecular Hepatology.2025; 31(2): e232. CrossRef
Viral oncogenesis and immune remodeling: Decoding the therapeutic potential of immune checkpoint inhibitors in virus-associated cancers Lihua Qi, Bai Hu, Canhui Cao, Ting Peng, Miaochun Xu, Shiyi Liu, Yashi Xu, Xiaojie Liu, Wencheng Ding, Li Li, Shitong Lin Biomedicine & Pharmacotherapy.2025; 191: 118515. CrossRef
As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does the prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD). Currently, 38% of all adults and 7–14% of children and adolescents have MASLD. By 2040, the MASLD prevalence rate for adults is projected to increase to more than 55%. Although MASLD does not always develop into progressive liver disease, it has become the top indication for liver transplant in the United States for women and those with hepatocellular carcinoma (HCC). Nonetheless, the most common cause of mortality among patients with MASLD remains cardiovascular disease. In addition to liver outcomes (cirrhosis and HCC), MASLD is associated with an increased risk of developing de novo T2D, chronic kidney disease, sarcopenia, and extrahepatic cancers. Furthermore, MASLD is associated with decreased health-related quality of life, decreased work productivity, fatigue, increased healthcare resource utilization, and a substantial economic burden. Similar to other metabolic diseases, lifestyle interventions such as a heathy diet and increased physical activity remain the cornerstone of managing these patients. Although several obesity and T2D drugs are available to treat co-morbid disease, resmetirom is the only MASH-targeted medication for patients with stage 2–3 fibrosis that has approved by the Food and Drug Administration for use in the United States. This review discusses MASLD epidemiology and its related risk factors and outcomes and demonstrates that without further global initiatives, MASLD incidence could continue to increase.
Citations
Citations to this article as recorded by
Normative values for quantitative MRI biomarkers of the liver in collegiate athletes Alexandra A. Anagnostopoulos, Julius F. Heidenreich, Amirhossein Roshanshad, Daiki Tamada, Nikolaos Panagiotopoulos, Lu Mao, Diego Hernando, Scott B. Reeder, Jitka Starekova Magnetic Resonance Imaging.2027; 135: 110772. CrossRef
Role of liver connexins and pannexins in the development of metabolic dysfunction-associated steatotic liver disease (MASLD) in the context of overnutrition: A narrative review Juan Pablo Bravo-Novoa, Ramón Norambuena-González, Matías Quiñones San Martín, Jorge E. Contreras, Daniel R. González, Jessica Zúñiga-Hernández Molecular and Cellular Endocrinology.2027; 623: 112897. CrossRef
Early burden, enduring risk: The alarming outcomes of pediatric MASLD Marialena Mouzaki Hepatology.2026; 83(3): 445. CrossRef
Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi Journal of Advanced Research.2026; 80: 893. CrossRef
Population perspectives on benefits and harms of screening for metabolic dysfunction–associated steatotic liver disease Alina M. Allen, W. Ray Kim, Patrizia Carrieri, Rachel Canning, Fang-Shu Ou, Joanne Benson, Jessica L. Olson, Sudhakar K. Venkatesh, Jiahui Li, Meng Yin, Maysa Eslami, Richard L. Ehman, Jennifer Hunter Berg, Jeffrey V. Lazarus Hepatology.2026; 83(2): 362. CrossRef
A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study Ho Soo Chun, Minjong Lee, Hye Ah Lee, Eun Seo Park, Jeong Yoon Choi, Hyo Song Baek, Tae Hun Kim, Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jé Clinical Gastroenterology and Hepatology.2026; 24(3): 688. CrossRef
The OGT–TFF2 axis mediates intrahepatic crosstalk and MASH pathogenesis Lei Zhang, Cuijuan Han, Man Mohan Shrestha, Jiamei Le, Wilhelm K. Berger, Yiheng Huang, Reina Desrouleaux, Eric Wang, Laszlo Nagy, Xiaoyong Yang Hepatology.2026; 83(5): 1215. CrossRef
Socioeconomic Factors Impact the Perception of Healthcare Experiences in Patients with Cirrhosis Nicole Ng, Subhanik Purkayastha, Xiaohan Ying, Arun Jesudian, Russell Rosenblatt Digestive Diseases and Sciences.2026; 71(2): 486. CrossRef
Intersections of vitamin D deficiency, HIV and chronic liver diseases Francesca Farina, Aurgho Datta, Suzanne N. Morin, Sahar Saeed, Bertrand Lebouche, Giovanni Guaraldi, Salvatore Petta, Giada Sebastiani HIV Medicine.2026; 27(1): 4. CrossRef
Hepatocellular carcinoma arising from ectopic liver tissue: a systematic review of the literature Sami Akbulut, Tevfik Tolga Sahin European Journal of Gastroenterology & Hepatology.2026; 38(3): 243. CrossRef
Pubertal exposure to glyphosate-based herbicide aggravates diet-induced steatosis and hormonal dysregulation in adult mice Jakeline Liara Teleken, Ana Paula Farina Rosolen, Joseane Morari, Sandra Lucinei Balbo, Rosane Aparecida Ribeiro, Maria Lúcia Bonfleur Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(3): 3589. CrossRef
Reliable Monitoring of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Using Imaging: A Systematic Literature Review and Meta-Analysis on Measurement Repeatability Michael Ndaa, Prashant K. Pandya, Jordan Swensson, Niharika Samala, Saima Ajaz, Deepak Joshi, Walid S. Ayoub, Fatih Akisik Endocrine Practice.2026; 32(2): 258. CrossRef
Semaglutide, the first approved GLP-1 receptor agonist for the management of metabolic dysfunction-associated steatohepatitis Chrysoula Boutari, Michael A. Hill, Christos S. Mantzoros Metabolism.2026; 174: 156397. CrossRef
The Bubble-Destruction Curve Obtained Using Contrast-Enhanced Ultrasound is Useful for Assessing Liver Fibrosis and Identifying At-risk MASH in Patients With MASLD Noritaka Wakui, Yu Ogino, Naohisa Kamiyama, Takuma Oguri, Tomoya Uchimura, Takahide Kudo, Kenichi Maruyama, Hideki Nagumo, Naoyuki Yoshimine, Kunihide Mouri, Kojiro Kobayashi, Takanori Mukozu, Teppei Matsui, Hidenari Nagai, Yoshinori Igarashi, Takahisa Ma Ultrasound in Medicine & Biology.2026; 52(1): 237. CrossRef
Outcome-Specific Cardiovascular and Hypertensive Risk Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights From a Competing Risk Cohort Analysis Masashi Hirooka, Teruki Miyake, Ryo Yano, Yoshiko Nakamura, Yuki Okazaki, Toyoki Shimamoto, Atsushi Yukimoto, Yasunori Yamamoto, Takao Watanabe, Osamu Yoshida, Kana Hirooka, Yoshio Tokumoto, Masanori Abe, Takeru Iwata, Yoichi Hiasa Gastro Hep Advances.2026; 5(1): 100806. CrossRef
Diabetes and the liver Ebo Dadey, Tiong Yeng Lim, Janine Makaronidis Clinical Medicine.2026; 26(1): 100528. CrossRef
Association between longitudinal weight change and clinical outcome in individuals with MASLD Yu Shi, Ruoqi Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Atsushi Nakajima, Hannes Hagström, Elisabetta Bugianesi, Wah-Kheong Chan, Jérôme Boursier, Boon-Bee George Goh, Arun J. Sanyal, Manuel Romero-Gomez, José Luis Ca Hepatology.2026; 84(2): 514. CrossRef
Valproic Acid Exacerbates Lipid Accumulation in High‐Fat Hepatocytes Induced by Oleic Acid: Insights From Lipidomic Analysis Shansen Xu, Xianglei Ma, Lingli Huang, Tingting Yue, Ya'nan Chen Lipids.2026; 61(1): 163. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults Herbert Tilg, Salvatore Petta, Norbert Stefan, Giovanni Targher JAMA.2026; 335(2): 163. CrossRef
Recognizing the Burden of Metabolic Liver Disease in IBD Raseen Tariq, Richard K Sterling Inflammatory Bowel Diseases.2026; 32(3): 584. CrossRef
Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis Joyce Lui, Yesung Kweon, Mohamed I. Elsaid Alimentary Pharmacology & Therapeutics.2026; 63(5): 750. CrossRef
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu Clinical Pharmacology & Therapeutics.2026; 119(2): 336. CrossRef
Protective effect of vitamin D on high-fat-diet-induced metabolic dysfunction-associated steatotic liver disease in mice Amal A. Mohamed, Wael Hafez, Said El-Feky, Mona G. Khalil, Amina S. Soliman, Karima Nasraldin, Ingy M. Ibrahim, Hanan A. Hegazy, Weam Shaheen, Abbas M. Abbas, Hager Shaheen, Marian FL. Abdelmalak, Hany N. Azzam, Omnia Ezzat, Noheir Ashraf Ibrahem Fathy Ha Steroids.2026; 225: 109718. CrossRef
The adipokine Isthmin-1 in obesity and its complications: recent research advances Yuting Zhuang, Jialuo Liu, Yanling Sui, Jiamin Song, Guoyue Yuan, Li Zhao Life Sciences.2026; 384: 124092. CrossRef
Integrated network toxicology, molecular docking and transcriptomics reveal the mechanistic role of phthalate esters in metabolic disease pathogenesis Yuancheng Shao, Qi Liu, Yicheng Jiang, Gang Zhou, Xihan Gu, Shufan Zhang, Shuai Chen, Jiaming Xue, Liming Tang Food and Chemical Toxicology.2026; 207: 115855. CrossRef
Commercial glyphosate formulations exceed active ingredient toxicity via mitochondrial ROS and transcriptomic disruption Jakeline Liara Teleken, Leticia Prates Roma, Rosane Aparecida Ribeiro, Alex Rafacho, Maria Lúcia Bonfleur Toxicology in Vitro.2026; 111: 106178. CrossRef
Effects of bariatric surgery on neurological disturbances and quality of life in patients with metabolic dysfunction-associated steatotic liver disease and obesity: a prospective longitudinal study Concepción Gómez, Juan José Gallego Roig, María Lapeña, Clara Alfaro-Cervelló, Alessandra Fiorillo, Adrià López-Gramaje, Raquel Alfonso Ballester, Norberto Casinello, María Capilla Lozano, María Desamparados Escudero-García, Cristina Montón, Amparo Urios Surgery for Obesity and Related Diseases.2026; 22(1): 113. CrossRef
Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases Nicola Pugliese, Matteo Spertino, Miriana Mercurio, Stefano Ciardullo, Gianluca Perseghin, Cesare Hassan, Roberto Vettor, Salvatore Petta, Alessio Aghemo Clinical Gastroenterology and Hepatology.2026; 24(3): 583. CrossRef
Novel dual AMPK/NRF2 activation by leucocyanidin from Hawthorn (Crataegus) for mitochondria repair-Targeted therapy of hepatic steatosis Yunheng Li, Minghua Ye, Qiaojun He, Bo Yang, Peihua Luo, Xiaochun Yang Phytomedicine.2026; 150: 157614. CrossRef
The role of liver sinusoidal endothelial cells in liver diseases: Key players in health and pathology Eric Felli, Yeldos Nulan, Martí Ortega-Ribera, Anabel Fernández-Iglesias, Jordi Gracia-Sancho Journal of Hepatology.2026; 84(3): 655. CrossRef
A comparative study between ultrasound-guided-attenuation-parameter (UGAP), controlled attenuation parameter (CAP), and proton density fat fraction (PDFF) for assessment of hepatic steatosis Marie Byenfeldt, Christer Grönlund, Patrik Nasr, Anna Lindam, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg Scandinavian Journal of Gastroenterology.2026; 61(1): 124. CrossRef
Hepatic steatosis can accurately be measured during free breathing using ultrasound-guided attenuation parameter (UGAP) technology. Technical note Marie Byenfeldt, Patrik Nasr, Anna Lindam, Christer Grönlund, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg European Journal of Radiology.2026; 195: 112602. CrossRef
Platelet Proteomics: A Glimpse Into Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis Iulia Minciuna, Maria Iacobescu, Ioana Rusu, Oana Nicoara‐Farcau, Petra Fischer, Andreea Maria Soporan, Ioana Ecaterina Pralea, Horia Stefanescu, Cristina Adela Iuga, Bogdan Procopet Hepatology Research.2026; 56(4): 446. CrossRef
The nexus of environmental endocrine-disrupting chemical exposure and metabolic dysfunction-associated steatotic liver disease: An emerging public health challenge Hongxia Chen, Hong Cui, Zhongji Meng Ecotoxicology and Environmental Safety.2026; 309: 119513. CrossRef
Transient elastography during pregnancy: a glimpse into maternal liver health Seung Mi Lee, Won Kim The Lancet Obstetrics, Gynaecology, & Women's Health.2026; 2(1): e2. CrossRef
Elevated adipose inflammation, but reduced hepatic triacylglycerol storage in diet-induced obese Plin4−/− mice Atanaska Ivanova Doncheva, Ryoko Higa, Prabhat Khanal, Martine Villemo Øksenvåg Ingebrigtsen, Yuchuan Li, Shrikant Kolan, Pratibha Kolan, Ales Kvasnicka, Ingunn Jermstad, Shaista Khan, Bjørn Steen Skålhegg, Svein Olav Kolset, Hilde Nebb, Marit Hjorth, Fro Journal of Biological Chemistry.2026; 302(2): 111043. CrossRef
Endohepatology: Evolving Indications, Challenges, Unmet Needs and Opportunities Akash Roy, Mithun Sharma, Anand V. Kulkarni, Sundeep Lakhtakia, Aniruddha Pratap Singh, Rakesh Kalapala, Gregory G. Ginsberg, D.Nageshwar Reddy, K. Rajender Reddy Gastro Hep Advances.2026; 5(2): 100838. CrossRef
Effectiveness and safety of saroglitazar in managing dyslipidaemia and liver enzymes in patients with type 2 diabetes, MASLD, and Stage 3 chronic kidney disease: A 12‐month observational study Gaurab Bhaduri, Shambo S. Samajdar, Sanjay Bandyopadhyay, Shatavisa Mukherjee, Shashank R. Joshi Diabetes, Obesity and Metabolism.2026; 28(3): 2449. CrossRef
Association of Liver Fibrosis Fibrosis-4 Score with Perioperative Complications and Mortality: A Retrospective Multicenter Analysis Shira Zelber-Sagi, Vikas N. O’Reilly-Shah, Ashish K. Khanna, Peter Rock, Itay Bentov Anesthesiology.2026; 144(2): 365. CrossRef
Distinct and complementary metabolic effects of GLP-1 and glucagon receptor agonism in diet-induced obese mice Marie Winther-Sørensen, Christine Rasmussen, Samuel A.J. Trammell, Caroline Hansen, Mogens Vyberg, Reza Serizawa, Erik A. Richter, Trisha J. Grevengoed, Lise Lotte Gluud, Rune E. Kuhre, Nicolai J. Wewer Albrechtsen Peptides.2026; 195: 171462. CrossRef
Nutrition in MASLD: a patient focused, evidence-based clinician’s guide Katrina Pekarska, Paul N Brennan, Dana Ivancovsky Wajcman, Jennifer Towey, Leah Cox, Katie Weatherby, Stuart McPherson, Jonathan Stine, Jose Willemse, Wenhao Li, William Alazawi, Jeffrey V Lazarus, Richard Parker Frontline Gastroenterology.2026; 17(3): 262. CrossRef
Noninvasive Assessment of Hepatic Steatosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease Patients by Using Ultrasound Attenuation Imaging Kun Wang, Qun Liu, Jing Wang, Minghui Wang, Jinqiao Zhang, Yanjie Yu, Ling Liu, Hairong Liu Journal of Ultrasound in Medicine.2026; 45(6): 1209. CrossRef
Hepatic adaptation to chronic metabolic stress primes tumorigenesis Constantine N. Tzouanas, Jessica E.S. Shay, Marc S. Sherman, Adam J. Rubin, Benjamin E. Mead, Tyler T. Dao, Junyan Tao, Brandon M. Lehrich, George Eng, Jeffrey Patterson-Fortin, Titus Butzlaff, Miyeko D. Mana, Kellie E. Kolb, Chad Walesky, Brian J. Pepe-M Cell.2026; 189(2): 435. CrossRef
Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus Virginia Markoutsaki, Georgios Dimakopoulos, Emmanouil Sinakos, Kalliopi Kotsa, Theocharis Koufakis Hormones.2026; 25(2): 475. CrossRef
Two‐Step Machine Learning Model Enhances Identification of High‐Risk Metabolic Dysfunction‐Associated Steatotic Liver Disease Zheng'ao Xu, Yongfen Zhu, Fengjuan Chen, Qiongyue Fan, Ruiqi Wang, Yilong Fu, Xunxun Wu, Li Zhu, Fushuang Ha, Qing Ye, Chunyan Ye, Xiaoming Chen, Meijie Chen, Jiale Niu, Yangyang Xie, Kaixin Chang, Jiakun Miao, Weili Liu, Junping Shi, Zhongjie Hu, Minghua Liver International.2026;[Epub] CrossRef
Risk of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis: A Retrospective Cohort Study Semiu O. Gbadamosi, David Shi, Abdalla Aly, Caichen K. Zhong, Husam Albarmawi, Aidan McGovern, Anthony Hoovler, Carlos Campos Diabetes Therapy.2026; 17(2): 251. CrossRef
Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2026; 32(1): 368. CrossRef
Linked Intronic Polymorphisms of the PNPLA3 Gene Are Associated with Serum Markers of Liver Injury in Patients with Spontaneous HCV Clearance Karina Gonzalez-Aldaco, Luis A. Torres-Reyes, Arturo Panduro, Sonia Roman International Journal of Molecular Sciences.2026; 27(1): 473. CrossRef
Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction Juan Ma, Ning Xie, Ziwei Wang, Xiru Liang, Yulong Han, Qiang Zhao, Ming Wang, Hongwei Lu, Wanyi Kou, William Alazawi, Jinhai Wang, Lu Li, Ning Liu, Na Liu, Haitao Shi, Feng Xu Advanced Science.2026;[Epub] CrossRef
A sex-specific brake on liver oestrogen signalling Pamela Kakimoto, Natalie Krahmer Nature Metabolism.2026; 8(1): 8. CrossRef
Mesenchymal Stromal/Stem Cell-Based Therapies for Liver Regeneration: Current Status and Future Directions Seohyun Choi, Jaemin Jeong International Journal of Molecular Sciences.2026; 27(2): 619. CrossRef
The burden and mortality impact of cardiovascular disease–metabolic dysfunction–associated steatotic liver disease comorbidity Siyuan Tan, Ting Huang, Zixi Zhang, Jiabao Zhou, Hao Chen, Tao Tu, Qiuzhen Lin, Yichao Xiao, Qiming Liu Diabetes Research and Clinical Practice.2026; 232: 113092. CrossRef
Non-alcoholic fatty liver disease in Northeast India: a narrative review of rising metabolic syndrome Shiludi Longkumer, Maitrayee Dutta Swargiary Egyptian Liver Journal.2026;[Epub] CrossRef
Dose‒response relationship between exercise and hepatic steatosis: A systematic review with Bayesian network meta-analysis of randomized controlled trials Xinyun Tan, Huihui Zou, Manjie Guo, Jiayu Liu, Xinjuan Huang, Ruoling Yu, Xuelian Liu, Chunxiang Qin Journal of Sport and Health Science.2026; 15: 101125. CrossRef
Kefiran, a polysaccharide from kefir grain, modulates gut microbiota and hepatic metabolism to mitigate metabolic dysfunction-associated steatotic liver disease Yuanyuan Cui, Jiajia Zhu, Jun Xi, Changhe Ding, Jun Meng International Journal of Biological Macromolecules.2026; 341: 150147. CrossRef
Assessment of the Diagnostic Performance and Clinical Impact of AI in Hepatic Steatosis: Systematic Review and Meta-Analysis Jiamei Song, Dan Liu, Jitong Li, Haoru Cong, Ruixue Deng, Yihan Lu, Jiayi Sun, Jingzhou Zhang Journal of Medical Internet Research.2026; 28: e78310. CrossRef
Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Dise Savvoula Savvidou, Elektra Augousti-Varela, Aikaterini Damianakou, Miltiadis Chalkias, Ioannis Stergiou Metabolic Syndrome and Related Disorders.2026; 24(3): 121. CrossRef
Oxidative stress in metabolic dysfunction-associated steatohepatitis: Mechanisms and emerging therapeutic strategies Yidan Chen, Hui Yu, Xinyu Kai, Runting Yin, Zhen Ouyang, Yuan Wei, Cai Zhang Biochemical Pharmacology.2026; 246: 117702. CrossRef
Diet intervention altered DNA methylation of potassium voltage-gated channel subfamily Q member 1 in metabolic dysfunction-associated steatohepatitis Xinyu Shi, Hualing Song, Xinying Xiong, Shuang Wei, Lei Zhang, Shengfu You, Wenjun Zhou, Guang Ji, Baocheng Liu, Na Wu Clinical Epigenetics.2026;[Epub] CrossRef
Mechanisms of scramblases in regulating hepatic lipoprotein secretion and autophagy Allen Chen, Chen Zhang, Wen-Xing Ding, Hong-Min Ni Journal of Lipid Research.2026; 67(2): 100979. CrossRef
Artificial Intelligence for Fibrosis Diagnosis in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review Neilson Silveira de Souza, Théo Cordeiro Veiga Vitório, Raphael Augusto de Souza, Marcos Antônio Dórea Machado, Helma Pinchemel Cotrim Diagnostics.2026; 16(2): 261. CrossRef
Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai Hepatology International.2026; 20(2): 292. CrossRef
Diagnostic Utility of Serum Activating Transcription Factor 4 and Toll-like Receptor 4 as Early Biomarkers of Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease Isa Yalcinkaya, Iskender Ekinci, Seyma Dumur, Eda Nur Duran, Hafize Uzun, Melda Yalcinkaya, Elif Kadioglu Yeniyurt, Omer Vehbi Alpaydin, Gulden Anataca, Omur Tabak Journal of Clinical Medicine.2026; 15(2): 559. CrossRef
Use of Artificial Intelligence-Assisted Histopathology for Evaluation of Sex-Specific Progression and Regression of Hepatocellular Carcinoma Related to Metabolic Dysfunction-Associated Fatty Liver Disease Ke Yin, Yuyun Song, Ran Fei, Xu Cong, Baiyi Liu, Zilong Wang, Xin Ai, Minjun Liao, Yayun Ren, Kutbuddin Akbary, Wei Wang, Qiang Yang, Xiao Teng, Nan Wu, Huiying Rao, Xiaoxiao Wang, Feng Liu Diagnostics.2026; 16(2): 234. CrossRef
Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs Lei Yang, Jiale Ruan, Yingying Fang, Anyi Xu Frontiers in Medicine.2026;[Epub] CrossRef
Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation Senping Xu, Zhaoshan Zhang, Zhongquan Zhou, Jiawei Guo Biology.2026; 15(2): 148. CrossRef
Phosphatidylserine Supplementation Improves Metabolic Liver Disease and Glycemic Control in the Presence of Suppressed Oxidative Glucose Metabolism Li Dong, Sihan Lin, John Slavin, Satya Gunnam, Zhili Cheng, Shuai Nie, Michael G. Leeming, Nicholas A. Williamson, Magdalene K. Montgomery Diabetes.2026; 75(2): 273. CrossRef
Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH Weiheng Wen, Zenghui Liu, Wenliang Tan, Yingzheng Tan, Wei Li, Jian Wan, Hongsai Hu, Zhengwu Jiang, Xing Tang, Jing Yang, Jiao Xiao, Xiongjin Tan, Xun Chen, Peili Wu, Yukun Li npj Digital Medicine.2026;[Epub] CrossRef
Morphological characterization of a novel model of steatohepatitis in the
FAH
-/-
pig
Silvana N. Wilken, Philipp Felgendreff, Anna Minshew, Boyukkhanim Ahmadzada, Seyed M. Hosseiniasl, Sara Kazeminia, Kachi Ezenekwe, Ameya Patil, Byoung U. Park, Ahmer Sultan, Lindsey Smith, Julio Cisneros Correa, Kamal Hussein, Harmeet Malhi, Roger K. More Veterinary Pathology.2026; 63(4): 746. CrossRef
Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts Huangxin Zhu, Lihua Liu, Sicheng Yang, Yunfeng Fu, Yating Pan, Qingan Fu, Fan Du, Xiaodong Zhou Cardiovascular Diabetology.2026;[Epub] CrossRef
Stemness CD24 activation promotes hepatocellular carcinoma progression via an immune escape mechanism Yin Cai, Lu-Yin Liu, Xiao-Xiao Xia, Hao Tang, Min Xu, Wen-Li Sai, Deng-Fu Yao, Min Yao World Journal of Gastroenterology.2026;[Epub] CrossRef
Targeting the 4-HNE–H₂S pathway as a therapeutic strategy for placental injury in pregnancy with MAFLD Tianxiao Hu, Jiayu Qi, Yinuo Xu, Jia He, Qingying Tan, Jie Hao, Jing Wang, Jiewei Hong, Jianwei Wang, Lin Chen, Xiaobing Dou International Immunopharmacology.2026; 172: 116245. CrossRef
Association of the Triglyceride-Glucose Index With Established Cardiovascular Disease in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study Soumayan Mondal, Sidharth S Pattnaik, Nihar Ranjan Mohanty, Sailendra Nayak, Ambika Mohanty, Shubhransu Patro Cureus.2026;[Epub] CrossRef
Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk Qiqi Zhao, Shengwen Lu, Yu Guan, Zhiwen Sun, Shi Qiu, Aihua Zhang Lipids in Health and Disease.2026;[Epub] CrossRef
Prognostic value of non-invasive fibrosis assessment scores in predicting mortality among individuals with metabolic dysfunction-associated steatotic liver disease Lingjie Wu, Shunling Cai, Zhongbin Lin, Ruilie Chen, Yuanfeng Zhang, Xiaobing Gong BMC Public Health.2026;[Epub] CrossRef
Dapagliflozin‐Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes Anna V. Naumova, Guilherme Moura Cunha, Nicole J. Kim, Jie Lu, Daniel Isquith, Baocheng Chu, Charles Maynard, Arash Mahdavi, Negar Firoozeh, Karen Ordovas, Xue‐Qiao Zhao, Francis Kim Obesity.2026; 34(3): 622. CrossRef
Association Between Metabolically Associated Steatotic Liver Disease (MASLD) and Cardiovascular Risk Scores in Urban Adults FARIS HUSSAIN, KELVIN KANAYO NWABUEZE, FATIMA IJAZ, SONIA OUTALEB, MAHMUDUL HASAN NAHID, SYED ABID, MARIAM SALEEM, KHANT NYI ZAYA, SAIFULLAH SYED, HUMAIRA JANANTH, MANAHIL ZARIEF Juntendo Medical Journal.2026; 72(1): 54. CrossRef
Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in Tanzania: prevalence and predictors Evangelista Malindisa, Illuminata Kafumu, Allen Rweyendera, Elisha Mkemangwa, David Majinge, Igembe Nkandala, Paulina Manyiri, Semvua Kilonzo BMC Endocrine Disorders.2026;[Epub] CrossRef
Body mass index and metabolic dysfunction associated steatotic liver disease remission among Chinese adults in a retrospective cohort study Jiwen Zhang, Yuyin Guo, Bi’e Li, Jiaqian Zhu, Chuang Gao, Qiongdan Zhang, Yong Han, Chuxuan Gu Scientific Reports.2026;[Epub] CrossRef
12,13-diHOME ameliorates MASLD by regulating Sestrin2-mediated AMPK/ULK1/Lipophagy in obese mice Kexin Zhang, Chengxia Kan, Hongyan Qiu, Junfeng Shi, Jian Chen, Tianpeng Zheng, Jingwen Zhang, Yujie Ma, Sufang Sheng, Ningning Hou, Fang Han, Xiaodong Sun Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2026; 1872(4): 168186. CrossRef
Burden of MASLD and liver fibrosis: evidence from Phenome India cohort Meghana Arvind, Anshul Verma, Sreeshma Raj K, Satyartha Prakash, Vignesh S. Kumar, Mohammad Azhar Uddin, Ayushi Narayan, Mamta Rathore, Nancy Rawat, Ankita Sahu, Yogesh Kumar, Pulkit Hasmukhbhai Leuva, Monika Sharma, Rajesh S, Dwaipayan Saha, Ankita Mridh The Lancet Regional Health - Southeast Asia.2026; 45: 100723. CrossRef
Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment Ina Bergheim, Jean Francois Cadranel, Jianguo Chen, Wenxing Ding, Robert Eferl, Carmen Garcia-Ruiz, Hartmut Jaeschke, Firouzeh Kazerouni, Amedeo Lonardo, Derek A. Mann, Nahum Méndez-Sánchez, Camelia Mokhtari, Han Moshage, Chiara Raggi, Pavel Strnad, Oren Exploration of Digestive Diseases.2026;[Epub] CrossRef
Prevalence and risk factors for metabolic dysfunction–associated steatotic liver disease in Sweden: Insights from the SCAPIS cohort Oumarou Nabi, Jonas Spaak, Göran Bergström, Gunnar Engström, Carl Johan Östgren, Andrei Malinovschi, Joel Kullberg, Anders Blomberg, Tomas Jernberg, Daniel P. Andersson, Hannes Hagström Journal of Internal Medicine.2026; 299(4): 481. CrossRef
Interactions Between the Gut Microbiome and Genetic and Clinical Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus from Different Geographical Regions of Argentina Bárbara Suarez, Adriana Mabel Álvarez, María Florencia Mascardi, Ana Laura Manzano Ramos, Dong Hoon Woo, María Mercedes Gutiérrez, Guillermo Alzueta, María del Carmen Basbus, Santiago Bruzone, Patricia Cuart, Guillermo Dieuzeide, Teresita García, Olga Esc Life.2026; 16(2): 283. CrossRef
Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review Abdulrahman Ismaiel, Vera Ciornolutchii, Stefan‐Lucian Popa, Dan L. Dumitrascu European Journal of Clinical Investigation.2026;[Epub] CrossRef
Predictive factors of metabolic dysfunction associated steatotic liver disease (MASLD) among individuals with cardio-metabolic risk factors, multicenter cross-sectional study, North East Ethiopia Getachew Bizuneh Aydagnuhm, Aklile Semu Tefera, Gebru Tesfaw Getahun, Ermiyas Endewunet Melaku BMC Gastroenterology.2026;[Epub] CrossRef
Temporal trends and racial/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022 Wenzhan Jing, Hang Pham, Samuel So JHEP Reports.2026; 8(4): 101754. CrossRef
Pirfenidone as a Pleiotropic Antifibrotic Agent in Metabolic Steatohepatitis: From Mechanisms to Clinical Evidence Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodríguez, Jorge L. Poo, Nahum Méndez-Sánchez Archives of Medical Research.2026; 57(4): 103387. CrossRef
Long-term dementia risk in metabolic dysfunction-associated steatotic liver disease: a population-based study Andreas Bartholdy, Kristine Frøsig Moseholm, Pernille Yde Nielsen, Nicolai J. Wewer Albrechtsen, Lise Lotte Gluud, Majken Karoline Jensen Metabolic Brain Disease.2026;[Epub] CrossRef
Outils diagnostiques de la fibrose hépatique dans la stéatohépatite dysmétabolique Candice Gea, Guillaume Feugray, Valéry Brunel Revue Francophone des Laboratoires.2026; 2026(579): 36. CrossRef
Mitochondrial dysfunction in MASH: Focusing on chronic inflammation and intercellular communication Wanyi Luo, Muxin Yu, Chuwei Zheng, Xiaowen Li, Xiaotian Ma, Guocheng Zeng, Jinming Zhang, Xia Ji, Liyan Sun Biochemical and Biophysical Research Communications.2026; 804: 153356. CrossRef
Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis Markos Kalligeros, Laurent Castera, Emmanuel A. Tsochatzis, Naim Alkhouri Clinics in Liver Disease.2026; 30(2): 323. CrossRef
La ballonisation hépatocytaire : une nouvelle cible thérapeutique dans la Physiopathologie de la MASH Arthur Cens, Bart Staels, Réjane Paumelle Revue Francophone des Laboratoires.2026; 2026(579): 28. CrossRef
Febuxostat Improves MASLD in Male Rats: Roles of XOR Inhibition and Associated JNK/NRF2/HO-1 Pathway Changes Zhiyu Pu, Yangyang Cen, Bowen Yang, Kaijun Xing, Linxi Lian, Xi Chi, Jianjun Yang, Yannan Zhang International Journal of Molecular Sciences.2026; 27(2): 1069. CrossRef
Association between blood heavy metal levels and subtypes of steatotic liver disease: A nationally representative cross-sectional analysis in South Korea Ji Hye Choi, Juyeong Kim, Yesol Yim, Hyunjee Kim, Jiyoung Hwang, Ho Geol Woo, Sang Youl Rhee, Yerin Hwang, Dong Keon Yon Medicine.2026; 105(4): e47365. CrossRef
Biological aging across the metabolic dysfunction–associated steatotic liver disease spectrum: A systematic review Chukwuemeka E. Ogbu, Stella C. Ogbu, Chidera P. Ogbu, Chinazor Umerah iLIVER.2026; 5(1): 100222. CrossRef
Fermented Foods and the Gut–Liver Axis: Modulation of MASLD Through Gut Microbiota Agnieszka Wesołek-Leszczyńska, Dawid Rosiejka, Kalina Bogdańska, Paweł Bogdański Nutrients.2026; 18(3): 542. CrossRef
Association of four insulin resistance indices with liver‐related adverse outcomes: A prospective cohort study Xiao‐Meng Wang, Hao Yan, Wen‐Fang Zhong, Jia‐Hao Xie, Huan Chen, Jun‐Jie Wang, Wei‐Qi Song, Dong Shen, Pei‐Dong Zhang, Xi‐Ru Zhang, Jiao‐Jiao Ren, Dan Liu, Zhi‐Hao Li, Chen Mao Diabetes, Obesity and Metabolism.2026; 28(5): 3598. CrossRef
Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials Khalid I. AlHussaini Frontiers in Medicine.2026;[Epub] CrossRef
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia Yusuf Yilmaz, Alina M. Allen, Jérôme Boursier, Juan P. Arab Clinics in Liver Disease.2026; 30(2): 289. CrossRef
Associations of relative fat mass with metabolic dysfunction–associated steatotic liver disease and liver fibrosis: evidence from the U.S. NHANES 2017–2023 Hai-Yuan Zhong, Ling-Dan Ma, Jin-Cheng Li, Dan Jiang, Yu-Mei Qin, Ming-Yu Lai, Guang Xiong BMC Gastroenterology.2026;[Epub] CrossRef
Gut microbiota, liver disease, and perioperative anesthesia: interactions, risks, and therapeutic opportunities Lei Shi, Ye Yu, Zihan Ma, Weiyi Jiang Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease Jeffrey V. Lazarus, Christopher J. Kopka, Aina Nicolàs, Safura Abdool Karim, Meena B. Bansal, Michael Betel, John F. Dillon, Pere Gines, Aleksander Krag, Veronica Miller, Cynthia A. Moylan, Alisa Pedrana, Paula Petrone, Jörn M. Schattenberg, Sunil S. Solo Nature Reviews Gastroenterology & Hepatology.2026; 23(4): 355. CrossRef
SIRT3 ameliorates hepatic inflammation, oxidative stress, and fibrosis in HFD- or MCD diet-fed mice Huifang Lv, Wenyue Sun, Cuixia Tian, Chunyong Bian, Zhongting Lu, Xin Guo The Journal of Nutritional Biochemistry.2026; 152: 110276. CrossRef
Paulobutalipin, a Lipid Accumulation Inhibitor from a Streptomyces sp. Thanh-Hau Huynh, Hoseo Lee, Sangwook Kang, Jeong-Hyeon Kim, Huiyeong Ju, Ki-Bong Oh, Sang-Jip Nam, Ja Hyun Koo, Dong-Chan Oh Journal of Natural Products.2026; 89(2): 682. CrossRef
MASLD, MASH, and the CKM Spectrum Faiez Zannad, Muhammad Shahzeb Khan, Nisha Bansal, Michael Böhm, Sven M. Francque, Nicolas Girerd, James L. Januzzi, Veronica Miller, Marie-Eve Piché, Vlad Ratziu, Bart Staels, Harriette G.C. Van Spall, Arun J. Sanyal, Javed Butler JACC.2026; 87(15): 2006. CrossRef
Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction–associated steatotic liver disease and its progression to hepatocellular carcinoma Thomai Kouti, Panayiota Christodoulou, Stephanos Christodoulides, Foula Protopapa, Charalambos Michaeloudes, Paraskevi A. Farazi Frontiers in Nutrition.2026;[Epub] CrossRef
Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and inter Lanlan Chen, Paul Horn, Frank Tacke Diabetes, Obesity and Metabolism.2026; 28(S2): 46. CrossRef
MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review Adela Gabriela Ştefan, Adina Mitrea, Diana Clenciu, Ionela Mihaela Vladu, Maria Magdalena Roşu, Diana Cristina Protasiewicz-Timofticiuc, Theodora Claudia Radu-Gheonea, Ion-Cristian Efrem, Anca Maria Amzolini, Beatrice Elena Vladu, Ana-Maria Efrem, Delia-V Medicina.2026; 62(2): 325. CrossRef
The active components of the Danshen-Shanzha herb-pair exert a protective effect on MASLD by synergistically promoting fatty acid oxidation via the activation of PPARα, Plin-5 and Plin-2 Ying Yang, Yaxing Li, Zirong Zhou, Hui Li, Yihan Ma, Wenjie Bi, Mengjiao Li, Xiaoli Liu, Qiang Jia, Liwen Han, Songsong Wang Journal of Ethnopharmacology.2026; 362: 121374. CrossRef
Efficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases I. Commins, D. Clayton-Chubb, N. Janko, A. Majeed, W. Kemp, S. K. Roberts Medical Sciences.2026; 14(1): 84. CrossRef
Detection of hepatic steatosis with ultrasound-guided attenuation parameter (UGAP) in metabolic dysfunction-associated steatotic liver disease (MASLD) compared with proton density fat fraction (PDFF): Impact of measurement number and region of interest (R Marie Byenfeldt, Christer Grönlund, Patrik Nasr, Anna Lindam, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg Ultrasound.2026; 34(3): 203. CrossRef
Artificial intelligence and digital transformation of gastroenterology and hepatology: A critical review of clinical applications and future challenges Miguel Suarez, Raquel Martínez, Félix González-Martínez, Ana María Torres, Jorge Mateo World Journal of Hepatology.2026;[Epub] CrossRef
Efficacy of ursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease: an umbrella review of meta-analyses on liver enzymes Alsu R. Khurmatullina, Dmitrii N. Andreev, Igor V. Maev, Andrey V. Zaborovsky, Yury A. Kucheryavyy, Petr A. Beliy, Philipp S. Sokolov Frontiers in Medicine.2026;[Epub] CrossRef
Panax notoginseng Saponins Ameliorate High‐Fat Diet‐Induced Liver Injury via Mechanisms Involving TLR4‐Mediated Signaling and Lipid Metabolism Rong Li, Junyu Ma, Mengyao Li, Bangzhao Zeng, Xuexun Li, Xiaoyan Bi, Xin Zhao, Qin Gao, Yanling Yao, Yang Jiang, Chunmei Zhang, Fuli Ya Food Science & Nutrition.2026;[Epub] CrossRef
MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5 Morgan C. Nelson, Liam C. O’Malley, Soh-Hyun Lee, Kaylyn M. Bauer, Arevik Ghazaryan, William W. Tang, Chad VanSant-Webb, Van B. Tran, Colton Hernandez, Ben Battistone, Amber Thibeaux, June L. Round, Micah J. Drummond, H. Atakan Ekiz, Kimberley J. Evason, Cancer Research Communications.2026; 6(2): 359. CrossRef
Imaging in MASLD Sudhakar K. Venkatesh Expert Review of Gastroenterology & Hepatology.2026; 20(3): 257. CrossRef
Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors Júlia Mayumi Tomaru, Iara Ribeiro Nunes, Caroline Fernandes de Souza Santiago, Alda Maria Machado Bueno Otoboni, Claudemir Gregorio Mendes, Adriana Maria Ragassi Fiorini, Elen Landgraf Guiguer, Claudia Cristina Teixeira Nicolau, Antonelly Cassio Alves Car Nutrients.2026; 18(4): 636. CrossRef
Occurrence and prognosis of metabolic dysfunction-associated steatosis liver disease and gastrointestinal tumors: a systematic review and meta-analysis Siyu Duan, Yiyi Wei, Zhuoyu Ding, Chaomin Pan, Li Yang, Yan Gu, Xinke Wang PeerJ.2026; 14: e20616. CrossRef
Liver involvement in dengue virus infection: a narrative review Madunil Anuk Niriella, Ravini Amila Premaratna, Shashini Hathurusinghe, Ranjan Premaratna, Anuradha Supun Dassanayake, Hithanadura Janaka de Silva Journal of Clinical Virology Plus.2026; 6(2): 100247. CrossRef
Toll Like Receptor 4: A Potential Link Between Obesity and Metabolic Diseases Ghadeer Alhamar, Joanna Razafiarison, Fawaz Alzaid, Fahd Al‐Mulla, Rasheed Ahmad Obesity Reviews.2026;[Epub] CrossRef
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD Xiao-Dong Zhou, Qin-Fen Chen, Qiong-Yue Fan, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah-Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victo Hepatology.2026; 84(2): 529. CrossRef
Editorial: Pharmacological and nutritional approaches to metabolic associated fatty liver disease: a step towards achieving SDG 3 Mahmut Bodur, Bojana Vidović, Anastasios Nikolaou, Birsen Yilmaz Frontiers in Pharmacology.2026;[Epub] CrossRef
Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus Jiwon Yang, Yeongseok Hwang, Jin-Sung Ju, Seungbong Han, Jihyun An, Ju Hyun Shim Hepatology.2026; 84(3): 851. CrossRef
Altered Tryptophan–Kynurenine Pathway and Low-Grade Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Insights from LC–MS/MS–Based Metabolite Profiling Kübranur Ünal, Leyla İbrahimkhanlı, Mehmet Emre Erol, Nemat İbrahimkhanlı, Sabri Engin Altıntop, Mahi Nur Cerit, Ethem Turgay Cerit, Halit Nahit Şendur International Journal of Tryptophan Research.2026;[Epub] CrossRef
Modulation of metabolic, inflammatory, fibrotic, and cell death pathways by resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a transcriptomic profiling study Chen-yang He, Zhi-hua Wang, Jian-ping Weng, Hans Strijdom, Suo-wen Xu Acta Pharmacologica Sinica.2026; 47(4): 1070. CrossRef
From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang Portal Hypertension & Cirrhosis.2026; 5(2): 170. CrossRef
Inflammation burden index as a complementary marker for the assessment of hepatic steatosis and fibrosis: evidence from NHANES 2017–2018 Shaoguang Chen, Lixiao Zhu, Yulou Jiang Abdominal Radiology.2026; 51(9): 4343. CrossRef
Deubiquitinase USP2 promotes hepatic stellate cell activation via p300 stabilization Seunghee Byun, Hyunsik Kim, Sun‐Ho Lee, Jae‐Hwan Kwon, Hyunseung Kim, Jung‐Yoon Yoo, Soo‐Yeon Park, Ho‐Geun Yoon FEBS Letters.2026; 600(9): 1318. CrossRef
Epidemiological Trajectories and Quality of Care Disparities of MASLD in Asia, 1990–2023 Kexin Zhang, Wei Xu, Chengxia Kan, Sufang Sheng, Fang Han, Jian Chen, Xuan Li, Ningning Hou, Xiaodong Sun, Ying Xue Digestive Diseases and Sciences.2026; 71(7): 2976. CrossRef
Impact of different subtypes of steatotic liver disease on immune checkpoint inhibitor-related drug-induced liver injury: a retrospective study Tianyi Ma, Zhanfang Guo, Haijia Bi, Huawei Yuan, Yu Li, Mei Sun European Journal of Gastroenterology & Hepatology.2026; 38(3): 351. CrossRef
Triglyceride glucose index—a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging Guodong Yang, Wenli He, Xin Qiu, Shuang Shen, Peishu Li, Yifei Feng, Jiayuan Zhang, Bangde Xiang Cardiovascular Diabetology.2026;[Epub] CrossRef
The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging Tugce Apaydin, Haluk Tarik Kani, Caglayan Keklikkiran, Yusuf Yilmaz, Dilek Gogas Yavuz Journal of Endocrinological Investigation.2026; 49(5): 1029. CrossRef
From Childhood to Old Age: Current Knowledge and Practical Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease Iwona Gorczyca-Głowacka, Michał Tarnowski, Anna Zmelonek-Znamirowska, Przemysław Wolak Journal of Clinical Medicine.2026; 15(4): 1536. CrossRef
Development of a Lipidomics-Based Cell Screening Platform for Indirect Antioxidants Targeting Oxidized Lipid Droplet Formation and Mitochondrial Membrane Abnormality Yuzu Shibata, Toshihiro Sakurai, Akiko Sakurai, Misuzu Sato, Shu-Ping Hui Nutrients.2026; 18(5): 719. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multisystemic Narrative Review of Cardiovascular and Oncological Implications Menatalla M. A. Mohamed, Maha M. M. I. Taha, Mohnd M. M. R. Ibrahim ASIDE Gastroenterology.2026; 2(2): 15. CrossRef
Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography Hidenao Noritake, Takafumi Inoue, Takashi Yonekura, Hiroki Tamakoshi, Yuya Ida, Moe Matsumoto, Tomohiko Hanaoka, Maho Yamashita, Masahiro Umemura, Kazuyoshi Ohta, Takeshi Chida, Kazuhito Kawata Journal of Clinical Lipidology.2026; 20(5): 947. CrossRef
Fecal microbiota transplantation alleviates steatosis and inflammation in high-fat and high-sugar diet-induced fatty liver in mice Fangxia Mi, Jinglu Guo, Wentao Zheng, Jianwei Shen, Hua Ye Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4α Xinru Chen, Nga Nguyen, Susan E. Turner, Albert K. Tai, Manal F. Abdelmalek, Lidija Covic, Athan Kuliopulos JHEP Reports.2026; 8(6): 101796. CrossRef
Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease Jason N. Chen, Bulent Tolga Delibasi, James Wang, Thomas Tran, Connie Hu, Charles W. Randall BMC Gastroenterology.2026;[Epub] CrossRef
Rab5 nucleotide binding promotes oxidative metabolism to fuel hepatocellular carcinoma cell proliferation Kelly O. Otakhor, Mohd Ali Abbas Zaidi, Rebecca E. Oberley-Deegan, Moorthy P. Ponnusamy, Kurt W. Fisher, Micah B. Schott Journal of Biological Chemistry.2026; 302(4): 111321. CrossRef
Using an integrative multi-omics and in vitro approach to investigate the role of tris(2-butoxyethyl) phosphate in promoting hepatic steatosis Gang Zhou, Xihan Gu, Xinyao Zhou, Shuai Chen, Hanyang Liu, Jing Wang BMJ Open Gastroenterology.2026; 13(1): e002123. CrossRef
Epigenetic regulation in MASLD – insight for therapeutic target discovery Jan H. Britsemmer, Nuria Lopez Alcantara, Henriette Kirchner Epigenomics.2026; 18(3): 311. CrossRef
Astaxanthin alleviates altered hepatic lipid metabolism and oxidative stress in animals fed a high-sucrose diet Matias Rodrigo Vargas, María del Rosario Ferreira, Paola Inés Ingaramo, Pablo Collins, María Eugenia D’Alessandro Frontiers in Nutrition.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa Mohamed El-Kassas, C. Wendy Spearman, Manal El-Sayed, Zobair M. Younossi Clinics in Liver Disease.2026; 30(2): 513. CrossRef
Patients’ Experience of Stigma as the Hidden Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Descriptive Qualitative Study with Thematic Analysis Johanne Lisa Jensen-LeBlanc, Pernille Andreassen, Mette Munk Lauridsen, Lea Ladegaard Grønkjær Healthcare.2026; 14(5): 579. CrossRef
Targeting magnesium homeostasis: a novel therapeutic strategy for liver diseases Lili Ji, Hanhan Yu, Ruwen Wang, Hongmei Yan, Xiaofeng Yin, Shanshan Guo, Ru Wang Frontiers in Nutrition.2026;[Epub] CrossRef
The Role of Butyrate in People with Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Metabolic Comorbidities: A Systematic Review Alicia González-González, Virginia Soria-Utrilla, María Isabel Fontalba-Romero, María Ángeles Núñez-Sánchez, Antonio Adarve-Castro, María Isabel Queipo-Ortuño, Bruno Ramos-Molina, José Ignacio Martínez-Montoro, José Carlos Fernández-García Current Obesity Reports.2026;[Epub] CrossRef
Creatinine-to-body weight ratio as an independent predictor of hepatic steatosis severity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study Xiaoning Sun, Xiaozhong Wang, Ayesha Younas, Shuanghu Wang, Muhammad Sohail, Jiaojian Lv, Zuxiu Huang, Yunxiao Liu BMC Gastroenterology.2026;[Epub] CrossRef
Metabolic liver imaging: What you need to know Luigi Asmundo, Amirkasra Mojtahed, Samay Prakash, Theodore T. Pierce, Jingwei Wei, Angelo Vanzulli Digestive and Liver Disease.2026; 58(4): 433. CrossRef
Gut microbiota supportive dietary pattern associated with reduced MASLD risk mediated by metabolomic profiles: a prospective cohort study Dong-Run Li, Ke-Ru Li, Ying Wang, Jia-Qi Zheng, Wen-Rui Zheng, Bang-Quan Liu, Jia-Cheng Liu, Rui-Han Bao, Ting-Ting Gong, Qiu-Ju Sheng, Shan-Yan Gao, Qi-Jun Wu Nutrition Journal.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America Claudia P. Oliveira, Mario Guimarães Pessoa, Luis Antonio Diaz, Juan Pablo Arab, Adrian Gadano, Marco Arrese Clinics in Liver Disease.2026; 30(2): 529. CrossRef
Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study Chao Yan, Xinxin Shen, Shaojie Han, Jinzheng He, Tongxu Wang, Xiaobing Gong, Jindong Ding Petersen Journal of Translational Medicine.2026;[Epub] CrossRef
Retatrutide in type 2 diabetes mellitus and obesity: an overview Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic, Nikolaos Papanas Expert Review of Clinical Pharmacology.2026; 19(4): 313. CrossRef
Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Optimal screening criteria for metabolic dysfunction-associated steatotic liver disease with fibrosis Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Annals of Hepatology.2026; 31(2): 102199. CrossRef
The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases Yirui Hu, Ye Yang, Shuyan Wang, Huikuan Chu npj Biofilms and Microbiomes.2026;[Epub] CrossRef
Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD Alex E. Henney, Jo Wilson, David R. Riley, Uazman Alam, Daniel J. Cuthbertson Liver International.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk of Gynecologic Cancer: A Nationwide Cohort Study Min Jin Jeong, Yong Seok Lee, Youn Jin Choi, Kyung Do Han Cancers.2026; 18(6): 894. CrossRef
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases Leonidas Diamantopoulos, Markos Kalligeros, Scott D. Isaacs, Didac Mauricio Clinics in Liver Disease.2026; 30(2): 271. CrossRef
Hospitalization Trends Due to Chronic Liver Diseases: Vicious Circle of Co-Morbidities and Hospitalization Length Ivana Pantic, Nikola Grubor, Sofija Lugonja, Nina Rajovic, Svetlana Miltenovic, Marija Brankovic, Tijana Gmizic, Tamara Milovanovic Clinics and Practice.2026; 16(3): 57. CrossRef
Integrated multi-omics analysis identifies and validates endoplasmic reticulum stress and mitophagy-related biomarkers in MASLD Quanrun Chen, Limin Liu, Jinqiu Feng, Chong Zhang, Zongming Zhang Scientific Reports.2026;[Epub] CrossRef
Non-invasive risk stratification of metabolic dysfunction-associated steatotic liver disease and liver fibrosis in adults with type 1 diabetes Manuel Ramón García-Sáenz, Marilu Cervantes-Maldonado, Luis Angel López-Cruz, Eduardo Salif Luna-Avila, Paulo César Gete Palacios, Cristina Martínez-Berdeja, Omar Jaime-Leal, Aldo Ferreira-Hermosillo Frontiers in Endocrinology.2026;[Epub] CrossRef
MEANDERLINE BASED MICROSTRIP ANTENNA DESIGN FOR LIVER TUMOR DETECTION Volkan Akdoğan, Fatih Özkan Alkurt Kahramanmaraş Sütçü İmam Üniversitesi Mühendislik Bilimleri Dergisi.2026; 29(1): 401. CrossRef
Metabolic-associated steatotic liver disease in children and adolescents: a scoping review and narrative synthesis of epidemiology, risk factors, and screening approaches with emerging implications for sub-Saharan Africa Bruno Basil, Peace Ngozi Okoro Frontiers in Endocrinology.2026;[Epub] CrossRef
The Gut‐Liver Axis in Metabolic Dysfunction‐Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics Shaoliang Zhu, Mengjie Zou, Qijun Wu, Yan Zou, Tingting Tan, Zhangnan Huang, Zheng Gong, Honglin Luo, Xiaofeng Dong The FASEB Journal.2026;[Epub] CrossRef
Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes Konstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, Emmanouil Sinakos Current Diabetes Reports.2026;[Epub] CrossRef
Association between weekend catch-up sleep and Metabolic dysfunction-associated steatotic liver disease in US adults Jinlong Chen, Wei Wang, Jie He, Xinxin Fang Clinical and Experimental Medicine.2026;[Epub] CrossRef
Ginsenoside Rg1 alleviates MASH by targeting GLS2 to enhance PINK1/Parkin-mediated mitophagy and improve mitochondrial function Zhijian Wang, Yinuo Wang, Peiyun Peng, Huating Luo, Liuling Xiao, Wenxiang Huang Biochemical Pharmacology.2026; 249: 117891. CrossRef
Heterogeneous associations of regional adipose depots with liver fibrosis in U.S. adults Kuan-Yu Lai, Chun-Yi Wang, Hsian-Han Kao, Wen-Yuan Lin, Tsung-Po Chen Metabolism Open.2026; 30: 100461. CrossRef
MASLD In Children - A Distinct Phenotype? Pervej Alom Barbhuiya, Manash Pratim Pathak Current Obesity Reports.2026;[Epub] CrossRef
DNA hypermethylation of choline kinases drives blockage of choline-phosphatidylcholine biosynthesis: lipidomic biomarkers and epigenetic insights of hepatic steatosis induced by arsenic Qiwen Fu, Qi Wang, Dingyi Song, Xingcheng Zhou, Hualin Chen, Shaofeng Wei, Lu Ma BMC Medicine.2026;[Epub] CrossRef
Comment on “Long-term serum ferritin dynamics in patients receiving antiviral treatment for hepatitis C virus infection” Preeti Lamba Journal of the Formosan Medical Association.2026; 125(11): 1496. CrossRef
Association between triglyceride glucose-body mass index and metabolic dysfunction-associated steatotic liver disease in South Korean pregnant women Yuqin Shen, Dongqian Yang, Li Zhang, Rong Shuai Scientific Reports.2026;[Epub] CrossRef
Combined effect of MASLD and low muscle strength on the risk of osteoporotic fractures: A UK Biobank cohort study Yongin Cho, Jong Hyun Jhee, Jong Ho Jhee, Hye-Sun Park European Journal of Endocrinology.2026; 194(3): 357. CrossRef
Hepatoprotective Effects of Combined Inulin-Glucomannan Non-Starch Polysaccharide Against Western Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease I Gede Putu Adhi Wedharga, Made Cahyani Trisna Ananda, Nadilla Faiza Richadini, Bernadette Dian Novita, Herjunianto Herjunianto, Silvia Sutandhio, Adi Pramono Hendrata, Mulya Dinata, Yu Hirata, Suryo Kuncorojakti, Hendy Wijaya, Dawei Chen, Ester Natalia D Journal of Pharmaceutical Innovation.2026;[Epub] CrossRef
Broccoli-Derived Exosome-like Nanoparticles Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulating the Gut–Liver Axis Feng Zhang, Ruolan Liu, Tongxiao Xu, Wentao Xu, Kunlun Huang, Xiaoyun He Nutrients.2026; 18(6): 953. CrossRef
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management Mary E. Rinella, Silvia Sookoian Nature Reviews Gastroenterology & Hepatology.2026; 23(6): 460. CrossRef
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease and Kidney Failure in the CKD Population Jin Kyung Kwon, Minsang Kim, Jinsun Lee, Jae-ik Oh, Jung Hun Koh, Min Woo Kang, Jeong Min Cho, Seong Geun Kim, Hyuk Huh, Sehyun Jung, Semin Cho, Soojin Lee, Eunjeong Kang, Yaerim Kim, Dong Ki Kim, Kyungdo Han, Sehoon Park Kidney International Reports.2026; 11(5): 106414. CrossRef
Cytoglobin in Hepatic Stellate Cells Plays Anti-Fibrotic Role in Chronic Liver Injury Norifumi Kawada Antioxidants.2026; 15(3): 383. CrossRef
Capabilities of magnetic resonance imaging in quantitative assessment hepatic steatosis in patients with different body mass index Yu. N. Savchenkov, G. E. Trufanov, V. A. Fokin, E. A. Ionova, T. A. Anosova, A. V. Anisonyan, E. S. Sbikina, O. V. Bodrova Medical alphabet.2026; (4): 40. CrossRef
MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Qin-Fen Chen, Michael D. Shapiro, Yuxing Dong, Ki-Chul Sung, Gregory Y. H. Lip, Jeffrey V. Lazarus, Ming-Hua Zheng Science China Life Sciences.2026; 69(6): 1950. CrossRef
Frailty, cardiovascular health, and the risk of mortality and extrahepatic diseases in patients with metabolic dysfunction-associated steatotic liver disease Jie Li, Jiang Li, Xiaoqin Xu, Ningjian Wang, Bin Wang, Yingli Lu Maturitas.2026; 208: 108917. CrossRef
Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study Yue Li, Zixian Li, Siyu Wu, Ling Cao, Beibei Qian, Junxian Tao, Zhimin Qian, Li Xie, Xiaoli Cai, Xiaofang Sun, Ying Li, Zhenwen Zhang, Caifeng Yan, Dunmin She BMC Endocrine Disorders.2026;[Epub] CrossRef
Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights Marina Idalia Rojo-López, Julia Niño-Narvión, Maria Antentas, Berta Fernández-Camins, Elizabeth Martínez-Rojo, Maria Poca, María Antonia Martínez-Sánchez, Bruno Ramos-Molina, Joana Rossell, Didac Mauricio, Josep Julve Nutrients.2026; 18(6): 996. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease James M. Paik, Linda Henry, Khalid AlNaamani, Ariana Nader, Maria Stepanova, Mei-Hsuan Lee, Ming-Lung Yu, Zobair M. Younossi Clinics in Liver Disease.2026; 30(2): 241. CrossRef
Assessing the Relationship Between Steatotic Liver Disease and Barrett’s Esophagus: A Cross-Sectional Analysis of 5507 Screening Participants Nikolaus Götz, Andreas Völkerer, Hannah Hofer, Sarah Wernly, Franz Singhartinger, Ewald Wöll, Elmar Aigner, Maria Flamm, Christian Datz, Bernhard Wernly Zeitschrift für Gastroenterologie.2026; 64(05): 470. CrossRef
Prevotella‐Derived Butyrate Inhibits CD8+ T‐Cell Glycolysis via AKT/mTOR Signalling to Alleviate MASH Feixiang Xiong, Fengna Yan, Yuyong Jiang, Xiaomin Ji, Tong Wu, Yang Zhou, Xuejie Zhang, Dandan Chen, Yixin Hou Liver International.2026;[Epub] CrossRef
CT-assessed abdominal visceral adiposity and MASLD: a sex-stratified cross-sectional analysis Linying Xu, Ting Chen, Yitian Xie, Xueyu Xiang, Yupeng Liu, Chongyong Xu, Shuran Wang Frontiers in Nutrition.2026;[Epub] CrossRef
MetALD at the crossroads of metabolic and alcohol-related liver disease Gustavo Ayares, Luis Antonio Díaz, Juan Pablo Arab, Marco Arrese Trends in Endocrinology & Metabolism.2026; 37(9): 815. CrossRef
Placebo-associated changes in MRI-PDFF and metabolic parameters in MASLD patients from phase Ib/IIa clinical trials: implications for early-phase trial design and translational endpoint interpretation Mengdi Lu, Hong Zhang, Xiaoxue Zhu, Jia Xu, Lin Xiang, Yue Hu, Jixuan Sun, Jiajia Mai, Yanhua Ding Frontiers in Pharmacology.2026;[Epub] CrossRef
Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease Aryoung Kim, Danbee Kang, Sung Chul Choi, Dong Hyun Sinn, Hye Ryoun Jang, Geum-Youn Gwak The Journal of nutrition, health and aging.2026; 30(5): 100827. CrossRef
Multi-omics integration reveals ANXA6-high γδ T cell–endothelial communication as a potential link between periodontitis and MASLD Zhongxuan Zhang, Zihan Ma, Ruidong Zhang, Min Ye, Zhongyu Shi, Miao Yu, Lingling Ou npj Systems Biology and Applications.2026;[Epub] CrossRef
Creatinine clearance rate predicts all-cause and cardiovascular mortality in patients with MASLD: a Shanghai cohort study Yingqi Hou, Yanqiu Huang, Chenghao Zhang, Wen Gu, Yadan Xu, Shuli Li, Jugang Wu, Jibin Liu, Honglin Liu Frontiers in Medicine.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and acute leukemias
– a literature review and future directions
Tareq Salah, Maximillian Stahl, Jan Philipp Bewersdorf Leukemia & Lymphoma.2026; 67(6): 1221. CrossRef
Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults Tina Reinson, Josh Bilson, Caroline Childs, Ryan M Buchanan, Giovanni Targher, Christopher D Byrne BMJ Medicine.2026; 5(1): e002038. CrossRef
XBP1s-Regulated GFPT1 via Facilitating O-GlcNAcylation of FASN S509 Is Involved in Arsenic-Induced MASLD through Promoting Fatty Acid Synthesis in Hepatocytes Wenjie Li, Bowen Fan, Han Li, Qiong Du, Jiaheng Lin, Yi Yang, Xiaolin Ding, Haoran Zhang, Haibo Xia, Binafsha Manzoor Syed, Cheng Cheng, Qizhan Liu Journal of Agricultural and Food Chemistry.2026; 74(14): 11814. CrossRef
Combination Training Improves Leptin Regulation, Reduces Body Fat, and Increases Skeletal Muscle Mass in Obese Females Dwi Cahyo Kartiko, Purwo Sri Rejeki, Dono Indarto, Irmantara Subagio, Sasminta Christina Yuli Hartati, Bekir Erhan Orhan, Yuni Nurwati, Adi Pranoto Physical Education Theory and Methodology.2026; 26(2): 380. CrossRef
Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH) Mirjana Grocic, Madison Nguyen, Arun J. Sanyal Diabetes, Obesity and Metabolism.2026; 28(S2): 3. CrossRef
Association of environmental chemical exposure with metabolic dysfunction-associated steatotic liver disease: a cross-sectional and network toxicology analysis Guodong Yang, Wenli He, Xin Qiu, Shuang Shen, Yifei Feng, Yi Peng, Taixin Yang, Zhaochan Wen, Peishu Li, Huili Luo, Xinyuan Wu, Ze Su, Bangde Xiang European Journal of Medical Research.2026;[Epub] CrossRef
Burden of metabolic dysfunction-associated steatotic liver disease in the Asia-Pacific region from 1990 to 2023 Xiao-Dong Zhou, Qin-Fen Chen, Giovanni Targher, Christopher D Byrne, Luca Valenti, Mark D Muthiah, Seung Up Kim, Daniel Q Huang, Masato Yoneda, Wenhao Li, Yusuf Yilmaz, Herbert Tilg, Vincent Wai-Sun Wong, Ming-Hua Zheng eGastroenterology.2026; 4(1): e100369. CrossRef
Unraveling the Mechanisms of Wuling Powder Against MASLD by Integrated Metabolomics–Gut Microbiota–Serum Pharmacochemistry Huan Yang, Yan-Mei Tang, Shao-Cong Han, Peng-Quan Wang, Yu-Xuan Tao, Hui-Qiong Yang, Min Zhang, Min Li, Jie Yu, Xing-Xin Yang Pharmaceuticals.2026; 19(4): 557. CrossRef
Endocrine disruptors reprogram hepatic metabolic and immune gene networks to promote hepatocellular carcinoma Yanggang Hong, Yi Wang, Qingyu Chen, Yirong Wang npj Gut and Liver.2026;[Epub] CrossRef
Exercise-responsive skeletal muscle genes mechanistically linked to metabolic dysfunction-associated steatotic liver disease Jia-Hui Zhang, Kang Chen, Xiao-Min Zhu, Huan Zhou, Jia-Mi Jiang, Yu-Qing Zou, Ke-Rong Liu, Le Zhang, Yun Li World Journal of Gastroenterology.2026;[Epub] CrossRef
Multimodal assessment of hepatic steatosis heterogeneity: segmental MRI-PDFF and ultrasound attenuation coefficient measurement M.M. Zhaivoronok, N.V. Deresh, I. Sporea, O.B. Dynnyk, S.V. Feysa, O.A. Pushkarenko, O.A. Fedusenko, O.V. Shcherbina, N.M. Kobyliak INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2026; 22(2): 103. CrossRef
Metabolic dysfunction-associated steatotic liver disease, biomarkers, and cardiovascular risk factors in children with excess weight Elisabeth A. Machado, Beatriz L.C. Themistocles, Jorge M.R. Teixeira, Fernanda M.G. Jannuzzi, Geísa Tomaz, Cecilia L. Oliveira, Isabel R. Madeira, Carlos Terra, Maria das Graças C. Souza, Alexandra Monteiro, Eliete Bouskela, Marise E. Marsillac, Paulo F. Jornal de Pediatria.2026; 102(3): 101534. CrossRef
Ubiquitin-Specific Protease 2 (USP2) as a Modulator of Energy Metabolism: A Review of Studies Using Animal and Cellular Models Hiroshi Kitamura, Jun Okabe, Himeka Hayashi, Tomohito Iwasaki Biomedicines.2026; 14(4): 783. CrossRef
Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim Diabetes, Obesity and Metabolism.2026; 28(6): 5240. CrossRef
Longitudinal performance of vibration controlled transient elastography in pediatric metabolic dysfunction associated steatotic liver disease Naima Diop‐West, Nicholas Denson, Ana Catalina Arce‐Clachar, Julie Bonn, Kristin Bramlage, Lisa Leesman, Rashmi D. Sahay, Emrah Gecili, Andrew T. Trout, Stavra Xanthakos, Marialena Mouzaki Journal of Pediatric Gastroenterology and Nutrition.2026; 82(6): 1366. CrossRef
LPCAT3 deficiency Drives phospholipid remodeling and mitochondrial oxidative dysfunction to accelerate MASH-HCC development Gaoxuan Shao, Chenhao Ye, Chenceng Sun, Jiashu Pan, Lu Lu, Lei Wang, Tao Wu, Zemin Lin, Guang Ji, Hanchen Xu Journal of Advanced Research.2026;[Epub] CrossRef
Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies Eleni A. Karavia, Andreas Pittaras, Ourania Andreopoulou, Aikaterini Hatziri, Amalia Makrydimitri, Dimitrios Anagnostopoulos, Patroklos Vareltzis, Kyriakos E. Kypreos Pharmaceuticals.2026; 19(4): 605. CrossRef
Studying serum immunoglobulin levels in metabolic dysfunction-associated steatotic liver disease Hazem Abosheaishaa, Emad Ahmad Awad Hussein, Shereen Abou Bakr Saleh, Mahmoud Nassar, Abdulaziz Elmaradny, Mohammed Abdelwahed, Amr Ali, Khaled Elfert, Ahmed Mohamed ElGhandour Egyptian Liver Journal.2026;[Epub] CrossRef
Association Between Periodontitis and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Cross‐Sectional Study Mizuki Saito, Yoshihiro Shimazaki, Saori Yoshii, Tetsuhito Kojima Clinical and Experimental Dental Research.2026;[Epub] CrossRef
Endoscopy for Metabolic Diseases Maria Valeria Matteo, Jana Kefah Ibrahim Hussein, Giorgio Carlino, Vincenzo Bove, Valerio Pontecorvi, Loredana Gualtieri, Martina De Siena, Mariachiara Di Vincenzo, Lorenzo Zileri Dal Verme, Daniele Salvi, Clarissa Ferrari, Cristiano Spada, Ivo Boskoski Journal of Clinical Medicine.2026; 15(8): 2832. CrossRef
Weekend warrior physical activity pattern and risk of all-cause and cardiovascular mortality among US adults with metabolic dysfunction-associated steatotic liver disease: A prospective cohort study of NHANES 2007–2018 Mengbiao Cai, Kai Jin, YuLong Wang, Jian Zhu, Changnan Xu, Yi Yang, Zhenxiang Guo Science Progress.2026;[Epub] CrossRef
Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson Diabetes, Obesity and Metabolism.2026; 28(7): 5684. CrossRef
Ferroptosis in MASLD: From molecular mechanisms to therapeutic opportunities Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Wei Xie, Qin-Fen Chen, Yuxing Dong, Fudi Wang, Daolin Tang, Ming-Hua Zheng Med.2026; 7(6): 101099. CrossRef
Toxic lipid-induced epigenetic activation of ICAM1 in liver sinusoidal endothelium regulates myeloid-driven fibro-inflammatory response in MASH Qianqian Guo, Nantawat Satthawiwat, Akitoshi Sano, Chady Meroueh, Asma Hamdi, Xin Dai, Khaled Warasnhe, Alexander M. Washington, Patrick P. Starlinger, Alex Krivonos, Sheng Cao, Enis Kostallari, Johan W. Jonker, Bart van de Sluis, Feda H. Hamdan, Samar H. Hepatology.2026;[Epub] CrossRef
Updates on paediatric MASLD: insights from an endocrine lens Natalie Segev, Marialena Mouzaki Diabetologia.2026; 69(11): 3121. CrossRef
An Integrated Nanozyme‐Exosome Platform for Multi‐Targeted Therapy of Metabolic‐Associated Steatotic Liver Disease Kun Yu, Xinwei Li, Yingying Liu, Haonan Zhang, Guojie Liu, Tuo Ji, Yuzhi Gao, Lin Wang, Yuwei Bian, Guohua Chen, Zhiwen Zhao, Feng Wang, Xiaoming Yu, Jiachen He, Xuzhu Gao Advanced Healthcare Materials.2026;[Epub] CrossRef
Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis Kiavash Semnani, Farbod Semnani, Seyed Sahab Aarabi, Shirin Esmaeili, Ehsaneh Taheri, Armita Mahdavi-Gorabi, Mohsen Rajabnia, Shirin Djalalinia, Saba Goodarzi, Amir Kasaeian, Mohammad Shadab Siddiqui, Mostafa Qorbani BMJ Open.2026; 16(4): e111933. CrossRef
Cholinesterase and the association between hepatic steatosis and liver fibrosis in patients with prior hepatitis E Ziteng Wang, Zhe Yu, Wen An, Herui Wei, Jing Luo, Mengqi Li, Lingling He, Jiali Ma, Fan Xiao, Lijuan Sun, Qi Gao, Hui Zhong, Hongshan Wei European Journal of Medical Research.2026;[Epub] CrossRef
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes Jonggi Choi, Gabby Mitchell, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung Hepatology Communications.2026;[Epub] CrossRef
Analysis of B-Scan Ultrasonography Using Neural Networks to Predict Risk of Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Josefine Stansch, Kien Vu Trung, Valentin Blank, Jakob Nikolas Kather, Moritz Herzog, Tobias Seibel, Paul-Henry Koop, Robert Haase, Thomas Berg, Johannes Wiegand, Thomas Karlas Ultrasound in Medicine & Biology.2026; 52(7): 1346. CrossRef
Hypertension in middle childhood Mirjam Močnik, Zala Hrovat, Sonja Golob Jančič, Martina Filipič, Mladen Crnobrnja, Nataša Marčun Varda BMC Pediatrics.2026;[Epub] CrossRef
Blood-based non-invasive tests show comparable accuracy in MetALD and MASLD for MRE-defined advanced fibrosis Akash Roy, Surabhi Jajodia, Shardhya Chakraborty, Shruti Keyal, Awanish Tewari, Nikhil Sonthalia, Sourish Roy, Rajat Khandelwal, Anand Kulkarni, Uday Chand Ghoshal, Rajender Reddy, Mahesh Kumar Goenka BMC Gastroenterology.2026;[Epub] CrossRef
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities Veronika A. Prikhodko, Sergey V. Okovityi Biomedicines.2026; 14(4): 909. CrossRef
Apple polyphenol extract mitigates high-fat diet induced cognitive impairment in C57BL/6 mice via a sex-dependent mechanism Jieyu Ma, Jiaxin Li, Le Wang, Jinlin Ma, Shilin Chen, Wenxue Luan, Xintong Tian, Siyuan Shang, Xinli Li Food Bioscience.2026; 80: 108892. CrossRef
Current status of research on the risk factors and pathogenesis of metabolic dysfunction-associated steatotic liver disease Dan Chen, Lingling Yan, Tong Wu, Junpeng Zhao, Xuebing Xu, Weisong Xu, Hong Zhang, Mingbing Xiao Frontiers in Endocrinology.2026;[Epub] CrossRef
Patatin-Like Phospholipase Domain-Containing Protein 3 rs2896019 and MASLD Susceptibility and Severity in Adults: A Systematic Review and Meta-Analysis of Case–Control Studies Wei-Yue Lim, Rosmawati Mohamed, Yuh-Fen Pung, Hak-Keith Leung, Rong-Xiang Ng, Shamsul Mohd Zain Metabolic Syndrome and Related Disorders.2026; 24(7): 285. CrossRef
Predictors of metabolic dysfunction-associated steatotic liver diseases (MASLD) in Vietnamese population Anh Gia Pham, An Vu-Khanh Le, Yen Thi-Hai Pham, Lanh Sy Nguyen, Huong Lan Nguyen, Nghia Chinh Quach, Thau Manh Cao, Hanh Thi Nguyen, Xuan Thanh Thai, Anh Tuan Luong, Thuy Thi Pham, Hai Duy Vu, Hai Thi-Thanh Tran, Lan Thi Le, Hai Vu, Giang Binh Tran, Hung Scientific Reports.2026;[Epub] CrossRef
Lactational Western‐Style Fat Exposure in Mice Programs Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) in Male Offspring Amy Y. Zhao, Haijing Sun, Leyi Yan, Oyewale Shiyanbola, Dave Bridges, Brigid Gregg Molecular Nutrition & Food Research.2026;[Epub] CrossRef
Monocyte reprogramming and trained immunity: Linking metabolism to inflammation in non-alcoholic fatty liver disease Stanislav Kotlyarov World Journal of Hepatology.2026;[Epub] CrossRef
Exercise as a Metabolic Therapy for MASLD: Beyond Weight Loss Toward Sustainable Exercise Strategies Hee-Tae Roh, Ju-Yong Bae Medicina.2026; 62(4): 784. CrossRef
Tissue-specific roles of IGFBP2 in glucose and lipid metabolism in obesity-related metabolic diseases Xiaoyu Song, Wentao Zhong, Hao Zheng, Xinyang Ou, Dongjin Zheng, Zhuo Li Frontiers in Nutrition.2026;[Epub] CrossRef
Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study Heejoon Jang, Yeonjin Kim, Yoo Kyoung Lim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Gi-Ae Kim, Woojoo Lee, Stefano Romeo, Won Kim Clinical and Molecular Hepatology.2026; 32(2): 737. CrossRef
High-fat diet, gut dysbiosis, and oxidative stress: A synergistic triangle in metabolic dysfunction-associated steatotic liver disease pathogenesis Zi-Rui Zhang, Ling She, Yi-Rong Cao, Yuan-Wen Chen World Journal of Hepatology.2026;[Epub] CrossRef
Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease Allen Anthony Laraño, Silvia Palmisano, Deborah Bonazza, Discipio Marina, Marica Meroni, Anna Ludovica Fracanzani, Lory S Crocè, Claudio Tiribelli, Paola Dongiovanni, Natalia Rosso, Pablo Giraudi Annals of Hepatology.2026; : 102206. CrossRef
Alcohol-driven phenotypic transition in MASLD and risk of liver-related events Seohui Jang, Jihun Song, Eun Seok Kang, Sangwook Cheon, Taeho Kwak, Yihyun Kim, Seokjin Kong, Jinhyeok Choi, Minjeong Kang, Jaewon Khil, Hye Jun Kim, Jeongin Lee, Hwamin Lee, Seogsong Jeong JHEP Reports.2026; 8(7): 101866. CrossRef
Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver diseas Yueying Yang, Ying Yang, Yan Lu Clinical and Molecular Hepatology.2026; 32(2): 957. CrossRef
Editorial on “Genome-wide interaction study with body mass index identifies CYP7A1 and GIPR as genetic modulators of metabolic dysfunction-associated steatotic liver disease” Julia Kozlitina Clinical and Molecular Hepatology.2026; 32(2): 931. CrossRef
Role of MicroRNAs in Precision Hepatology Youngwoo Lee, Eunho Choi, Young-Sun Lee Journal of Digestive Cancer Research.2026; 14(1): 102. CrossRef
Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan Clinica Chimica Acta.2026; 589: 121028. CrossRef
Bupleuri Radix ameliorates MASLD induced by high-fat diet and circadian disruption in rats: Involvement of the NR1D1–SREBF1/CYP7A1 circadian–metabolic axis Shuheng Wang, Shuaidong Bai, Tianhui Zhou, Yukun Wang, Xue Bai, Yiming Wang, Junwen Ma, Xuemei Qin, Xiaoxia Gao Journal of Ethnopharmacology.2026; 367: 121770. CrossRef
Comment on “High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C” Wen-Rui Li Journal of the Formosan Medical Association.2026;[Epub] CrossRef
Calorie restriction mitigates steatotic liver disease in obese rats after bariatric surgery Yu-Ning Lin, Chin-Ying Wu, Yin-Ru Hsieh, Yi-Tung Lin, Weu Wang, Chun-Chao Chang, Shih-Yi Huang, Wei-Yu Kao Nutrition Research.2026; 151: 52. CrossRef
Fucoxanthin Ameliorates MASLD by Directly Targeting GRP78 to Restore ER Homeostasis and Activate AMPK Signaling Lin Zhang, Ruifen Zhang, Yu Wu, Binbin Chen, Chao Wang, Cheng Wang, Zhengshun Wen, Jingui Zhang, Haibin Tong, Liang Hong Food Science & Nutrition.2026;[Epub] CrossRef
Familial hypobetalipoproteinemia in pediatric patients with fatty liver: an under-recognized cause Nurit Loberman Nachum, Eyal Shteyer, Hofit Cohen, Odelia Chorin, Maya Granot, Batia Weiss Frontiers in Medicine.2026;[Epub] CrossRef
The effect of a two-week low glycaemic index, higher fibre diet versus high glycaemic index diet on body composition, ectopic lipids, inflammatory biomarkers, gastrointestinal hormones and gut microbiota in metabolic dysfunction-associated steatotic liver Amina A. Al-Awadi, Jane I. Grove, Stephen Bawden, Amrita Vijay, Ana M. Valdes, Penny Gowland, Moira A. Taylor, Guruprasad P. Aithal Clinical Nutrition ESPEN.2026; 73: 103306. CrossRef
Di(2-ethylhexyl) phthalate exposure: Association with metabolic associated steatotic liver disease and underlying mechanisms Dapeng Yin, Yan Li, Wei Wu, Jiacheng Cheng, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li Ecotoxicology and Environmental Safety.2026; 317: 120210. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Evaluation of Factors Affecting Alpha Fetoprotein Levels in Patients With Hepatocellular Carcinoma in a Large Multicenter Cohort Nicole Shu Ying Tang, Ethan Kai Jun Tham, Nicholas Syn, Ken Liu, Gang Chen, Beom Kyung Kim, Mark Muthiah, Takumi Kawaguchi, Asahiro Morishita, Sung Won Lee, Karn Wijarnpreecha, Hirokazu Takahashi, Daniel Q. Huang Journal of Gastroenterology and Hepatology.2026; 41(6): 1883. CrossRef
Integrated bioinformatics analysis and experimental validation of SRF as a potential senescence biomarker in MASLD Mengyue Li, Chang Gao, Yuhui Shi, Wenyu Peng, Yuan Yin, Bin Lu, Zhang Fu Frontiers in Molecular Biosciences.2026;[Epub] CrossRef
The Role of MicroRNAs in the Progression of Metabolic Dysfunction-associated Steatotic Liver Disease Jang Hyun Choi Journal of Digestive Cancer Research.2026; 14(1): 82. CrossRef
GCSH promotes MASH progression by regulating cuproptosis through the glycine–GSH metabolic pathway Xuan Fu, Yunmeng Li, Jing Chen, Baolong Yin, Mahbuba Nasrin, Rui Huo, Shuxin Tian Free Radical Biology and Medicine.2026; 252: 1. CrossRef
A Descriptive Analysis of Mediterranean Diet Meal Plans Using the Dietary Inflammatory Index, Dietary Antioxidant Index, and Dietary Lipid Indices: Implications for Dietary Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Melvin Bernardino, Claudio Tiribelli, Natalia Rosso Nutrients.2026; 18(8): 1281. CrossRef
From Genomic Instability to Epigenetic Signatures: The Evolving Landscape of Circulating Cell‐free DNA in Metabolic Dysfunction‐Associated Steatotic Liver Disease Wei‐Yue Lim, Rosmawati Mohamed, Yuh‐Fen Pung, Shamsul Mohd Zain Hepatology Research.2026; 56(6): 914. CrossRef
Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review Brittany Bromfield, Jeremy Chimene-Weiss, Gregory Gheewalla, Theodore Feldman, Emilie K. Mitten, Piero Portincasa, Gyorgy Baffy eClinicalMedicine.2026; 95: 103921. CrossRef
Concerns about the health effects of industrially produced seed oils are without scientific foundation: a scoping narrative review of the clinical and observational evidence Matthew Nagra, David M. Goldman, Martha A. Belury, Mark Messina Critical Reviews in Food Science and Nutrition.2026; 66(27): 5386. CrossRef
Neutrophils in Liver Diseases: Functions and Challenging Therapies Rui Ma, Haoran Meng, Xiutong Chen, Haiyuan Shen, Li Zuo, Hua Wang Seminars in Liver Disease.2026; 46(02): 089. CrossRef
The Degree of Liver Steatosis Is Associated with Abnormally High Serum Levels of Markers of Blood–Brain Barrier Dysfunction and Systemic Inflammation in Patients with Morbid Obesity Gabriela Hurtado-Alvarado, Karol Iliana Ávila-Soto, Marlene Monserrat Juárez, Lucía Angélica Méndez-García, Verónica Cevallos-López, Juan Antonio Peralta-Calcaneo, Marcela Esquivel-Velázquez, Antonio González-Chávez, Julio César Zavala-Castillo, Ana Alfar Medicina.2026; 62(5): 821. CrossRef
Portal Vein Thrombosis in Cirrhotic Candidates for Liver Transplantation and Its Impact on the Transplant Accessibility Simona Parisse, Flaminia Ferri, Adriano De Santis, Fabio Melandro, Mario Corona, Quirino Lai, Pierleone Lucatelli, Gianluca Mennini, Massimo Rossi, Stefano Ginanni Corradini Journal of Clinical Medicine.2026; 15(9): 3358. CrossRef
c-FLIP as a master regulator of immune homeostasis and disease mechanisms Eliana Urbini, Annalisa Adamo, Yushu Hu, Luca Giacobazzi, Silvia Dusi, Francesco De Sanctis, Carmine Carbone, Davide Gibellini, Sara Pilotto, Vincenzo Corbo, Vincenzo Bronte, Fulvia Vascotto, Stefano Ugel Cell Death & Disease.2026;[Epub] CrossRef
Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective Enrico Torre, Sergio Di Matteo, Chiara Martinotti, Giacomo Bruno, Alessandro Cabrino, Emma Fogliati, Andrea Giusti, Marco Barbieri, Luigi Bottaro, Giorgio Colombo ClinicoEconomics and Outcomes Research.2026; Volume 18: 1. CrossRef
Clinical differentiation between alcohol-associated and metabolic dysfunction-associated steatotic liver disease: a comparative case report Chang-Gue Son The Journal of Internal Korean Medicine.2026; 47(1): 70. CrossRef
Bacterial Extracellular Vesicles in Aging: Mechanisms and Therapeutic Prospects Junfei Tan, Muhammad Zubair, Lin Zhang, Likang Liu, Kangrong Li, Yihua Wang, Yongmin Yan, Wenyan Xu International Journal of Nanomedicine.2026; Volume 21: 1. CrossRef
Elevated liver fat content is independently associated with insulin resistance in people with type 1 diabetes Jonathan Mertens, Maarten Spinhoven, Rie Braspenning, Floris Vanhevel, Eveline Dirinck, Christophe De Block, Sven Francque JHEP Reports.2026; 8(8): 101887. CrossRef
Metabolic dysfunction-associated steatotic liver disease in cushing’s syndrome: a case controlled FibroScan study Tugce Apaydin, Caglayan Keklikkiran, Haluk Tarik Kani, Yusuf Yilmaz, Dilek Gogas Yavuz Journal of Endocrinological Investigation.2026; 49(8): 1871. CrossRef
Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction–Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic Individuals Tinsay A Woreta, Samer Gawrieh, Laura A Wilson, Yuchen Xin, Eduardo Vilar-Gomez, Kathleen E Corey, Richard K Sterling, Jordan E Lake, Susanna Naggie, Sonya Heath, Holly Crandall, Jennifer C Price, Rohit Loomba, Naga Chalasani, Mark S Sulkowski Open Forum Infectious Diseases.2026;[Epub] CrossRef
Development and validation of the HABIT score: a practical and robust tool to predict hepatic steatosis using HbA1c, BMI, and triglycerides in patients with unexplained elevated liver enzymes Eike Humbert, Verena Wilkens, Semjon Bugaichuk, Karoline Horvatits, Ansgar W. Lohse, Samuel Huber, Sven Pischke, Thorben Fründt Annals of Hepatology.2026; 31(2): 102218. CrossRef
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease Zobair M. Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, Khalid M. Al-Naamani, Frank Tacke, Emmanouil Tsochatzis, Javier Crespo, Mohamed El-Kassas, Fernando Bril, Marco Arrese, Cyrielle Caussy, C. Wendy Spearman, Amalia Gastaldelli, Mário Guimarães Pe Clinical Gastroenterology and Hepatology.2026; 24(9): 2333. CrossRef
Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) Roberto Vettor, Maria Letizia Petroni, Idit Dotan, Gadi Lalazar, Martin Haluzík, C. Wendy Spearman, Joel A. Dave, Faisal Abaalkhail, Salah Abusnana, Ali Alshehri, Radan Bruha, Mariann Harangi, Ahmad Jazzar, Michał Kukla, Shiva Kumar, Vaia Lambadiari, Geor Reviews in Endocrine and Metabolic Disorders.2026; 27(2): 213. CrossRef
Advances in Diagnostic and Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease Ryan Njeim, Omar Abureesh, Ali Sohail, Ryan Tam, Liliane Deeb Livers.2026; 6(3): 35. CrossRef
The role of the resveratrol-sirtuin axis in the treatment of metabolic dysfunction-associated diseases Jiale Yang, Shuping Chen, Tiantian Zeng, Yuxuan Zhang, Zhaoxin Li, Haifang Li Exploration of Endocrine and Metabolic Diseases.2026;[Epub] CrossRef
GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes Xianhua Mao, Hong Fan, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen Hepatology.2026;[Epub] CrossRef
Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease Ralf Weiskirchen, Amedeo Lonardo Expert Opinion on Therapeutic Targets.2026; 30(5): 473. CrossRef
Weight Loss-Induced Metabolic Remodeling in Metabolic dysfunction-associated steatotic liver disease: A Cohort Study Stratified by Genetic Risk J. Troisi, P. Torre, L. Schiavo, B.M. Motta, M. Lombardi, M. Festa, T. Sarcina, M. Masarone, M. Persico Clinical Nutrition.2026; 61: 106672. CrossRef
Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model Jens Bjelke Kristensen, Jacob Nøhr-Meldgaard, Susanne E. Pors, Jenny Norlin, Sanne S. Veidal, Kristian Moss Bendtsen, Kristoffer Niss, Maja W. Andersen, Lea M. Harder, Mathilde Teilmann Dalhoff, Martin Rønn Madsen, Kristoffer Voldum-Clausen, Markus Latta, American Journal of Physiology-Gastrointestinal and Liver Physiology.2026; 330(6): G659. CrossRef
Effectiveness of therapeutic strategies based on dietary patterns on cardiovascular and hepatic markers in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) ‒ A systematic review of clinical trials Valeria Antonia Rivera Marín, Camila Sanchez, Andrea Herrera-Santelices, Luisa Amanda Ramírez Araya, Edson Yáñez-Barros, Sebastian Cofré Nutrición Hospitalaria.2026;[Epub] CrossRef
Extracellular Vesicle from Chlorella vulgaris Alleviates Hepatic Fibrosis in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulation of Inflammatory Signaling Hinata Harada, Yusuke Ohsaki, Afifah Zahra Agista, Hsin-Jung Ho, Takuo Hirose, Kotaro Yamada, Mutsumi Furukawa, Tomonori Nochi, Wan-Chun Chiu, Ya-Ling Chen, Chiu-Li Yeh, Suh-Ching Yang, Takefumi Mori, Hitoshi Shirakawa International Journal of Molecular Sciences.2026; 27(9): 3735. CrossRef
Nitric oxide pathway: Emerging therapeutic strategies for MASLD Yanling Zhang, Ying Zhang, Hongjin Chen, Fangfang Qi Pathology - Research and Practice.2026; 284: 156516. CrossRef
Distinct Roles of Myeloid‐ and Hepatocyte‐PLA2G6 Deletion in Mice With Metabolic Dysfunction‐Associated Steatotic Liver Disease Gang Li, Simone Staffer, Sabine Tuma‐Kellner, Uta Merle, Walee Chamulitrat Liver International.2026;[Epub] CrossRef
MASLD Management in Spain: A Nationwide Survey of Gastroenterologists Highlighting Gaps in Risk Assessment and Primary Care Coordination Carolina Jiménez-González, Paula Argos Vélez, Lorena Cayón, Ana Belén García-Garrido, Noelia Fontanillas Garmilla, Antonio Cuadrado, Paula Iruzubieta, Javier Crespo Journal of Clinical Medicine.2026; 15(9): 3259. CrossRef
Predicting MASLD in People With HIV Using Anthropometric Measures: A Multicenter Cross-Sectional Study Jihad Slim, Murad Qirem, Paul Bellafiore, Bereket Tewoldemedhin, Tala B Shahin, Kevin Leyden, Ronald Poblete, Sandhya Nagarakanti, Hugo Vargas Open Forum Infectious Diseases.2026;[Epub] CrossRef
Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia Soo Lim, Hui Zhou, Wataru Ogawa Journal of Obesity & Metabolic Syndrome.2026; 35(2): 130. CrossRef
The gut-liver/bile axis: Gut microbiota and bacterial extracellular vesicles remodeling hepatobiliary pathogenesis Siyang Hu, Chunhui He, Kunqi Sun, Hongye Zhou, Xueyan Liu, Hao Wang, Sen Li, Haifeng Yu, Ke Xu, Wei Li iScience.2026; 29(5): 115623. CrossRef
Effects of Animal-Based Foods on Metabolic Outcomes in Adults with MASLD and Comorbidities: A Systematic Review of Randomized Controlled Trials (2020–2026) Joanna Michalina Jurek, Katarzyna Zablocka-Slowinska, Joanna Pieczynska, Anna Lipert, Helena Clavero-Mestres, Teresa Auguet Nutrients.2026; 18(10): 1508. CrossRef
Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications Yinan Zhao, Ziyan Li, Guoying Yu Frontiers in Nutrition.2026;[Epub] CrossRef
Impact of modern glucose-lowering therapies on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes A.M. Urbanovych, N.Ya. Sidelnyk, O.Z. Lishchuk INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2026; 22(3): 340. CrossRef
The Economic Burden of Metabolic Dysfunction‐Associated Steatohepatitis (MASH) With Cirrhosis: A Systematic Review Jeffrey V. Lazarus, Caroline Freeman, Hannes Hagström, Mazen Noureddin, Riku Ota, Mary E. Rinella, Giada Sebastiani, Fotis Tefos, Zobair M. Younossi Liver International Communications.2026;[Epub] CrossRef
Evolving B-mode ultrasound-based techniques for assessing metabolic dysfunction-associated steatotic liver disease: Now and beyond Walaa Abdelhamed, Mohamed Elbadry, Mohamed El-Kassas Liver Research.2026; 10(2): 109. CrossRef
Comparative effectiveness of tirzepatide versus thiazolidinedione in adults with MASLD: a propensity score-matched cohort study Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai Frontiers in Pharmacology.2026;[Epub] CrossRef
Association between metabolic dysfunction-associated steatotic liver disease and overactive bladder: A cross-sectional study Shengqi Zheng, Xu Cui, Longyao Xu, Hong Chen, Liang Zheng, Chaoming Zhou Continence.2026; 18: 102466. CrossRef
Tumor microenvironment and metabolic reprogramming in MASLD-related hepatocellular carcinoma Vanilla X. Zhang, Tiffany C.-Y. Yu, Yu M. Tsui, Irene O.-L. Ng Trends in Molecular Medicine.2026;[Epub] CrossRef
Trends of metabolic dysfunction-associated steatotic liver disease in Mexico, 1990–2023: insights from the Global Burden of disease study Israel Rico-Alba, Alberto Retana-Guzmán, Marcela Agudelo-Botero, Claudio Alberto Dávila-Cervantes Annals of Hepatology.2026; 31(2): 102224. CrossRef
Cross‐Vendor Validation of Proton Density Fat Fraction and T1 Mapping Using a Combined Proton Density Fat Fraction—T1 Phantom Jitka Starekova, Sebastian Weingärtner, David R. Rutkowski, Garrett C. Fullerton, Won C. Bae, Hung P. Do, Ananth J. Madhuranthakam, Vadim Malis, Sheng Qing Lin, Suraj D. Serai, Takeshi Yokoo, Scott B. Reeder, Jean H. Brittain, Diego Hernando Journal of Magnetic Resonance Imaging.2026; 64(2): 482. CrossRef
ПСИХОЛОГІЧНИЙ СТАН ПАЦІЄНТІВ ЗІ СТЕАТОТИЧНОЮ ХВОРОБОЮ ПЕЧІНКИ, АСОЦІЙОВАНОЮ З МЕТАБОЛІЧНОЮ ДИСФУНКЦІЄЮ, ЗА УМОВ ПОЄДНАННЯ З ГІПЕРУРИКЕМІЄЮ: ПІЛОТНЕ ОДНОЦЕНТРОВЕ КРОС-СЕКЦІЙНЕ ДОСЛІДЖЕННЯ Ігор Свінціцький , Валерія Каташинська Actual Problems of Nephrology.2026; (36-37): 26. CrossRef
Natural Product Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Targeted Mitochondrial Quality Control Jing Liu, Fuxing Li, Qianru Zeng, Wenxiao Hu, Le Yang, Shengping Luo, Fang Lv, Dingxiang Li, Yihui Deng Drug Design, Development and Therapy.2026; Volume 20: 1. CrossRef
The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe? Shang-Chin Huang, Tai-Chung Tseng Gut and Liver.2026; 20(3): 350. CrossRef
KCMF1 promotes MASLD progression via K48-linked ubiquitination and degradation of AMPKα Min Tang, Yunqin Ma, Jiaqi Wang, Han Cao, Shuangshuang Yao, Xiaohui Wei, Yijiong Tan, Hua Yang, Yi Lin, Bin Hu, Yang Yu, Jiaying Yang, Yufan Wang, Xingdong Zheng, Xiaofang Tang, Fang Liu, Yongde Peng, Nengguang Fan Metabolism.2026; 182: 156651. CrossRef
Liver Disease Diagnosis: Fuzzy c-means and Scoring Ranking Approach Gabriel A. Leite, Beatriz Flamia Azevedo, Sofia Ribeiro Ferreira, Maria F. Pacheco, Florbela P. Fernandes, Ana I. Pereira SN Computer Science.2026;[Epub] CrossRef
Mitochondrial Dysfunction in MASLD: Evidence in Dietary Models and Potential Therapeutic Interventions Elda Cristina Villaseñor-Tapia, Edgar Rubén Mendieta-Condado, David Alejandro Curiel-Pedraza, Edwin Estefan Reza-Zaldívar, Ana Laura Márquez-Aguirre, Venkata Ramireddy Narala Biochemistry Research International.2026;[Epub] CrossRef
Protocol for volumetric quantification of intrahepatic triglyceride content in adults with obesity Alba Camacho-Cardenosa, Antonio Clavero-Jimeno, Alejandro López-Vázquez, Mara Concepción, José L. Martín-Rodríguez, Idoia Labayen, Jonatan R. Ruiz, Rafael Cabeza STAR Protocols.2026; 7(2): 104585. CrossRef
Gut-liver metabolic and enterohormonal remodeling drives progression from metabolic dysfunction-associated steatotic liver disease to steatohepatitis Jaclyn A. Rivas, Alexandria C. Murphy, Praveena Prasad, Mahmoud S. Yahia, Siem S. Goitom, Aaron S. Romero, Crystal Madera Enriquez, Brianna B. Maes, Prithvi R. Akepati, Marcus A. Garcia, Fredine T. Lauer, Rama R. Gullapalli, Kristen M. Gonzales, Jessica M Metabolism.2026; 181: 156652. CrossRef
Post-Translational Modification Networks in Ferroptosis: Orchestrating Defense, Drug Resistance, and Therapeutic Opportunities in Hepatocellular Carcinoma Jie Chen, Lingling Li, Sufang Fang, Haitao Zhou Journal of Hepatocellular Carcinoma.2026; Volume 13: 1. CrossRef
Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD Elda Cristina Villaseñor-Tapia, Adriana Franco-Acevedo, Rebeca Rosas-Campos, Juan Armendariz-Borunda Pharmaceutics.2026; 18(5): 584. CrossRef
Improving Care Quality for Metabolic Dysfunction-associated Steatotic Liver Disease Through a Structured Yogic Intervention: Protocol for a Randomised Controlled Trial Gautam Panwar, Garima Singh, Kanchan Joshi, Sanjay Gupta, Kuldeep Singh, Vikas Upadhyay Annals of Neurosciences.2026;[Epub] CrossRef
The Evolution of MASLD Management: From Revised Nomenclature to Disease-Modifying Therapies Karolina Kornatowska, Szymon Kopciał, Mateusz Wiekiera, Adrianna Wiekiera, Paweł Budzik, Mateusz Tyniec, Kamal Morshed Gastroenterology Insights.2026; 17(2): 33. CrossRef
Metabolomics-Enhanced Liquid Biopsy Identifies Early Heptocellular Injury in Females with MetALD Anika Volkmar, Gregor Mattert, Florian Deisinger, Kornelius Schulze, Asmus Heumann, Werner Dammermann, Selina Strathmeyer, Steffen Heelemann, Thomas Kalinski, Stefan Lüth, Janine Kah International Journal of Molecular Sciences.2026; 27(11): 4695. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Profile, Phenotypes, and Risk Stratification. A Narrative Review Zalina Yuryevna Sozaeva, Marina Vsevolodovna Atayeva, Elizaveta Olegovna Salatova, Irina Kazbekovna Alikova, Alexandra Evgenievna Dolgaya, Amin Gasaevich Magomedov, Kamilla Ramisovna Hafsi, Nur-Mukhamed Aslanovich Shomakhov, Elena Mukhadinovna Pshukova, Y Journal of Biochemical Technology.2026; 17(2): 30. CrossRef
X-chromosome gene dosage shapes MASLD beyond sex hormones Mohamad Jamalinia, Giovanni Targher, Amedeo Lonardo Trends in Endocrinology & Metabolism.2026;[Epub] CrossRef
Mediating roles of insulin resistance and inflammatory markers between healthy sleep scores and metabolic dysfunction-associated steatotic liver disease Qing-Tao Yu, Yun-Ying Lin, Zi-Hao Gui, Hua-Lin Duan, Jun-Jie Yang, Yuan Meng, Xue-Tao Peng, Lan Liu, Heng Wan, Jie Shen World Journal of Gastroenterology.2026;[Epub] CrossRef
Acute Effects of Cannabinoid Combination Therapies in a Western Diet-Induced Murine Model of Metabolic Liver Disease Jerome Lian, Mohan Patil, Ricky R. Lareu, Marco Falasca International Journal of Molecular Sciences.2026; 27(11): 4872. CrossRef
Dantrolene attenuates steatohepatitis and liver fibrosis by suppressing Ca2+ dysregulation Juri Sakamoto, Takeshi Yamamoto, Minami Sato, Ayano Sasakura, Yoshihide Nakamura, Naoomi Tominaga, Masako Inamitsu, Naoki Yamamoto, Taro Takami, Motoaki Sano Biochemical and Biophysical Research Communications.2026; 827: 154042. CrossRef
Epigenetic antifibrotic effect of expression of long noncoding RNAs lncR-p21, MEG3, H19 on the development of fibrosis in metabolic dysfunction-associated steatotic liver disease (systematic review and meta-analysis) A.E. Abaturov, A.O. Nikulina GASTROENTEROLOGY.2026; 60(2): 133. CrossRef
Metabolic dysfunction–associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart–liver metabolic axis perspective Xuebi Wu, Yongxin Ma, Xueshi Yin, Jianping Liu, Yongheng Zhang Frontiers in Pharmacology.2026;[Epub] CrossRef
Impact of severe hepatic iron overload on MR and ultrasound time-harmonic elastography Steffen P. Häseli, Jakob Schattenfroh, Tom Meyer, Paul Spiesecke, Tobias Puengel, Florian Roßner, Bernhard Gebauer, Raphael Mohr, Münevver Demir, Frank Tacke, Ingolf Sack, Rolf Reiter Journal of the Mechanical Behavior of Biomedical Materials.2026; 180: 107480. CrossRef
Determination of ultrasound diagnostic thresholds for detecting early hepatic steatosis in children: a comparative evaluation of different ultrasound systems using MRI-PDFF as the reference standard O.A. Pushkarenko, M.M. Zhaivoronok, O.B. Dynnyk, O.T. Yemets, N.V. Deresh, V.V. Kaliy GASTROENTEROLOGY.2026; 60(2): 90. CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026; 17(7): e01042. CrossRef
Four new amide alkaloids from the fruits of
Piper longum
and their anti-adipogenic activities
Xue-Ting Cui, Ling-Yu Li, Jia Liu, Hui-Hui Wang, Tao Zhang, Zhong-Mei Zou Journal of Asian Natural Products Research.2026; : 1. CrossRef
Upcycling Agricultural By‐Products: RNA‐Seq‐Based Elucidation of Body Weight‐Independent Hepatoprotective Mechanisms of Cucumis melo var. makuwa Leaf Extract in Diet‐Induced Obese Mice Ji Young Hwang, Ji Yun Van, Hyeon Hak Jeong, Yerin Seong, Seokmin Lee, Jaeseong Seo, Bo‐Mi Ryu, Seungjun Lee, Suhyeon Baek, Sanggil Lee, Won‐Kyo Jung, Jae‐Il Kim, Bonggi Lee eFood.2026;[Epub] CrossRef
Machine learning-based prediction of hepatocellular carcinoma risk in steatotic liver disease: A nationwide cohort study Log Young Kim, Ji Soo Lee, Jeong-Ju Yoo, Eun Ju Cho, Sang Gyune Kim, Young Seok Kim, Tyng-Yuan Jang PLOS One.2026; 21(5): e0349593. CrossRef
Rendimiento del puntaje MAFLD-S para el tamizaje no invasivo de esteatosis hepática metabólica en el primer nivel de atención J.A. Torres-Díaz, A. Olivas-Martinez, J.A. Ruiz-Manriquez, A. Kammar-García, L.C. Chávez-García, L.F. Uscanga-Domínguez, S.E. Martínez-Vázquez Revista de Gastroenterología de México.2026;[Epub] CrossRef
Impact of liver and pancreatic steatosis on behavioral responses in rats under experimental conditions and after cessation of combined exposure to steatogenic factors A.M. Halinska, O.A. Maltseva, O.O. Halinskyi GASTROENTEROLOGY.2026; 60(2): 82. CrossRef
Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease Roberta Chianetta, Lydia Giannitrapani, Alessio Giuseppe Lipari, Assunta Brunone, Claudia Cannizzo, Roberto Citarrella, Maurizio Soresi, Antonio Liguori, Nadia Panera, Filomena Morisco, Luca Miele, Anna Licata Biomolecules.2026; 16(6): 797. CrossRef
EASL position paper on preclinical models of steatotic liver disease Suchira Gallage, Rui E. Castro, Jennifer Estall, Ira Tabas, Quentin M. Anstee, Dina G. Tiniakos, Gyongyi Szabo, Jun Yu, Chantal Desdouets, Frank Tacke, Fiona Oakley, Mathias Heikenwalder Journal of Hepatology.2026; 85(2): 345. CrossRef
Liver Endothelial Heg1 Signal Limits Hepatic Steatosis via Wnt-Mediated Fatty Acid Oxidation in Hepatocytes Xiyun Rao, Qianqian Zhao, Jinbiao Chen, Min Zheng, Mingyue Xing, Yu Feng, Jiayuan Chen, Shichao Zhu, Zhiming Han, Geoffrey W. McCaughan, Xiangjian Zheng Cellular and Molecular Gastroenterology and Hepatology.2026; 20(9): 101807. CrossRef
Risk factors for atherosclerotic plaque formation in MASLD patients: insights from cross-sectional and Mendelian randomization analyses Wei-hao Peng, Jing Zhang, Yu-hua Ruan, Yan Li, Ye Liu, Ming-jia Dai, Jing-kun Jin, Xue-bin Yan, Fang Ji Nutrition, Metabolism and Cardiovascular Diseases.2026; : 104815. CrossRef
Structural characterization of the pectic polysaccharide from corn silk and its protective mechanism against MASLD via regulation of the gut-liver axis Haichao Wang, Jiajing Yan, Haolin Jia, Xiaoyan Li, Bingxuan Li, Xuefang Zhang, Shujun Wang, Zheng Li, Yuhong Liu, Yifei Bian Carbohydrate Polymers.2026; 388: 125510. CrossRef
Association of Hepatic Steatosis Burden With Microalbuminuria in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study Komal S Jog, Harini Bopaiah, Guru Yogendra Muthyal, Sai Deepika R Cureus.2026;[Epub] CrossRef
Renal Dysfunction Across Etiologies of Chronic Liver Disease: A Cross-Sectional Study From a Tertiary Care Center Asha Saranya Rapeti, Rakesh Pilla, Gayathri Chouthai, Abhinav Maharaj Thota, Mrinal Shashidhar, Chaithanya Shanthi Vanamada Cureus.2026;[Epub] CrossRef
Steatotic liver disease in Latin America: current views and perspectives Francisco Idalsoaga, Luis Antonio Díaz, Francisco Barrera, Adrian Gadano, Claudia P. Oliveira, Juan Pablo Arab, Marco Arrese Nature Reviews Gastroenterology & Hepatology.2026; 23(9): 722. CrossRef
Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies Ioannis Katsaros, Dimitrios Schizas Life.2026; 16(6): 915. CrossRef
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603. CrossRef
Post-transplant MASLD: a risk-stratified approach to assessment and personalized management He-Yu Huang, Zhong-Qi Fan, Guo-Yue Lv Frontiers in Medicine.2026;[Epub] CrossRef
The efficacy of carbohydrate-restricted diets on reducing visceral and liver fat in individuals with overweight and obesity: a systematic review and pairwise and network meta-analyses Mousa Khalafi, Aref Habibi Maleki, Mahsa Ehsanifar, Maryam Aghaeinejad, Mohammad Hossein Sakhaei, Sara K. Rosenkranz, Michael E. Symonds, Fatemeh Ramezani Critical Reviews in Food Science and Nutrition.2026; 66(30): 6387. CrossRef
Synbiotics and antioxidants synergistically attenuate disease progression in metabolic dysfunction-associated steatotic liver disease Zhilu Xu, Wenyi Zhu, Qiyun Xia, Wenli Huang, Yuanyuan Chi, Haoyu Qi, Oi Yee Pessy Chan, Jessica YL Ching, Francis KL Chan, Nor Norman Chan, Siew C. Ng Biomedicine & Pharmacotherapy.2026; 201: 119656. CrossRef
Integrative Multi‐Omics Analysis Elucidates the Progressive Disease Landscape and Reveals Dynamic Protein Biomarkers for MASLD Surveillance Kejun Liu, Bozhi Zhang, Yezhen Tang, Zhenyao Tan, Yang Bu, Yongxue Lv The FASEB Journal.2026;[Epub] CrossRef
A novel serum metabolite classifier for identifying Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) integrating metabolomics and machine learning Binghui Li, Yiru Zhang, Ziyang Li, Zhiyang Chen, Zhe Guo, Weimin Wu, Li Tan, Lini Dong, Xiangyu Zhang, Xing Lyu, Min Hu, Qichen Long BMC Gastroenterology.2026;[Epub] CrossRef
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal, Ant Nature Medicine.2026; 32(8): 2948. CrossRef
Bisphenol S induces hepatic steatosis and insulin resistance through AMPK inhibition and endoplasmic reticulum stress Vinicius Sepúlveda-Fragoso, Emanuelle Barreto-Reis, Thais de Souza Carvalho-Laureano, Milena Barcza Stockler-Pinto, Eliete Dalla Corte Frantz, Denise Pires de Carvalho, Xavier Palomer, Emma Barroso, Manuel Vázquez-Carrera, Leandro Miranda-Alves, D'Angelo Food and Chemical Toxicology.2026; 215: 116222. CrossRef
The association between six heavy metal levels and the risk of liver fibrosis in women without gestational diabetes mellitus Juan Yu, Li Wang, Shu-lan Zhu, Min Xiao, Hai-xing Huang, Yan-hong Shao, Qi-chen Bao, Miao-miao Ma, Ying-ying Chen The American Journal of the Medical Sciences.2026; 372(3): 250. CrossRef
Strengthening Dietary Antioxidant Capacity in Primary Care: A Low-Cost Strategy to Prevent Metabolic Syndrome and MASLD in Iran M Sepehrinia, A Nikparast, J Mirzay Razzaz, Reza Homayounfar Iranian Journal of Nutrition Sciences and Food Technology.2026; 20(5): 83. CrossRef
Diversity in metabolic dysfunction-associated steatotic liver disease: a framework for precision medicine Donghyun Ko, Jordan Low, Peter Low, Damien Chua, Yock Young Dan, Vincent Chen, Jonathan A. Fallowfield, Timothy J. Kendall, Hirokazu Takahashi, Cheng Han Ng, Nicholas Syn, Mark Muthiah npj Gut and Liver.2026;[Epub] CrossRef
Shall You Get an Invasive Examination? An AI-Driven Risk Stratification Model for Individuals with Suboptimal Health Status Chia-Yu Lai, Jen Yu, Chieh Lee, Guan-Yu Wang, Shania Andea Perdana, Tsung-Hsing Chen, Ta-Sen Yeh Service Science.2026; 18(3): 177. CrossRef
Incorporating Insulin Resistance Biomarkers into Machine Learning Models Enhances Diagnostic Accuracy for Metabolic Dysfunction–Associated Steatotic Liver Disease Jingyuan Nie, Jing Zhou, Yuanjia Hu, Changhong Zhang, Pingping Yu, Xun Lei Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1. CrossRef
Exposure to Per- and Polyfluoroalkyl Substances and the Risk of Sarcopenia: The Mediating Role of Serum Albumin Mingkun Sun, Chu Chu, Kun Zhao, Zhengmin Qian, Mario Schootman, Stephen McMillin, Jiaxiang Dong, Wenwen Bao, Muhammad Amjad, Haseeb Moryani, Yang Zhou, Yan Yang, Peipei Wang Toxics.2026; 14(6): 478. CrossRef
Non-alcoholic fatty liver disease and Helicobacter pylori infection: problems and solutions. A review Elena V. Onuchina Consilium Medicum.2026; 28(5): 387. CrossRef
Impact of Volatile Organic Compound Mixtures on Cardiovascular Health in Adults With Metabolic Dysfunction–Associated Fatty Liver Disease: A US Population Study Qingping Wu, Meiling Jin, Shan Liu, Yue Wu, Tarek Alshaal Indoor Air.2026;[Epub] CrossRef
A Single-Food Substitution Strategy (SFSS) Improves Fat Mass and Metabolic Parameters in MASLD: A Prospective Pilot Study Nicole Cerabino, Caterina Bonfiglio, Leonilde Bonfrate, Rosanna Donvito, Pasqua Letizia Pesole, Dolores Stabile, Endrit Shahini, Gianluigi Giannelli Nutrients.2026; 18(12): 1873. CrossRef
Limited Agreement of Different Elastography Techniques in Assessing Liver Stiffness in Postmenopausal Women with Early-Stage Metabolic Dysfunction-Associated Steatotic Liver Disease Ilias D. Vachliotis, Vasileios Rafailidis, Athanasios D. Anastasilakis, Nikoletta Pyrrou, Stergios A. Polyzos Livers.2026; 6(3): 53. CrossRef
Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease Kuo Fang, Ji Miao, Guobin Song Frontiers in Endocrinology.2026;[Epub] CrossRef
Edible extracellular vesicle-like particles from Exocarpium Citri Grandis: A natural nanoplatform for oral treatment of metabolic dysfunction-associated steatotic liver disease Jingxiu Zhao, Tao Huang, Chengshi Fu, Yingjie Xiong, Anran Gao, Kui Wang, Yujia Song, Zanxiang Luo, Xiangyun Teng, Wei Zhao, Jianhua Xu International Journal of Biological Macromolecules.2026; 372: 152952. CrossRef
Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction–associated steatotic liver disease Rishi Chowdhary, Manjeet Kumar Goyal, Megh Patel, Rahul Chowdhary, Kirti Arora, Varun Mehta, Akash Batta, Omesh Goyal, Ashita Rukmini Vuthaluru Frontiers in Epidemiology.2026;[Epub] CrossRef
Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review Karol P. Sagan, Zuzanna Lipiec-Rzepecka, Martyna Patalong-Wójcik, Michał P. Wasilewicz, Elżbieta Andrysiak-Mamos, Anhelli Syrenicz Journal of Endocrinological Investigation.2026;[Epub] CrossRef
Cardiovascular risk factors in Greece: looking beyond the classics. A narrative review George Michas, Grigorios Trikas, Athanasios Trikas Hellenic Journal of Cardiology.2026;[Epub] CrossRef
Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus Ying Zhao, Zhaoyue Li, Tian Yu, Yan Yang, Tingting Du BMJ Open Diabetes Research & Care.2026; 14(3): e005841. CrossRef
Prevalence and Predictors of MASLD and Fibrosis in an Urban Outpatient Setting: A Cross-Sectional Study Nicolás Ortiz-López, Daniela Simian, Máximo Cattaneo, Katherine Rojas, Daniel Durán, Martina Contreras, Diego Lizama, María Fernanda Eyssautier, Camila Meza, Catalina Molina, Gerardo Jara, Jaime Poniachik Journal of Clinical Medicine.2026; 15(12): 4533. CrossRef
Mortality trends in diabetes with proxy-defined steatotic liver disease in the United States, 1999–2023 Hongzhou Liu, Ru Wang, Liqin Cui, Linlin Wang, Jia Liu, Yangfan Du, Song Dong, Kaide Xia Frontiers in Endocrinology.2026;[Epub] CrossRef
Nanoformulations for obesity-driven MASLD and MASH: Cell-specific hepatic drug delivery, comorbidity outcomes, and translational perspectives Polu Picheswara Rao Obesity Medicine.2026; 62: 100720. CrossRef
Fatty acid‑activated proton transporter SR4 prevents hepatic steatosis and metabolic alterations in diabetic mice by improving mitochondria function, energy balance and oxidative stress James Figarola, Jyotsana Singhal, Sharad Singhal Experimental and Therapeutic Medicine.2026; 32(1): 1. CrossRef
Non-Invasive Tests in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Diagnosis to Treatment Monitoring Han Ah Lee, Young Youn Cho, Hyung Joon Kim Clinical Ultrasound.2026; 11(1): 1. CrossRef
Selenoprotein P deficiency in MASLD: association with insulin resistance and liver fibrosis: a prospective case-control study Mona A Hegazy, Samar Saad Mohamed, Eman H Saad, Ahmed Abdelghani, Dalia Abd el Fattah, Mohamed Ahmed Elsayed Mekki, Mona Fathy, Nora Hassan, Omar Ashoush BMC Gastroenterology.2026;[Epub] CrossRef
MASLD and sarcopenia research (2012–2025): a multi-database bibliometric analysis Keyan Gao, Liwen Xun, Shalei Hao, Min An, Lingfeng Zuo, Jiayu Wang, Ying Wang, Junhua He Frontiers in Nutrition.2026;[Epub] CrossRef
Integrating UHPLC-Q-TOF/MS and multi-omics to elucidate the regulatory mechanisms of Xiong's Shiwei Wendan decoction in MASLD Miao Jiang, Qiu Wu, Rong Yu, Zehua Zhang, Ge Wen, Yuan Zhong, Zhoujin Tan, Zhijian Li, Xuejiao Xie Journal of Chromatography B.2026; 1281: 125181. CrossRef
Korean red ginseng saponins ameliorate metabolic dysfunction-associated steatohepatitis in mice by inhibiting caspase-11 and NLRP3 inflammasomes Eojin Kim, Hee Ryeong Lim, Deok-Hyeong Choi, Young-Su Yi Journal of Ginseng Research.2026; 50(5): 101075. CrossRef
Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation System Naim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, Eric Lawitz, Edward Mena, Nadege T. Gunn, Khurram Jamil, Seth Zuckerman, Stephen A. Harrison, Naga Chalasani Gastro Hep Advances.2026; 5(8): 101004. CrossRef
Integrating the Fatty Liver Index into Primary Care: A Low-Cost Strategy for Early Identification of Chronic Kidney Disease Risk in Iran S Bazmi, M Farjam, J Mirzay Razzaz, matin Sepehrinia, R Homayounfar Iranian Journal of Nutrition Sciences and Food Technology.2026; 20(5): 117. CrossRef
Obesity Management in Primary Care: Clinical Approaches and Policy Implications in the Era of Incretin-Based Therapies Chung-woo Lee Korean Journal of Family Practice.2026; 16(2): 81. CrossRef
A celastrol derivative–based multifunctional nanozyme for oxidative stress scavenging and lipid metabolism regulation in metabolic dysfunction-associated steatotic liver disease Haoran Yang, Xue Cui, Kun Yu, Zhiwen Zhao, Longlong Jin, Qing Wang, Huiying Yang, Xinwei Li, Xuzhu Gao, Xianfu Wu Biomaterials Advances.2026; 188: 215027. CrossRef
Hepatoprotective effects of the branched-chain fatty acids 12-methylmyristic and 13-methylmyristic against palmitate-induced lipotoxicity Sara Rico-Chazarra, Carmen García-Melgares, Inmaculada Ros-Madrid, María A. Martínez-Sánchez, Lidia Sánchez-Alcoholado, Alba Oliva-Bolarín, Virginia E. Fernández-Ruiz, Mercedes Ferrer-Gómez, Antonio J. Ruiz-Alcaraz, Carlos M. Martínez, Adriana Mika, María Biomedicine & Pharmacotherapy.2026; 201: 119687. CrossRef
Reshaping the Future of MASLD - From Pathophysiological Mechanisms to New Therapeutic Horizons Dimitrios Patoulias, Manfredi Rizzo Current Pharmaceutical Design.2026; 32(20): 1537. CrossRef
Steatotic Shadows: The Dark Link Between Metabolic Dysfunction-associated Steatotic Liver Disease and Cancer Risk Shakta Mani Satyam, Mohamed El-Tanani, Syed Arman Rabbani, Alaa A. Aljabali, Yahia El-Tanani, Dimitrios Patoulias, Manfredi Rizzo Current Pharmaceutical Design.2026; 32(20): 1539. CrossRef
Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort Hyo Jung Cho, Seong Hee Kang, Hye Yeon Chon, SungA Bae, Eunju Kim, Seong Kyun Na, Su Jin Kim, Dooyeon Kim, Hye Ri Ahn, Huigyeong Kim, Jae Youn Cheong, Soon Koo Baik, Young Kul Jung, Soon Sun Kim, Hyung Joon Yim Journal of Korean Medical Science.2026;[Epub] CrossRef
LY6D promotes hepatic steatosis via the GRB2–AMPK–SREBP1 signaling axis Qiurong Zhao, Linxin Chen, Sha Xie, Juanjuan Meng, Wei Cui, Yao Wu, Ting Zeng, Huaming Mou, Xiaohe Luo International Journal of Obesity.2026; 50(7): 1588. CrossRef
The hepato-exposome axis: How endocrine disruptors hijack liver receptors to drive MASLD María Martín-Grau, Jorke H. Kamstra, Tuulia Hyötyläinen, Matej Orešič, You Song, Nataša Veličković, Ana Djordjevic, Danijela Vojnovic Milutinovic, Roeland F. Jackson, Robert van Vorstenbosch, Julie Massart, Antonio Vidal-Puig, Stefania Carobbio Journal of Hepatology.2026;[Epub] CrossRef
Association of metabolic dysfunction-associated steatotic liver disease trajectories with incident liver cancer: a UK Biobank cohort study Ryuk Jun Kwon, Yohwan Lim Frontiers in Endocrinology.2026;[Epub] CrossRef
Therapeutic effects and mechanisms of Artemisia species on metabolic diseases: A systematic review Naiyu Wang, Minmin Li, Mingjing Lu, Zheng Wang, Hualin Wang, Meiyue Yao, Hailing Ding, Muhammad Shahbaz, Muhammad Ijaz Medicine.2026; 105(25): e49379. CrossRef
Dysregulated Lipid Metabolism in Hepatocellular Carcinoma: Mechanisms and Therapeutic Strategies Yi Yi, Xi Liu, Xi Zhang, Yongsheng Li, Huakan Zhao MedComm – Oncology.2026;[Epub] CrossRef
Fibroblast- and Macrophage-Derived Thrombospondin-1 Orchestrates the Fibroinflammatory Niche in Metabolic Dysfunction-Associated Steatohepatitis-Induced Fibrosis Sung Woo Cho, Jung Hoon Cha, Deok Wha Seo, Mi Hyun Kwon, Kwon Yong Tak, Hee Sun Cho, Keungmo Yang, Seo Young Jung, SuHyun Hwangbo, Jae Yong Ryu, Si Hyun Bae, Pil Soo Sung Diabetes & Metabolism Journal.2026;[Epub] CrossRef
Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer Clinical Pharmacology & Therapeutics.2026;[Epub] CrossRef
Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study Hyuk Kim, Jeong-Ju Yoo, Young Chang, Jae Young Jang, Tom Ryu, Soung Won Jeong, Sang Gyune Kim, Young Seok Kim, Suyeon Park Frontiers in Medicine.2026;[Epub] CrossRef
Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review Dina Mahoon, Fares Kellany, Imad Khan, Somieya Khan, Alexandra E. Butler International Journal of Molecular Sciences.2026; 27(12): 5618. CrossRef
Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD Eva Katharina Messer, Janett Fischer, Toni Herta, Albrecht Boehlig, Madlen Matz-Soja, Adrienn Tuennemann-Tarr, Susanne Gaul, Ulrich Laufs, Thomas Berg, Pavel Strnad PLOS One.2026; 21(6): e0349666. CrossRef
Aging and Western Diet Synergistically Impair Hepatic Thyroid Hormone Signaling to Promote Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) in Mice Xinru Zhang, Madhulika Tripathi, Chun Ting Goh, Chee Seng Chan, Anita Boelen, Paul M. Yen, Brijesh Kumar Singh, Eveline Bruinstroop Aging Cell.2026;[Epub] CrossRef
Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States Ali A. Abdeen, Turgay Ayer, Aanan Biswas, Chase J. Wehrle, Sobia N. Laique, Ali Aminian Diabetes, Obesity and Metabolism.2026; 28(9): 8378. CrossRef
Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010–2023 Jialin Wu, Bonan Chen, Fuda Xie, Jiahui Hu, Mingyu Liang, Yang Lyu, Peiyao Yu, Tiejun Feng, Muyang Huang, Canbin Fang, Ka Fai To, Terry Cheuk-Fung Yip, Xingxin Wang, Wei Kang Hepatology International.2026;[Epub] CrossRef
Letter to the Editor: Steatotic liver disease in chronic hepatitis C - a marker of systemic risk, not direct-acting antiviral treatment failure Abdo Imad El Tawil, Claudia Alexandra Pontes Ivantes World Journal of Hepatology.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Inflammatory Bowel Disease: A Cross-Sectional Study of Prevalence and Associated Factors Hüseyin Aykut, Nermin Mutlu Bilgiç, Duygu Demirtaş, Süleyman Sayar, Kamil Özdil Metabolites.2026; 16(7): 450. CrossRef
Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review Jeong-Hwan Lee, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Journal of the Korean Medical Association.2026; 69(6): 492. CrossRef
Decoding the Gut–Fat–Heart Axis: From Molecular Communication Networks to Clinical Translation Strategies Zijin Sun, Wei Shao, Haojia Zhang, Kai Wang, Yongchao Liu, Rui Zhou International Journal of Molecular Sciences.2026; 27(12): 5596. CrossRef
Macrophage–neutrophil crosstalk via the Selplg–Sell–YAP axis drives NETosis and MASH-associated liver fibrosis Fulin Nian, Chen Wu, Dejun Wu, Yifan Ma, Yueying Chen, Lin Xu, Yuqin Li, Ling Dong, Wujun Xiong Hepatology.2026;[Epub] CrossRef
Diagnostic Performance of Ultrasound-Guided Attenuation Parameter (UGAP) for Hepatic Steatosis Assessment: Comparison with MRI-PDFF and Evaluation of Cohort-Derived Thresholds Dimitrios Kavvadas, Natalia-Valeria Pentara, Dimitrios Kourdakis, Aris Liakos, Emmanouil Sinakos, Panos Prassopoulos, Vasileios Rafailidis Diagnostics.2026; 16(13): 2006. CrossRef
Metabolic dysfunction associated fatty liver disease (MAFLD), metabolic dysfunction associated steatotic liver disease (MASLD), metabolic associated steatohepatitis (MASH) and obesity Davor Štimac Best Practice & Research Clinical Gastroenterology.2026; : 102116. CrossRef
Ammonia in the crosshairs: microbial targets for metabolic dysfunction–associated steatohepatitis prevention Vanessa A. Leone, Arion Kennedy Journal of Clinical Investigation.2026;[Epub] CrossRef
Fibrosis and Perinatal Features Correlated with Telomere Shortening in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease Maria Rita Braghini, Salvatore Daniele Bianco, Marzia Bianchi, Giulia Andolina, Antonella Mosca, Cristiano De Stefanis, Michela Piccione, Paola Francalanci, Clara Balsano, Luca Miele, Tommaso Mazza, Anna Alisi Life.2026; 16(7): 1068. CrossRef
The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH Caichen Zhong, Nana Boame, Semiu O. Gbadamosi, Maximilian Jara, Rakesh Luthra, Alex Salamun, Yu Hong, Abdalla Aly, Fernando Bril, Mary E. Rinella Expert Review of Pharmacoeconomics & Outcomes Research.2026; : 1. CrossRef
Editorial: Advancing immune research in chronic liver diseases through new approach methodologies Sara Massironi, Ana C. Maretti-Mira Frontiers in Immunology.2026;[Epub] CrossRef
Association of Sleep Characteristics With Suspected Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Risk Among Adults Attending a Community Health Center Tushar Prabhakar, Gahan S Jois, Satya V Singh, Bronica Saini, Adarsh Mohan Cureus.2026;[Epub] CrossRef
Vitamin E dosing study (VEDS) in patients with metabolic dysfunction–associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial Srinivasan Dasarathy, Emily P. Mitchell, Laura A. Wilson, Brent A. Neuschwander-Tetri, Naga Chalasani, Jeanne M. Clark, Anna Mae Diehl, Bilal Hameed, Rohit Loomba, Liyun Yuan, Kris V. Kowdley, Arun J. Sanyal Hepatology.2026;[Epub] CrossRef
MASH‐Related Liver Cancer Estimates Need Aetiology‐Specific Validation in the Asia‐Pacific Region Haoyang Hu Liver International.2026;[Epub] CrossRef
Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics Fuliang Li, Hongmei Li, Dulguun Juramt, Kai Kou, Frank Tacke, Lanlan Chen BMJ Open Gastroenterology.2026; 13(1): e002343. CrossRef
Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications Kenneth Tachi, Adwoa Agyei-Nkansah, Yacoba Atiase, Bright Forkuo, Victoria Akosua Agyen-Frimpong BMJ Open Gastroenterology.2026; 13(1): e002294. CrossRef
Artificial intelligence predicts sex-specific risk of metabolic dysfunction-associated steatotic liver disease Mohamad Jamalinia, Giovanni Targher, Amedeo Lonardo, Seyed Taghi Heydari, Kamran Bagheri Lankarani Biology of Sex Differences.2026;[Epub] CrossRef
A carotenoid-rich functional tomato sauce (OsteoCol®) reduces liver fat content in adults with metabolic dysfunction-associated steatotic liver disease: a randomized clinical trial Rosario Mare, Yvelise Ferro, Samantha Maurotti, Elisa Mazza, Alberto Castagna, Carmelo Pujia, Francesca Rita Noto, Angelo Galluccio, Angela Mirarchi, Giuseppe Andrea Giampà, Marta Moraca, Tiziana Montalcini, Arturo Pujia European Journal of Nutrition.2026;[Epub] CrossRef
Association of the cholesterol-HDL-glucose index with prevalent metabolic dysfunction-associated steatotic liver disease and its incremental metabolic-hepatic assessment value: a hospital-based cross-sectional study Ziqian Song, Hao Sun, Cai Wang, Yuantao Qi, Yuan Liu Frontiers in Nutrition.2026;[Epub] CrossRef
Apigenin attenuates hepatocyte senescence in metabolic dysfunction-associated steatotic liver disease by targeting the TGF-β signaling pathway Lijun Cao, Yongna Zhao Cytotechnology.2026;[Epub] CrossRef
A TyG–UHR-based machine learning model for screening lean MAFLD: development and external validation Yansong Ji, Hui Zhang, Jingjing Xia, Guilian Chen, Hong Li BioMedical Engineering OnLine.2026;[Epub] CrossRef
Intermittent fasting strategies for metabolic dysfunction-associated steatotic liver disease: A systematic review and frequentist network meta-analysis of randomized controlled trials Husam Abu Suilik, Ahmed Farid Gadelmawla, Mohamed Rifai, Moayad Alhawi, Abdellrahman Ashour, Hassan Abdalshafy, Omar Abdullah Bataineh, Hazem Rezq, Anas Bani Hani, Ismail Elkhattib, Mohamed Abuelazm Clinical Nutrition ESPEN.2026; 75: 103415. CrossRef
Non-alcoholic fatty liver disease: Modern approaches to therapy and possibilities of using tirzepatide V. V. Gorban, E. V. Gorban, P. E. Kocherga Meditsinskiy sovet = Medical Council.2026; (8): 126. CrossRef
Progression of Metabolic Dysfunction–Associated Steatohepatitis in US Adults Using Linked Records and Claims Yestle Kim, Romina Fakhraei, John C. O’Donnell, Karissa Johnston, Melissa Bather, Reem Mustafa, Andrew R. Kennedy, Amreen Dinani Gastro Hep Advances.2026; 5(9): 101031. CrossRef
Interactive Roles of Metabolic Dysfunction‐Associated Steatotic Liver Disease and Nutritional Status in the Prognosis of Patients With Hepatocellular Carcinoma After Surgical Resection Chun‐Ting Ho, Chien‐An Liu, Chia‐Jung Ho, Yi‐Chen Lin, Shin‐Yu Tsai, Hao‐Jan Lei, Shu‐Cheng Chou, Yi‐Hsiang Huang, Ming‐Chih Hou, Jaw‐Ching Wu, Chien‐Wei Su The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Comparative performance of insulin resistance-related indices in predicting adverse cardiovascular events among individuals with NAFLD and MASLD: a multi-center cohort study Yanqiu Huang, Yadan Xu, Chenghao Zhang, Wen Gu, Yue Li, Haojia Zhang, Tian Wang, Tangyi Su, Yangchen Lhamu, Yichen Chen, Liang Zhou, Lipeng Hao, Yang Yang, Hui Wang Cardiovascular Diabetology.2026;[Epub] CrossRef
Piezo1 as a novel therapeutic target of salvianolic acid B for metabolic dysfunction-associated steatotic liver disease Yuxue Zhang, Chang Liu, Weiyi He, Wenhui Li, Wentao Duan, Chaofeng Wu, Hui Jia, Jieying Lan, Zeyu Tong, Qiaohui Du, Haiyan Lin, Zhuowei Gao, Wenxia Zhao, Piao Luo, Lei Gao Phytomedicine.2026; 159: 158546. CrossRef
Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: Evidence from two observational studies Jialin Wu, Wenting Wei, Terry Cheuk-Fung Yip, Xinyi Deng, Bonan Chen, Yang Lyu, Peiyao Yu, Tiejun Feng, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Wei Kang Clinical and Experimental Medicine.2026;[Epub] CrossRef
Weight loss and alcohol reduction synergize for hepatic steatosis remission in elderly patients with metabolic alcohol-associated liver disease (MetALD): a retrospective cohort study Tianxiang Lin, Xiaoxue Yuan, Yanrong Zhao, Wei Wang, Chen Wu, Song Yang, Yinwei Qiu International Journal of Obesity.2026;[Epub] CrossRef
Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic‐Dysfunction Associated Steatotic Liver Disease Jarell Jie‐Rae Tan, Joo Wei Ethan Quek, Sean Shao Wei Lam, Ming‐Hua Zheng, Christophe Corpechot, Aldo J. Montano‐Loza, Yu Jun Wong Liver International.2026;[Epub] CrossRef
A Simple Clinical Prediction Model for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Obesity Yang Liao, Fei Wang, Ting-Ting Tian, Xiu-Fen Li Indian Journal of Pediatrics.2026; 93(9): 933. CrossRef
Esteatosis hepática metabólica en el síndrome cardio-reno-metabólico: la «H» silenciada Javier Crespo, Paula Iruzubieta, Tomas de Vega, Jose Luis Calleja Medicina Clínica.2026; 166(9): 107536. CrossRef
Clinically Inferred Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Association with Atrial Fibrillation Subtypes: A Prospective Clinical and Cardiometabolic Analysis Monika Różycka-Kosmalska, Boguslawa Luzak, Marcin Kosmalski Life.2026; 16(7): 1101. CrossRef
Association between oxidative balance score and metabolic dysfunction-associated steatotic liver disease in US adolescents: A cross-sectional NHANES analysis Zhen Liu, Fei Wang, Liting He, Xiaoqing Huang, Fengfeng Liu, Lan Zhang Medicine.2026; 105(28): e49723. CrossRef
Fucoxanthin Suppresses Lipid Accumulation and Inflammatory Responses in FFA-Induced Hepatocyte Models via the EGR2-CD36 Axis Xiangyu Li, Chen Yang, Qionghui Chen, Xianchuan Xu, Lian Wang, Peng Zhang, Qiang Hu, Danxiang Han, Aiqun Yu, Jing Jiang, Qizhou Lian Molecules.2026; 31(14): 2423. CrossRef
Indole-3-carbaldehyde mitigates fibrosis progression in MASH with T2DM via the SIRT1/TGF-β/SMAD signaling pathway Lu Li, Zeyu Wang, Yinglan Ji, Raorao Wang, Xiangjuan Qi, Yana Zhu, Yaping Wang, Xiaoyang Zhang, Man Li, Yong Jiang Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2026; 1872(8): 168363. CrossRef
Preliminary In Silico Evaluation of Extra Virgin Olive Oil-Derived Bioactive Compounds as Multi-Target-Directed Ligands in Metabolic Dysfunction-Associated Steatotic Liver Disease Ludovico Abenavoli, Maja Milanović, Giuseppe Guido Maria Scarlata, Nataša Milošević, Maria Luisa Gambardella, Nataša Milić Life.2026; 16(7): 1146. CrossRef
Association between the skeletal muscle-to-visceral fat area ratio and liver fibrosis risk in patients with non-alcoholic fatty liver disease: a cross-sectional study Jingru Liu, Xitong Jiao, Lu Liu, Anqi Chen, Qixue Kang, Jiayue Guo, Yuxing Wang, Yanmeng Qi, Lili You Frontiers in Public Health.2026;[Epub] CrossRef
Drug Development for MASH‐Related Compensated Cirrhosis: Past, Present and Future Ren‐Qiang Zeng, Yi‐Xuan Shao, Ru‐Tao Lin, Xu‐Ting Shen, Qin‐Mei Sun, Xin Xin, Ping Liu, Jian‐Gao Fan, Yi‐Yang Hu, Qin Feng Liver International.2026;[Epub] CrossRef
Mediterranean diet adherence and non-alcoholic fatty liver disease risk in Turkish adults: a case–control study Reza Khoshbakht Farshad, Elif Akbaş, Yasemin Ertaş Öztürk British Journal of Nutrition.2026; : 1. CrossRef
Childhood Underweight and Adulthood Obesity Associated With Increased Risk of MASLD and Cirrhosis: A Prospective Cohort Study of 375,125 Adults Jiadong Zeng, Jian Liang, Hao Zhang, Hanming Wang, zheyang Lin, Wenzhe Zhang, Haobin Zhang, Xudong Deng, Jiahui Lin, Minqi Liu, Minwen Chen, Yue Qiu, Zhen Zhang, Zhaohua Zhu, Yi Zeng Hepatology Research.2026;[Epub] CrossRef
Dietary folate intake and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study Qingchun Li, Xinyu Zhang, Fengyuan Zhao, Dongfeng Zhang, Weijing Wang, Zhongyang Zhang, Feng Yang Nutrition & Metabolism.2026;[Epub] CrossRef
Comorbid type 2 diabetes and cardiovascular disease drive higher healthcare costs in MASLD/MASH: a retrospective Swedish cohort study Helena Skröder, Mattias Ekstedt, Stergios Kechagias, Riku Ota, Ying Shang, Fotis Tefos, Emilie Toresson Grip, Johan Vessby, Hannes Hagström Scandinavian Journal of Gastroenterology.2026; 61(10): 1117. CrossRef
Development of a machine learning-based noninvasive diagnostic model for liver fibrosis in metabolic-associated steatotic liver disease Yixin Hui, Yuping Zeng, Mei Zhang European Journal of Gastroenterology & Hepatology.2026; 38(9): 1063. CrossRef
Body Mass Index and Mucosal Healing in Japanese Patients with Ulcerative Colitis: A Cross-Sectional Study Masakazu Hanayama, Shinya Furukawa, Teruki Miyake, Osamu Yoshida, Hironubu Nakaguchi, Ayumi Kanamoto, Masumi Miyazaki, Yoshimasa Murakami, Keiichiro Horiuchi, Kazuhiro Tange, Shogo Kitahata, Tomoyuki Ninomiya, Seiyuu Suzuki, Katsuhisa Ohashi, Hideomi Tomi Digestion.2026; : 1. CrossRef
Metabolite-driven remodeling of hepatic lipid metabolism by the plasticizer di-isononyl phthalate Sini Pitkänen, Henriikka Hakomäki, Olli Kärkkäinen, Marko Lehtonen, Sreejita Das, Jaana Rysä, Jenni Küblbeck, Anna-Liisa Levonen Molecular Metabolism.2026; 110: 102412. CrossRef
Longitudinal association of dietary spermidine with hepatic function indexes and cardiometabolic traits in older adults with metabolic syndrome Andrés López-González, Esther Cuadrado-Soto, José M. Ordovás, Miguel Ángel Martínez-González, Dolores Corella, Jordi Salas-Salvadó, Montserrat Fitó, J. Alfredo Martínez, Ángel M. Alonso-Gómez, Julia Wärnberg, Jesús Vioque, Dora Romaguera, José López-Miran European Journal of Nutrition.2026;[Epub] CrossRef
Composite dietary antioxidant index and risk of metabolic dysfunction – associated steatotic liver disease: evidence from a prospective cohort study Matin Sepehrinia, Sina Bazmi, Ali Nikparast, Elahe Etesami, Farhad Vahid, Gholamali Javdan, Hananeh Rozbahani, Jalaledin Mirzay Razaz, Mohammad Shafi Kuchay, Reza Homayounfar Nutrition & Metabolism.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): From Steatosis to Systemic Metabolic Failure: Classical Pathophysiology, Emerging Systemic Mechanisms and Modifiable Lifestyle Determinants Stefania Capuccio, Caterina Cocuzza, Grazia Letizia Di Marco, Alessandra Scamporrino, Salvatore Piro, Maurizio Russello Nutrients.2026; 18(14): 2316. CrossRef
Human stem cell-derived hepatic cells recapitulate polygenic risk in MASLD development and highlight CD36 as a key mediator Alexandra Gatzios, Marth Stinckens, Anouk Verhoeven, Matthias Rombaut, Dinja De Win, Anja Heymans, Arne Loosen, Freddy Van Goethem, Joery De Kock, Robim M. Rodrigues, Joost Boeckmans, Tamara Vanhaecke Life Sciences.2026; 402: 124587. CrossRef
Racial and gender disparities in access to living donor liver transplantation between 1999–2021 Nicole Ng, Alexander Zhao, Nathaly Llore, Benjamin Samstein, Abhishek Mathur, Jennica Kim, Pamela Cobbs, Alyson Fox, Jason Hawksworth, Russell Rosenblatt Journal of Liver Transplantation.2026; 23: 100364. CrossRef
Epitranscriptomic Remodeling: m6A Methylation as a Master Regulator of de novo Lipogenesis in MASLD Pervej Alom Barbhuiya, Pompy Patowary, Manash Pratim Pathak Current Hepatology Reports.2026;[Epub] CrossRef
Lipidomics and proteomics in MASLD: reading the molecular script toward precision therapeutics Anna Sofia Germanidou, Theocharis Koufakis Hormones.2026;[Epub] CrossRef
High Cardiometabolic Risk Burden Predicts Adverse Outcomes in Patients with MASLD-Related Hepatocellular Carcinoma Yeonhong Do, Young Hyeon Ahn, Young Chang, Jeong-Ju Yoo, Sae Hwan Lee, Soung Won Jeong, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Hong Soo Kim, Keungmo Yang, Tom Ryu Gut and Liver.2026; 20(4): 655. CrossRef
Relationship between metabolic dysfunction-associated steatotic liver disease and cardiovascular mortality risk in individuals with CKM stages 0–2: Mediating roles of inflammation and insulin resistance Zhuoxing Li, Qianyu Yang, Li Zang, Hongwei Leng, Panpan Qin, Simeng Li, Buyuan Tian, Xumao Deng, Yun Sun, Xiang Xiao Diabetes Research and Clinical Practice.2026; 239: 113411. CrossRef
High salt supplementation of a MASH-inducing diet causes lean MASH phenotype with increased hepatic urea cycle activity and EIF5A hypusination Shaopeiwen Luo, Norihiko Morisawa, Anissa Anindya Widjaja, Brijesh Kumar Singh, Derek John Hausenloy, Paul Michael Yen, Jin Zhou Molecular Metabolism.2026; 111: 102417. CrossRef
Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study Shashank Joshi, Shambo Samrat Samajdar, Arvind Gupta, Mithun Bhartia, Sailesh Lodha, Supratik Bhattacharyya, Krishna Seshadri, Lakshmi Nagendra, A. G. Unnikrishnan, Dakshata Padhye, Lakshmi Nalini Kopalle, Ashok Kumar Das, Om Lakhani, Jothydev Kesavadev, Frontiers in Clinical Diabetes and Healthcare.2026;[Epub] CrossRef
Metabolic and Lifestyle Profiles of Metabolic Dysfunction-Associated Steatotic Liver Disease in Romanian and Italian Adults Naomi-Adina Ciurea, Harshitha Shanmugam, Cristina Monica Pantea, Paul Grama, Irina-Bianca Kosovski, Simona Bataga, Agostino Di Ciaula, Piero Portincasa Medicina.2026; 62(7): 1403. CrossRef
Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives Mario Romeo, Claudio Basile, Andrea Imperatore, Giambattista Mozzi, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Marcello Dallio, Alessandro Federico Cells.2026; 15(14): 1292. CrossRef
Deep behavioral phenotyping reveals novel features in a mouse model of metabolic dysfunction-associated steatohepatitis Naoaki Sakamoto, Takamasa Numano, Yui Kobayashi, Masahiro Fukuda, Maria Osaki, Keisuke Omori, Taichi Yamamoto, Takahisa Murata Scientific Reports.2026;[Epub] CrossRef
MYH11 upregulation attenuates autophagy dysfunction through modulation of ATG4A in metabolic dysfunction-associated steatotic liver disease Guang-Peng Liu, Xiao-Han Ma, Hong-Qian Wang, Cheng-Cheng Tong, Xi Chen Biochemical Pharmacology.2026; 253: 118279. CrossRef
Clinical applications and advances in noninvasive prognostic assessment of metabolic dysfunction-associated steatotic liver disease Xin-Long He, Rui-Xu Yang, Jian-Gao Fan Hepatoma Research.2026;[Epub] CrossRef
Association between chrononutrition patterns and metabolic dysfunction-associated steatotic liver disease in adolescents: a population-based study Yueju Wang, Mingxin Wang, Jingya He, Congwei You, Cai Tang, Lihong Zhu, Le Zhang, Xiaodie Yao Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.2026;[Epub] CrossRef
Outcome after liver transplantation: Predicting the unpredictable Ylenia Capraro, Leonard Lamfu, Martina Milana, Ilaria Lenci, Leonardo Baiocchi World Journal of Hepatology.2026;[Epub] CrossRef
Letter to the Editor: Xietu Hemu prescription: A novel therapeutic strategy for obesity and metabolic dysfunction-associated steatotic liver disease? Alessia Provera, Anteneh Nigussie Sheferaw, Emmanuel Kivumbi, Salvatore Sutti World Journal of Hepatology.2026;[Epub] CrossRef
Integrated computational analysis identifies FABP4, PTGS2, and HPGD as Key molecular targets linking PET microplastic exposure to metabolic dysfunction-associated steatotic liver disease Yi Zhang, Yao Yu, Bin Ge, Dacai Gong, Lan Zheng, Yuanyi Wang, Peng Chen, Seth Agyei Domfeh PLOS One.2026; 21(7): e0354607. CrossRef
LAP-defined hepatic steatosis and cardiometabolic risk in rheumatoid arthritis: a post-hoc analysis of the FRANCIS randomized trial A. N. Saidi, B. Burggraaf, A. J. van der Lelij, E. van der Zwan-van Beek, M. Castro Cabezas Rheumatology International.2026;[Epub] CrossRef
Decreased degree of adipocyte differentiation in visceral adipose tissue contributes to metabolic dysfunction-associated steatotic liver disease Kyla Z. Gelev, Seung Hyuk T. Lee, Marcus Alvarez, Rosellina M. Mancina, Federica Tavaglione, Oveis Jamialahmadi, Umberto Vespasiani-Gentilucci, Asha Kar, Zitian Wang, Dorota Kaminska, Minna U. Kaikkonen, Ville Männistö, Sini Heinonen, Tuure Saarinen, Anne Nature Communications.2026;[Epub] CrossRef
Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases Ana Flávia Pontes Sodré, Lucca Gonsales Rodrigues, Kátia P. Sloan, Lance A. Sloan, Masaru Tanaka, Rui Curi, Larissa Naomi Takeda, Ricardo de Alvares Goulart, Ana Luiza Decanini Miranda de Souza, Claudia Rucco Penteado Detregiachi, Antonelly Cassio Alves C International Journal of Molecular Sciences.2026; 27(15): 6554. CrossRef
MASLD In PBC: A Shift From Liver‐Centred to Cardiometabolic Risk Assessment? Francesca Colapietro, Mauro Viganò Liver International.2026;[Epub] CrossRef
Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies Lashin S. Ali, Mohamed O. Mostafa, Dana Alsharayiah, Mohamed A. Elkholy, Khaled A. Ahmed, Ahmed A. El-Mansy, Abd El Rahman M. Sharfeldeen, Gehan El Wakeel, Abdelnaser A. Badawy, Ahmed H. Sulaiman, Elryah I. Ali, Mariam Shabram Alenazi, Mohammed M. Alruwai Frontiers in Pharmacology.2026;[Epub] CrossRef
Time-dependent predictive accuracy of noninvasive liver scores for chronic kidney disease onset in metabolic dysfunction-associated steatotic liver disease Huttakan Navadurong, Padoemwut Teerawongsakul, Thananda Trakarnvanich, Witchakorn Ruamtawee, Nutachat Treerasoradaj, Supatsri Sethasine World Journal of Hepatology.2026;[Epub] CrossRef
Reframing MASLD: A Hepatic Condition with Systemic Clinical Impact Patricia S. Castillo-Flores, Itzayana Rodríguez-Antonio, Misael Uribe, Norberto C. Chávez-Tapia, Eduardo E. Montalvo-Javé, Natalia Nuño-Lámbarri Journal of Clinical and Experimental Hepatology.2026; : 103631. CrossRef
Hepatic inflammation after exposure to a mixture of low-dose arsenic and cadmium in a murine model of fatty liver disease Nivetha K Subramaniam, Natascha Gagnon, Cynthia Guilbert, Rushmi Perinpanathan, Madelyn Abraham, Christophe Goncalves, Jaymie R Meliker, Sonia Del Rincon, Koren K Mann Toxicological Sciences.2026;[Epub] CrossRef
Human placenta extract declines fat deposition in an in vitro novel 3D MASLD model Parisa Taheri, Fatemeh Majidi, Kosar Nouri, Masoumeh Nouri, Morteza Zarrabi, Elham Rismani, Abbas Piryaei, Massoud Vosough In vitro models.2026;[Epub] CrossRef
DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα Hyun Ahm Sohn, Hanyong Go, Tae Hyeon An, Jun Min Lee, Hee-Jin Kim, Keeok Haam, Amal Magdy, Hyo-Jung Jung, Yang-Ji Shin, Hyun Jung Lim, Yujin Jeong, Yejin Bae, Youngae Jung, Seong-Hwan Park, Kyung Chan Park, Myeong Jun Song, Eun-Wie Cho, Eun-Soo Kwon, Jeon Clinical and Molecular Hepatology.2026; 32(3): 1201. CrossRef
Hepatic fibro-inflammation measured by magnetic resonance imaging iron-corrected T1 predicts extrahepatic cancer risk: a UK Biobank study Hye Yeon Chon, Seok-Jae Heo, SungA Bae, Tae Seop Lim, Ja Kyung Kim Clinical and Molecular Hepatology.2026; 32(3): 1349. CrossRef
Andrias davidianus Liver-Derived Peptides Ameliorate MASH Accompanied by Attenuation of PPARγ Signaling and Selective Modulation of Gut Microbiota Xing Shen, Ya-Na Qu, Yi-Xiao Huang, Chen-Yu Liang, Si-Jia Liu, Na Liu, Zi-Jie He, Shuai-Kun Su, Qing-Zhu Sun, Tai An, Hua Han Metabolites.2026; 16(8): 532. CrossRef
Blood Urea Nitrogen to Serum Albumin Ratio Is Associated with MASH and Significant Fibrosis: Report from a Turkish Biopsy-Proven MASLD Cohort Ali Kirik, Eda Kaya, Caglayan Keklikkiran, Yusuf Yilmaz Journal of Clinical Medicine.2026; 15(15): 5892. CrossRef
The natural history and individualized prediction of liver stiffness-based fibrosis risk in metabolic dysfunction-associated steatotic liver disease Yu Shi, Ruoqi Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Manuel Romero-Gomez, Emmanuel Tsochatzis, Philip Newsome, Hannes Hagström, George Boon-Bee Goh, Wah-Kheong Chan, José-Luis Calleja, Jerome Boursi Clinical and Molecular Hepatology.2026; 32(3): 1333. CrossRef
Capturing systemic disease burden in MASLD: Toward integrated liver–kidney–cardiovascular economic models: Reply to correspondence on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic live Anna Di Sessa, Gianmario Forcina, Emanuele Miraglia del Giudice Clinical and Molecular Hepatology.2026; 32(3): e447. CrossRef
Selective SGLT2 inhibitors in MASLD/MASH: an outcome-specific systematic review and meta-analysis of hepatic and cardiometabolic outcomes Danilo Caponio, Giuseppina Alessia Acucella, Michele Acucella Acta Diabetologica.2026;[Epub] CrossRef
Therapeutic Targets for Hepatic Fibrosis Driven by Hypoxia-Mediated Hepatic Stellate Cell Activation Wenteng Li, Tong Li, Jingwei Mao Biomolecules.2026; 16(8): 1089. CrossRef
Dapagliflozin in Metabolic Dysfunction–Associated Steatotic Liver Disease: Clinical Evidence and Therapeutic Potential Rajesh Upadhyay, Mangesh Tiwaskar, Bharat Saboo, L Sreenivasamurthy, Kirti Sonawale, Charmy Prajapati, Parthasarathy Muralidharan Euroasian journal of hepato-gastroenterology.2026; 16(1): 98. CrossRef
Understanding regional differences in MASLD: the Indian perspective Karthik Shree Harini, Devaraj Ezhilarasan npj Metabolic Health and Disease.2026;[Epub] CrossRef
MASLD and Pancreatic Diseases: From Shared Mechanisms to Clinical Implications and Future Directions Jesús Rivera-Esteban, Belén Agudo, Beatrice Patrizi, Alejandra Manzur, Daniel de la Iglesia, Víctor Valverde, Neus García Ferris, Carlos Esteban, Elena Santos, Fernando Pons, Marta Hernández-Conde, Javier Abad, Mariano González-Haba, José Luis Calleja Nutrients.2026; 18(15): 2480. CrossRef
Liver muscle bone axis in metabolic dysfunction-associated steatotic liver disease Binhua Li, Yimeng Zhang, Can Zhou, Haixia Cao, Jing Zeng Metabolism and Target Organ Damage.2026;[Epub] CrossRef
Screening for Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence, Challenges, and the Role of Imaging—From the AJR Special Series on Screening Shin Mei Chan, Cheng William Hong, Lael Ceriani, Manish Dhyani, Kathryn J. Fowler, Michael S. Middleton, Theodore T. Pierce, Perry J. Pickhardt, Scott B. Reeder, Anthony E. Samir, Adam Searleman, Dorathy Tamayo-Murillo, Claude B. Sirlin American Journal of Roentgenology.2026;[Epub] CrossRef
Characterization of posttranslational modification in metabolic dysfunction-associated steatohepatitis: acetylation, lactylation, and phosphorylation Kuan Li, Yundong Li, Yuqing Zhang, Shuxian Song, Chengzhou Pa, Chen Du, Lianjun Yang, Guoyou Xue, Hongqiang Gao Journal of Lipid Research.2026; 67(9): 101116. CrossRef
Fibroblast growth factor 21 in metabolic dysfunction-associated steatotic liver disease and beyond: from bench to bedside Hak-Keith Leung, Guo-Jeng Tan, Wei-Kei Wong, Farahani Khamis, Shamsul Mohd Zain, Wah-Kheong Chan Hepatoma Research.2026;[Epub] CrossRef
Strategy to Improve Diagnostic Performance of Hepatic Steatosis Grading Using Ultrasound: Combination of Qualitative and Quantitative Approaches Abdusattorov Shavkat Shokirjon ugli, Sunyoung Lee, Ja Kyung Yoon, Jae Seung Lee, Seung-seob Kim Medicina.2026; 62(8): 1467. CrossRef
A WHA resolution on steatotic liver diseases – A global call to action Khaled Abdel Ghaffar, El Amira Rashwan, Mohamed Hassany Journal of Hepatology.2026;[Epub] CrossRef
A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper Tao Chen, Ashok Choudhury, Wei Liu, Meng Zhang, Wenhui Wu, Huiling Xiang, Xiaojing Wang, Zaigham Abbas, Tatsuo Kanda, Ramazan Idilman, Kemal Fariz Kalista, Hai Li, Rosmawati Binti Mohamed, Paolo Angeli, Mohamed Elbasiony, Hasitha S. Wijewantha, Charles Pa Hepatology International.2026; 20(4): 963. CrossRef
Adipose Tissue Browning in MASLD and Its Molecular Mechanisms and Metabolic Crosstalk Jonathan Jaime G. Guerrero, Mark Angelo S. del Rosario, Paolo C. Encarnacion, Chen-Sung Lin, Lu-Te Chuang, Kin Israel Notarte, Jiayan Zhou, Chih-Hao Wang, Ching-Wen Chang, Wan-Chun Li Current Obesity Reports.2026;[Epub] CrossRef
Nationwide Characteristics of Patients Admitted to Hospital for the First Time Due to Primary Liver Cancer and Intrahepatic Bile Duct Cancer in Poland in 2012–2023 Agnieszka Genowska, Jerzy Jaroszewicz, Dorota Zarębska-Michaluk, Katarzyna Lewtak, Krystyna Dobrowolska, Krzysztof Kanecki, Anna Parfieniuk-Kowerda, Aneta Nitsch-Osuch, Piotr Rzymski, Robert Flisiak Cancers.2026; 18(16): 2579. CrossRef
MASLD: Spatial Mechanisms and New Therapeutics Christian Stoess, Janset Onyuru, Yanzhu Hu, Yuan Jiang, Zhengyi Xin, Aryan Panchal, Phillipp Hartmann Biomolecules.2026; 16(8): 1129. CrossRef
Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review Wah-Kheong Chan, Hak-Keith Leung, Guo-Jeng Tan, Quan-Hziung Lim, Lee-Ling Lim, Jeyakantha Ratnasingam, Shireene Ratna Vethakkan Journal of Obesity & Metabolic Syndrome.2026; 35(3): 298. CrossRef
Helicobacter pylori Infection and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis Longgang Zhao, Yun Chen, Xinyuan Zhang, Catherine Mezzacappa, Xiaomei Ma, Bubu Banini, Jung Eun Lee, Chen Liu, Xuchen Zhang, Ann W. Hsing, Mindie H. Nguyen, Chul S. Hyun, M. Constanza Camargo, Katherine A. McGlynn, Lifang Hou, Tamar H. Taddei, Xuehong Zha Cancer Epidemiology, Biomarkers & Prevention.2026; 35(8): 1421. CrossRef
Portal hypertension mortality in the United States (1999–2023): Insights from the CDC WONDER database Raymond Haward, Nikhil Duseja, Het Hirpara, Harkanwar Sandhu, Swathi Deepak Kulkarni, Rachel Haward, Mobeen Abid, Mir Mehdi Hussain, Newton Ashish Shah, Iswariya Mani, Pooja Prasad, Jai Kumar Rajavoor Muniswamy Medicine.2026; 105(32): e50127. CrossRef
EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE Margarida Augusto, Robert Bauer, Simon Clancy, Aslak Sindbjerg Poulsen, Fotis Tefos, Michelle Long JHEP Reports.2026; 8(11): 101993. CrossRef
Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy Young Eun Chon, Kyung‐Do Han, Ju Dong Yang, Ju‐Yeong Park, Hyun‐Seok Kim, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2026; 41(9): 2913. CrossRef
Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study Dhir Gala, Sameer Rao, Manas Gunani, Kajol Shah, Anand V. Kulkarni, Karn Wijarnpreecha, Daniel Q. Huang, Pojsakorn Danpanichkul, Ahmed Al‐Khazraji, Kaveh Hajifathalian, Vivek Lingiah, Paul Gaglio, Nikki Duong, Christine Gerula Alimentary Pharmacology & Therapeutics.2026;[Epub] CrossRef
Golgi Protein 73 and Laminin‐γ2 Monomer‐Based Score for the Diagnosis of Advanced Liver Fibrosis in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease Xin‐Tong Ng, Jin‐Ying Teh, Pavai Sthaneshwar, Izzatul Aliaa Badaruddin, Pavitratha Puspanathan, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Wah‐Kheong Chan JGH Open.2026;[Epub] CrossRef
Gut Microbiota–Metabolite Alterations Associated with Early Metabolic Dysfunction and Hepatic Steatosis in Adolescents Natalia Zeber-Lubecka, Paweł Czarnowski, Joanna Ziemska-Legięcka, Aldona Wierzbicka-Rucińska, Wojciech Jańczyk, Jacek Michałkiewicz, Łukasz Obrycki, Mieczysław Litwin, Michał Mikula, Piotr Socha, Jerzy Ostrowski Computational and Structural Biotechnology Journal.2026;[Epub] CrossRef
Pharmacotherapy of metabolically associated fatty liver disease E. E. Mulyukova, E. L. Novikova, I. A. Skirdov, K. S. Usmanova, N. V. Yusifzade Experimental and Clinical Gastroenterology.2026; (8): 156. CrossRef
Olive pomace-derived pectin limits lipid droplet hypertrophy and collagen deposition and is associated with hepatic transcriptional changes in a MASLD murine model Luna Barrera-Chamorro, Jose L. del-Rio-Vazquez, Africa Fernandez-Prior, Elvira Marquez-Paradas, Carmen M. Claro-Cala, Teresa Gonzalez-de la Rosa, Maria Torrecillas-Lopez, Sergio Montserrat de la Paz Food Bioscience.2026; 84: 109680. CrossRef
Sarcopenia and Frailty in Hepatocellular Carcinoma: From Prognostic Marker to Therapeutic Target: A Narrative Review Brittany Bromfield, Astrid Ruiz-Margáin, Laura Kulik, Andres Duarte-Rojo Current Hepatology Reports.2026;[Epub] CrossRef
A polysaccharide-rich preparation from Moutan Cortex alleviates non-alcoholic fatty liver disease by ameliorating intestinal flora and bile acid metabolism Huanhuan Zhang, Hongwei Zhang, Xueshuai Ye, Jing Yang, Fazhan Li, Xujie Sun, Tingting Xu, Yongze Guo, Huicong Dong Phytomedicine.2026; 160: 158695. CrossRef
Metabolic Dysfunction–Associated Steatohepatitis Comorbidity Burden and Overall, Waiting-List, and Post–Liver Transplant Mortality Winnie Gaya Shivega, John R. Montgomery, Madelaine Hack, Alexandra C. Bolognese, C. Kristian Enestvedt, Erin Maynard, Oren Shaked, Christopher R. Connelly JAMA Surgery.2026; 161(10): 1095. CrossRef
Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns A. J. Venkatakrishnan, K. Purushotham, Gowtham Varma, Avinash Aman, Karthik Murugadoss, Venky Soundararajan npj Gut and Liver.2026;[Epub] CrossRef
Pharmacological effects of dihydromyricetin in preclinical models of NAFLD: a systematic review and meta-analysis stratified by dose and duration Le Li, Jiahui Chen, Wenxin Hu, Jiachen Wang, Fangran Wang, Chenxuan Dong, Lisha Wang, Tianying Chang, Jiajuan Guo, Yingzi Cui, Xing Liao Frontiers in Pharmacology.2026;[Epub] CrossRef
Association between UMAP-identified body composition phenotypes and metabolic dysfunction-associated steatotic liver disease in the general population of China Huimin Yin, Yangtian Wang, Li Yuan, Shuaiju Liao, Li Ding, Lili Liu, Dan Xiang Frontiers in Nutrition.2026;[Epub] CrossRef
The MASLD–Cardio-Oncology Triangle: Dietary Patterns, Metabolic Remodelling and Implications for Cancer Therapy Tolerance Francesca La Rocca, Graziella Privitera, Calogero Geraci, Valentina Morello, Giulio Geraci, Valentina Paternò, Ciro Santoro, Roberta Esposito Nutrients.2026; 18(15): 2527. CrossRef
Life’s crucial 9, plasma proteomics, and the risk of major complications and mortality in MASLD Bing-Yun Zhang, Yi-Xin Wang, Hong-Xuan Huang, Xu-Lian Tang, Shu-Min Lai, Zhi-Yuan Xiong, Ling Kuang, Hao-Jie Chen, Hui Zhu, Ya-Xuan Li, Si-Qi Chen, Er-La Huang, Yan-Song Li, Hai-Ying Wang, Junguo Zhang, Zhi-Hao Li npj Metabolic Health and Disease.2026;[Epub] CrossRef
Liver, Portal, and Systemic Thyroid Hormone Concentrations in End-Stage MASH Reveal Distinct Roles for T3/rT3 Ratio and T4 Xinru Zhang, Zhixiong Ying, Tonguç Utku Yilmaz, Piter Bosma, Maarten Tushuizen, Anita Boelen, Eveline Bruinstroop Thyroid®.2026; 36(10): 1116. CrossRef
A pan-tissue multi-omics resource atlas of coordinated immune, metabolic, and fibrotic alterations in diet-induced MASH Huajing Yu, Shanshan Liu, Yiqiao Zhang, Yu Ji, Yiyang Min, Danyang Yin, Tingting Wang, Xuemei Ma, Jionghuang Chen, Weihua Yu, Liping Cao, Luyang Wei, Mengyi Li, Chengjian Guan, Zhongtao Zhang iScience.2026; 29(8): 117139. CrossRef
MASLD and the cardiovascular-kidney-liver-metabolic syndrome Angeliki M Angelidi, Chrysoula Boutari, Michail Kokkorakis, Konstantinos Stefanakis, Dimitri P Mikhailidis, George Jacob, Christos S Mantzoros Endocrine Reviews.2026;[Epub] CrossRef
Hepatocyte MLKL drives obesity-driven hepatocellular carcinoma progression via mitochondrial dysfunction independent of necroptosis in MASLD Phoebe Ohene-Marfo, Sabira Mohammed, Chao Jiang, Shylesh Bhaskaran, Kara Kneuper, Satoshi Matsuzaki, Bo Hagy, Randal J. May, Constantin Georgescu, Megan John, Julianne N. Hoang, Kevin Pham, Albert Tran, Chinthalapally V. Rao, Tae Gyu Oh, Michael Kinter, W Hepatology.2026;[Epub] CrossRef
Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye Hilmi Erdem Sumbul, Ali Kirik, Selcuk Yaylaci, Alihan Oral, Sibel Ocak Serin, Kubilay Issever, Nizameddin Koca, Ahmet Aydin, Ismail Demir, Nevzat Gozel, Pinar Yildiz, Oguzhan Sitki Dizdar, Enes Seyda Sahiner, Seyit Uyar, Emin Gemcioglu, Hasan Esat Yucel, Hepatology International.2026;[Epub] CrossRef
The impact of short-term reduction in hepatic triglycerides on vascular health in adults with or at risk of metabolic dysfunction-associated steatotic liver disease Tianyu Wang, Isabelle Gallagher, Jessica Park, Yanrong Li, Marie Caillaud, Taha A. Alhalimi, Lin-Sheng Chen, Natalie N. McLaurin, Jack Knight-Scott, Jeffrey D. Browning, Andreana P. Haley, Hirofumi Tanaka, Aleksandra Klisic PLOS One.2026; 21(8): e0345338. CrossRef
Revisiting macrophage metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease: mechanisms, regulation, and therapeutic breakthroughs Li Zhu, Bo Wu Frontiers in Immunology.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and the consequence of extra-hepatic malignancy Benjamin Blaske, Michael Ward, Ragesh Babu Thandassery World Journal of Hepatology.2026;[Epub] CrossRef
Lived Experience, Concerns, and Support Needs of Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Qualitative Study Sue Shea Wynyard, Lou Atkinson, Chris Kite, Christos Lionis, Harpal S. Randeva, Ioannis Kyrou Healthcare.2026; 14(16): 2569. CrossRef
Fibroblast Growth Factor 21 Resistance and Metabolic Dysfunction–Associated Steatotic Liver Disease Mateo Chvatal-Medina, Adrian Post, Robin P.F. Dullaart Metabolic Syndrome and Related Disorders.2026; 24(5): 179. CrossRef
Association of red blood cell distribution width to albumin ratio with all-cause and cardiovascular mortality among adults with MASLD Ze-Bin Ni, Lian-Zhen Huang, Qi-Rong Yao, Qian Li, Ji Li, Wei-Feng Huang, Jin-Yan Zhang, Yan-Qing Wang BMC Gastroenterology.2026;[Epub] CrossRef
Body composition assessment for risk stratification of hepatic steatosis in patients with type 2 diabetes and MASLD undergoing osteoporosis screening Clelia Asero, Cecilia Oliveri, Maria Stella Franzè, Giorgio Basile, Antonino Catalano, Irene Cacciola Frontiers in Endocrinology.2026;[Epub] CrossRef
Extracellular Vesicle‐Based miRNA Profiling in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Secondary Analysis of the MULTISITE Clinical Trial Katja Lund Cliff, Dominic Guanzon, Andrew Lai, Katherin Scholz‐Romero, Gunna Christiansen, Aase Handberg, Carlos Salomon, Maiken Mellergaard Journal of Extracellular Biology.2026;[Epub] CrossRef
The Role of Insulin Resistance in Mediating the Association Between Proinflammatory Diets and Metabolic Dysfunction‐Associated Steatotic Liver Disease Zongbiao Tan, Haodong He, Yang Meng, Yu pu, Yanrui Wu, Jixiang Zhang, Weiguo Dong Food Science & Nutrition.2026;[Epub] CrossRef
Letter to the Editor: Natural product intervention in metabolic dysfunction-associated steatotic liver disease: From allyl isothiocyanate to signaling networks Rui Tian, Yi-Xin Wu, Jie-Yu Guo, Xing-Zhen Chen, Jing-Feng Tang, Ce-Fan Zhou World Journal of Hepatology.2026;[Epub] CrossRef
Weight Gain Is Associated with Short-Term FIB-4 Increase and Concurrent Metabolic Change in People with HIV and Metabolic Dysfunction-Associated Steatotic Liver Disease Wei Xu, Li Liu, Meiyan Sun, Renfang Zhang, Jun Chen, Yinzhong Shen Viruses.2026; 18(8): 896. CrossRef
Naringin and hepatic metabolic dysfunction in diabetes and metabolic syndrome: mechanisms and therapeutic perspectives María Paula Combina Herrera, Gabriela Natalia Ávila Sabattini, Gabriela Picotto, Valeria Andrea Rodríguez European Journal of Pharmacology.2026; 1032: 179243. CrossRef
The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia Su Yin Lau, Victoria Sinq‐Ling Kok, Soek‐Siam Tan, Syuhada Dan Adnan, Wei‐Lin Ng, Ban‐Hong Ang, Nur Yazmin Yaacob, Yeong Yeh Lee, Senamjit Kaur, Rosmawati Mohamed, Ping‐Foo Wong, Lee‐Ling Lim, Mohana Letchumanan, Shireene Ratna Vethakkan, Nurain Mohd Noor Journal of Gastroenterology and Hepatology.2026; 41(9): 2639. CrossRef
Takeaway food consumption and the risk of metabolic dysfunction-associated steatotic liver disease in adult populations: an international multicohort study with biopsy-verified evidence Yeqing Gu, Kexin Li, Piaoyi Tong, Xu-Fen Zeng, Hao Geng, Shunming Zhang, Mengyi Zhai, Ge Meng, Qing Zhang, Li Liu, Hongmei Wu, Dongli Wang, Shaomei Sun, Xing Wang, Qiyu Jia, Kun Song, Tao Huang, Ming-Hua Zheng, Kaijun Niu American Journal of Epidemiology.2026;[Epub] CrossRef
Higher adherence to the EAT–lancet diet is associated with reduced risk of metabolic dysfunction–associated steatotic liver disease: a 5-year middle eastern cohort study Farzam Kamrani, Mobina Imannezhad, Elahe Etesami, Nazanin Zamanian, Jalaledin Mirzay Razaz, Sayed Hossein Davoodi, Reza Homayounfar, Ali Nikparast Diabetology & Metabolic Syndrome.2026;[Epub] CrossRef
Evaluation of sirtuin 1 serum level and gene expression in patients with metabolic syndrome accompanied by metabolic dysfunction-associated steatotic liver disease Fawzy A.F. Elmessallamy, Mayada M. Mousa, Ahmad Sallam Soliman, Osama Ibrahim El-Dosoky, Samia Hussein, Basma S. Elsayed, Sara Mohamed Osama The Egyptian Journal of Internal Medicine.2026;[Epub] CrossRef
Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma Zobair M. Younossi, George Papatheodoridis, Emmanuel Tsochatzis, Maria Buti, Lorenza Rimassa, Massimo Pinzani, Ana Lleo, Debbie Shawcross, Frank Tacke, Vincent Wai‐Sun Wong, Shira Zelber‐Sagi, Andreas E. Kremer, David J. Pinato, Josep M. Llovet, Paolo Ang Liver International.2026;[Epub] CrossRef
Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics Malek Ayoub, Tsubasa Tsutsumi, Mary E. Rinella Alimentary Pharmacology & Therapeutics.2026;[Epub] CrossRef
Sarcopenia and Frailty in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Impact of Steroid Hormones Triada Bali, Jennifer Lai, Niki G. Mourelatou, Aristi Saridaki, Sofia Tsitsou, Magdalini Adamantou, Aikaterini Kamiliou, Christos Chologitas, Margarita Sarri, Dimitra Pavlopoulou, Evangelos Liberopoulos, Anna Angelousi, Evangelos Cholongitas International Journal of Molecular Sciences.2026; 27(16): 7431. CrossRef
The “viral–metabolic” interaction mechanisms and management challenges in chronic hepatitis B combined with metabolic dysfunction-associated fatty liver disease: from clinical evidence to an integrated multidisciplinary framework Qianqian Zhu, Chengde Su, Qiaoqiao Yao, Ting Yang, Yali Xu, Mingdan Li, Qian Liu, Yawen Luo, Ping Yang Frontiers in Immunology.2026;[Epub] CrossRef
Genetic Susceptibility Versus Fibrosis Progression in North Indian Metabolic Dysfunction–Associated Steatotic Liver Disease: Distinct Roles of APOC3 and PNPLA3 in a Candidate Gene Study Nandini Tomar, Sangeeta Choudhury, Anil Arora, Praveen Sharma, Rishikant Vaibhav, Rizwana Hasan, Shayesta Jan, Rajwinder Kaur, Tarun Rajput, Medha S. Lomada, Sandhya K. Pemmasani, Ashish Kumar Journal of Clinical and Experimental Hepatology.2026; 16(6): 103638. CrossRef
Interplay between cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease: Clinical evidence on cardiovascular disease Jorge Gutiérrez-Cuevas, Ana Sandoval-Rodriguez, Jesús Garcia-Bañuelos, Marcelo Heron Petri, Juan Armendariz-Borunda World Journal of Gastroenterology.2026;[Epub] CrossRef
The C-Reactive Protein–Triglyceride–Glucose Index as a Biomarker of Metabolic Dysfunction-Associated Steatotic Liver Disease: Results from the Population-Based Italian NUTRI-HEP Cohort Gianluigi Casimo, Rossella Donghia, Caterina Bonfiglio, Rossella Tatoli, Giovanni Maria Biancofiore, Gianluigi Giannelli Biomedicines.2026; 14(8): 1860. CrossRef
From evidence to action: The WHO–Imperial–EASL Collaborating Centre on Steatotic Liver Disease Pinelopi Manousou, Debbie L. Shawcross, Irene Mosqueira, Gundo Weiler, Kremlin Wickramasinghe, Pavlos Theodorakis, Ana Lleo, Shira Zelber-Sagi, Massimo Pinzani, Hans Henri P. Kluge, Mark Thursz Journal of Hepatology.2026;[Epub] CrossRef
Modern nutritional approaches to the prevention of digestive system diseases in the population and to the rehabilitation of veterans Mariia Zinoviivna Paska, Oryslava Ivanivna Hrafska, Volodymyr Vasylovych Hrafskyi Academic Visions.2026;[Epub] CrossRef
Association between low skeletal muscle mass assessed by deep learning-based CT and MASLD: a prospective cohort study Yaping Wang, Jing Lu, Jiulou Zhang, Wen Guo, Shumei Miao, Xinyuan Ge, Wentao Yao, Hongwei Xu, Yuxiang Yan, Chengxiao Yu, Ci Song, Qun Zhang Diabetology & Metabolic Syndrome.2026;[Epub] CrossRef
Experimental evaluation of high-dose L-ornithine L-aspartate in nonalcoholic steatohepatitis and its extrahepatic complications V. A. Prikhodko, T. M. Matuzok, K. S. Doroshchuk, A. A. Fedorova, V. E. Karev, A. S. Samarich, V. E. Kovanskov, E. A. Karelina, N. A. Muraveva, M. O. Pyatchenkov, A. G. Markov, S. V. Okovityi Drug development & registration.2026; 15(3): 241. CrossRef
Sex-specific associations between pubertal development and MASLD in children: evidence from the PROC study Huiming He, Mengying Guan, Tuerxunayi Abudumijiti, Miao Li, Yuchen Zou, Sten H. Vermund, Dayong Huang, Yifei Hu Pediatric Research.2026;[Epub] CrossRef
When the Liver Flares: Inflammatory and Immunometabolic Mechanisms Driving the Transition from MASLD to MASH Cristina Vecchio, Anteneh Nigussie Sheferaw, Emmanuel Kivumbi, Ian Stoppa, Deepika Pantham, Foteini Christaki, Alessia Provera, Umberto Dianzani, Salvatore Sutti Inflammation.2026;[Epub] CrossRef
Risk and mechanisms of artificial sweetener-induced metabolic dysfunction-associated steatotic liver disease: Insights from multi-level bioinformatics and in vitro assays Ruting Wang, Hongxi Wu, Jiale Liang, Huiping Luo, Zhenjin Huang, Ruohan Zhang, Rongxin Zhang, Hongzhen Tang, Feng Jiang Ecotoxicology and Environmental Safety.2026; 323: 120705. CrossRef
AI-Driven Radiomics Assisted Prognostic Modeling for Hepatocellular Carcinoma with Portal Vein Invasion: A Retrospective Study Tao Zhang, Xue Li, Yingli Guo, Junsong Zeng, Maosen Xu, Yan Tie Biomedicines.2026; 14(9): 1894. CrossRef
Circulating metabolite signatures mediating the association between minerals in domestic water and incident MASLD: a prospective cohort study Keyang Li, Yincheng Liu, Wenlong Li, Li Qin, Danrui Zhang, Hong Chen, Zhiyu Yin, Hanwen Zhou, Biao Xie, Xiaoni Zhong Frontiers in Nutrition.2026;[Epub] CrossRef
Association Between Food Insecurity and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study in South Korea Seong-Uk Baek, Jin-Ha Yoon Nutrients.2026; 18(17): 2806. CrossRef
Obesity phenotypes, omics signatures, and risk of adverse liver outcomes Longgang Zhao, Yun Chen, Jun Li, Cong Wang, Tamar H Taddei, Xiaomei Ma, Shuangge Ma, Olga Demler, Azam Yazdani, Oluwafeyisola Osifala, Diego Martínez Urbistondo, Miguel A Martínez-González, Deirdre K Tobias, Edward Giovannucci, Howard D Sesso, JoAnn E Man JNCI: Journal of the National Cancer Institute.2026;[Epub] CrossRef
Role of adipocytes and their derived extracellular vesicles in the progression, diagnosis and treatment of liver diseases (Review) Kangrong Li, Muhammad Zubair, Yongmin Yan, Jiahao Xu International Journal of Molecular Medicine.2026; 58(4): 1. CrossRef
Modified Citrus Pectin-Mediated Gal-3 Reduction Attenuates Metabolic Dysfunction-Associated Steatohepatitis in an Experimental Model Anne R. M. Santos, Alessandra G. Cruz, Felipe N. Camargo, Jessica D. M. Santos, Jorge F. A. Model, José F. T. Silva, Sandro L. Matos, Layanne C. C. Araujo, João Paulo Camporez Cells.2026; 15(17): 1544. CrossRef
Bifidobacterium breve CBT BR3 and Lactiplantibacillus plantarum CBT LP3 Alleviate Hepatic Steatosis by Suppressing Hepatic Lipogenesis and Improving Metabolic Hormone Profiles In Vitro and In Vivo Yeongju Yeo, Jong Won Kim, Yusook Chung, Gyeyeong Kong, Misun Yun, Sanghyun Lim Journal of Microbiology and Biotechnology.2026;[Epub] CrossRef
Inulin alleviates metabolic dysfunction-associated steatotic liver disease-induced bone loss potentially by activating the Nrf2/GPX4 signaling pathway Shaobo Gu, Junzhuo Wang, Kangpeng Zhong, Xuejie Yao, Jinfeng Wen, Dahua Chen, Deyi Yan, Zongkai Zhang, Honghui Chen, Xiaoyun Ding, Siyi Yu, Yi Chen, Chunxiao Li Molecular and Cellular Biochemistry.2026; 481(9): 5049. CrossRef
Real-world management of hypoparathyroidism: the impact of endocrinology specialist follow-up on biochemical and clinical outcomes - a retrospective cohort study Sezin Doğan Çakır, Mine Adaş BMC Endocrine Disorders.2026;[Epub] CrossRef
The Global Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease: Regional Hotspots, Trends, and Future Projections Saleh A. Alqahtani, Adam Buckholz, Carolin V. Schneider Current Hepatology Reports.2026;[Epub] CrossRef
Liver-nervous system axis in MASLD: mechanistic insights and emerging targeted therapies Xin Wang, Jianlei Zhang, Junzhe Guo, Boya Sheng, Jinwei Xu, Yinuo Yuan, Wajahat Mehal, Li Zuo, Hua Wang eGastroenterology.2026; 4(3): e100397. CrossRef
Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice Philip N. Newsome, Saima Ajaz Journal of Internal Medicine.2026; 300(4): 440. CrossRef
Polysaccharide III from Polygonatum cyrtonema Hua alleviates diabetes-associated MASLD via PPAR pathway-mediated regulation of lipid metabolism and gut microbiota modulation Sisi Chen, Zeming Ren, Zhongxiu Guo, Xiyu Mei, Xuan Chen, Yeling Tong, Xiangcheng Fan, Guanhai Dai Journal of Agriculture and Food Research.2026; 31: 103254. CrossRef
Current therapeutic landscape and future treatment perspectives of MASH Suchira Gallage, Olivier Govaere, Quentin M. Anstee, Gerald I. Shulman, Frank Tacke, Mathias Heikenwalder Nature.2026; 657(8130): 76. CrossRef
Hepatic steatosis risk in nonobese Chinese adults with type 1 diabetes Zehua Jin, Jianhua Ma, Yuanyang Zhao, Yi Luo, Christopher K Rayner, Tongzhi Wu, Yong Luo Journal of Diabetes Investigation.2026;[Epub] CrossRef
From Molecular Mechanisms to Clinical Strategies: A Comprehensive Overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Damian Świerczek, Maja Dreger, Jakub Jatkowski, Jakub Kancerek, Bogna Drozdzowska, Romuald Wojnicz International Journal of Molecular Sciences.2026; 27(17): 7825. CrossRef
Medical therapy of MASLD – consequences of the paradigm shift from histology to non-invasive tests Eva Katharina Messer, David Petroff, Katsutoshi Sugimoto, Philip N. Newsome, Fuminori Moriyasu, Shalimar, Marco Dioguardi Burgio, Cosmin Sebastian Voican, Valérie Vilgrain, Victor de Lédinghen, Daniel Jesper, Stephan Baumeler, Deike Strobel, Wah Kheong C JHEP Reports.2026; : 101996. CrossRef
Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications William R. Marshall, Smeeta Sinha, Darren Green, Philip A. Kalra Current Opinion in Nephrology & Hypertension.2026; 35(6): 666. CrossRef
Bacteroides cellulosilyticus
-derived 2-hydroxyphenylacetic acid rectifies hepatic lipid homeostasis in MASLD by targeting the PPARγ-CD36 axis
Kaiwei Chen, Zizhen Yang, Jixing Peng, Chunyan Liu, Ying Yu, Xinchi Cai, Bei Liu, Shuao Li, Tiantian Chen, Samil Jung, Yu Tian, Qianyue Xu, Xing Rao, Zhinan Wu, Haoyu Wang, Yan Di, Linna Wang, Jianxun Wang, Myeong-sok Lee, Yuanqiang Zou, Ningning He, Shan Gut Microbes.2026;[Epub] CrossRef
Hepatic exposome as an emerging contributor to metabolic dysfunction-associated steatotic liver disease Ahmed Salman, Ahmed Elewa, Ahmad Marwan, Mohamed A Salman World Journal of Translational Medicine.2026;[Epub] CrossRef
Cyclo(Val-Pro) and cyclo(Phe-Phe) alleviate MASLD via distinct CCR2- and ADCY7-associated pathways Jun Zhou, Haojie Jin, Yifan Zheng, Kunying Ding, Yu Long, Chenjie Yu, Yueran Zhang, Fen Zhuge, Minhua Chen, Zhengwei Fu, Yinhua Ni Life Sciences.2026; 405: 124669. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease Is Associated With Adverse Social Factors: An Analysis Using All of Us Manuela Araque, Stephanie M. Garces, Hui Yu, Mengsheng Zha, Sakina Qazi, Yan Guo, David Goldberg, Vatche Agopian, Jacob L. McCauley, Yvonne N. Flores, Patricia D. Jones Gastro Hep Advances.2026; 5(11): 101077. CrossRef
Molecular mechanisms and pathogenesis of MASH Suchira Gallage, Olivier Govaere, Quentin M. Anstee, Gerald I. Shulman, Frank Tacke, Mathias Heikenwalder Nature.2026; 657(8130): 59. CrossRef
Dietary one-carbon metabolism nutrients and risk of MASLD progression: a prospective cohort study Lijun Shen, Kai Wang, Renjie Li, Yafang Li, Yunchong Guo, Fangping Li, Jinqiu Yuan, Zhen Yang, Bin Xia, Xiahong Lin European Journal of Clinical Nutrition.2026;[Epub] CrossRef
Molekulare Mechanismen der MASLD- und MASH-Entwicklung Gerhard P. Püschel Adipositas - Ursachen, Folgeerkrankungen, Therapie.2026; 20(03): 141. CrossRef
Molecular smugglers in obesity-driven MASLD: snitching on adipose-derived extracellular vesicles Qiuyang Chen, Taisiia Shevchenko, Dewen Zhan, Ningning Ma, Sander Lefere, Joost Boeckmans, Joery De Kock, Freddy Van Goethem, Yong He, Tamara Vanhaecke, Robim M. Rodrigues Acta Pharmaceutica Sinica B.2026;[Epub] CrossRef
Associations of the insulinemic potential of diet and lifestyle with metabolic dysfunction-associated steatotic liver disease (MASLD) risk in adults with type 2 diabetes Danial Fotros, Ali Jafari, Azita Hekmatdoost, Marieh Salavatizadeh, Hossein Poustchi, Mohammad Ebrahim Khamseh, Zahra Yari Scientific Reports.2026;[Epub] CrossRef
Heart–liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework Xiao-Dong Zhou, Seogsong Jeong, Qin-Fen Chen, Giovanni Targher, Christopher D. Byrne, Nicholas W. S. Chew, Zobair M. Younossi, Gregory Y. H. Lip, Herbert Tilg, Jacob George, Norbert Stefan, Laurence S. Sperling, Hung N. Luu, Marat Fudim, Rohit Loomba, Min Nature Reviews Gastroenterology & Hepatology.2026;[Epub] CrossRef
Advances in the application of insulin resistance-related indicators in the clinical evaluation of metabolic dysfunction-associated steatotic liver disease Yi Li, Huan Li, Bolun Zhang, Qingming Wu, Hui Long Frontiers in Gastroenterology.2026;[Epub] CrossRef
Subclinical liver disease and incident cardiovascular events Le Li, Lingmin Wu, Zhicheng Hu, Limin Liu, Tao Zhang, Likun Zhou, Zhenhao Zhang, Yulong Xiong, Lihui Zheng, Ligang Ding, Yan Yao European Heart Journal.2026;[Epub] CrossRef
Intermittent time-restricted feeding recapitulates the physiological benefits of daily time-restricted feeding in male mice with chronic metabolic disease Andre Sarmento-Cabral, Marta G. Novelle, Luz Marina Sánchez-Mendoza, Natalia Herman-Sanchez, Samanta Lozano de la Haba, Marta Rodriguez-Vazquez, Pablo Iturbe, Eduardo Chicano-Gálvez, Francisco Javier Cubero, Raul M. Luque, Jose Cordoba-Chacon, Juan L. Lop Molecular Metabolism.2026; 113: 102432. CrossRef
Accumulation and Time-Dependent Changes in Unfavorable Eating Behaviors and the Risk of Incident Metabolic Dysfunction-Associated and Alcohol-Related/Associated Steatotic Liver Disease: A Retrospective Cohort Study Tatsuya Fukuda, Takahiro Okamoto, Takahiro Fukaishi, Akio Kawakami, Makoto Tanaka, Tetsuya Yamada, Koshiro Monzen Nutrients.2026; 18(18): 2957. CrossRef
Vitamin E treatment modulates steatotic and attenuates oxidative stress in a MASLD in vitro model Seyedeh Kiana Teymoorian, Kosar Nouri, Mahmoud Alipour Choshali, Moustapha Hassan, Elham Rismani, Massoud Vosough, Abbas Piryaei Molecular Biology Reports.2026;[Epub] CrossRef
Photoacoustic Imaging for Liver Disease: The Systems and the Molecules Bowen Jiang, Zhixian Lin, Xiaoquan Yang Biosensors.2026; 16(9): 497. CrossRef
Aqueous extract of Artemisia capillaris Thunb. herbal tea alleviates liver injury in MASLD mice and lipotoxicity in HepG2 cells by inhibiting apoptosis and promoting autophagy Yi Guo, Xiao Xiao, Shuhui Liu, Aige Han, Chen Xu, Binglin Wang, Yuyi Zhang, Xiaowen Jiang, Wenhui Yu Food Research International.2026; 245: 120606. CrossRef
Genome-wide DNA methylation profiling during metabolic dysfunction-associated steatohepatitis-related hepatocarcinogenesis in patients in Japan and the United States Junko Kuramoto, Eri Arai, Mao Fujimoto, Hiroki Muramoto, Hidenori Ojima, Yosuke Seki, Kazunori Kasama, Nobuaki Funahashi, Haruhide Udagawa, Takao Nammo, Kazuki Yasuda, Nobuyoshi Hiraoka, Teruhiko Yoshida, Kimberley Jane Evason, Yae Kanai Scientific Reports.2026;[Epub] CrossRef
Association of progesterone and prolactin with hepatic steatosis in premenopausal women: A prospective cross-sectional study Muhammed Aziz Ulusoy, Mustafa Comoglu, Oguzhan Zengin, Huseyin Camli, Esma Andac Uzdogan, Emra Asfuroglu Kalkan, Ihsan Ates Hormone and Metabolic Research.2026;[Epub] CrossRef
Letter to the Editor: Skeletal muscle transcriptomics in metabolic dysfunction-associated steatotic liver disease - balancing promise with validation María Victoria Delpino World Journal of Gastroenterology.2026;[Epub] CrossRef
Amyloid‐Forming Amylin Secreted by the Pancreas Promotes Hypoxia‐Inducible Factor Activation and Mitochondrial Alterations in Liver and Heart During Type 2 Diabetes Pathogenesis Alice E. Knapton, Nirmal Verma, Deepak Kotiya, Alice P. Sowton, Benjamin D. Thackray, Lorenz M. W. Holzner, Paula M. Darwin, Sanda Despa, Florin Despa, Andrew J. Murray Comprehensive Physiology.2026;[Epub] CrossRef
Cholesterol Metabolism Regulation by Native and Oxidized Low-Density Lipoprotein in a Liver Cell Line Nakyoung Kim, Toshihiro Sakurai, Himeno Sakuma, Akiko Sakurai, Nanao Murakami, Iku Sazaki, Shu-Ping Hui Journal of Atherosclerosis and Thrombosis.2026;[Epub] CrossRef
Assessment of health literacy among family caregivers of school-aged children with metabolic dysfunction associated steatotic liver disease Yueju Wang, Xiaoyan Feng, Qing Li, Jun Liu, Qingqing Zheng, Le Zhang Journal of Pediatric Nursing.2026; 91: 723. CrossRef
From targeted drug delivery to tissue regeneration: the evolving role of nanoparticle therapies in liver disease Jyothi U. Menon, Siddharth S. Menon Regenerative Medicine.2026; : 1. CrossRef
Shear wave elastography demonstrates similar risk stratification performance to vibration-controlled transient elastography in FIB-4–based two-step algorithms for MASLD Jaejun Lee, Hyun Yang, Si Hyun Bae, Sunhong Yoo, Soon Woo Nam, Jiwoon Yoon, Jung Hyun Kwon, Soon Kyu Lee Hepatology.2026;[Epub] CrossRef
Fructose and Alcohol Hepatotoxicity: Demographic Overlap and Mechanistic Interactions Arthur D. Stem, Athina Lisgara, Mohammad Alayyoub, Domenica Berardi, Oladimeji Aladelokun, Caroline H. Johnson, Richard J. Johnson, Vasilis Vasiliou Livers.2026; 6(5): 92. CrossRef
Immune metabolic reprogramming in MASLD Joanna Razafiarison, Nicolas Venteclef, Florent Ginhoux, Camille Blériot JHEP Reports.2026; : 102027. CrossRef
Key Hepatokines Linking MASLD and Type 2 Diabetes: From Pathophysiological Mechanisms to Therapeutic Modulation Georgeta Liliana Foia, Ancuta Goriuc, Ionut Luchian, Dana Gabriela Budala, Vasilica Toma, Maria Bogdan, Bogdan Minea, Larisa Ghemiș International Journal of Molecular Sciences.2026; 27(17): 7917. CrossRef
Older people living with HIV: a population with high prevalence and severity of metabolic dysfunction-associated steatotic liver disease ‒ A cross-sectional study Rafaella Italiano Peixoto, Andrea Dória Batista, Armando Ykaro Soares de Oliveira, Ana Lúcia Coutinho Domingues, Paulo Sérgio Ramos de Araújo The Brazilian Journal of Infectious Diseases.2026; 30(5): 105967. CrossRef
Targeting the E3 ubiquitin ligase RNF10 ameliorates metabolic dysfunction–associated steatohepatitis in mice Chunyuan Du, Yinliang Zhang, Hongkai Chang, Chaofan Xu, Sufang Sheng, Ke Xu, Wei Qiao, Yanjun Liu, Tongtong Zhang, Yong Gao, Peng Li, Yongsheng Chang Journal of Clinical Investigation.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease in the cardio-renal-metabolic syndrome: The silenced ‘H’ Javier Crespo, Paula Iruzubieta, Tomas de Vega, Jose Luis Calleja Medicina Clínica (English Edition).2026; 166(9): 107536. CrossRef
Artificial Intelligence in Endohepatology: Toward an Intelligent One‐Stop Shop for Liver‐Directed Endoscopy Ahmed Abdallah Salman Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
miR-582-5p promotes hepatic steatosis and inflammation via FAIM/PPARα axis in MASH Pei Liu, Dawei Cheng, Xinyu Cheng, Pengcheng Wu, Jinghua Gu, Xu Fan, XuDong Zhang, Rick F. Thorne, Hua Wang, Xiaoying Liu, Xinying Li Experimental Cell Research.2026; 462(2): 115171. CrossRef
Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study Tien Hoang Tran, Hyung‐Seok Kim, Rozalina G. McCoy, Zafar Zafari Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Metabolically Healthy Obesity, Its Resolution, and the Risk of Incident Hepatic Steatosis in Chinese Children: Evidence From Two Prospective Cohorts Jiaxiang Wang, Lili Yang, Zhuo Gong, Min Zhao, Yifei Hu, Bo Xi American Journal of Gastroenterology.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Vascular Complications: Associations with Serum Testosterone Levels in a Korean Multicenter Male Cohort Hyo Jung Cho, Seong Hee Kang, Hye Yeon Chon, SungA Bae, Eunju Kim, Seong Kyun Na, Su Jin Kim, Dooyeon Kim, Hye Ri Ahn, Huigyeong Kim, Soon Sun Kim, Jae Youn Cheong, Soon Koo Baik, Young Kul Jung, Hyung Joon Yim Gut and Liver.2026; 20(5): 870. CrossRef
Differential Cancer Risks and Noninvasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis Hana Park, Ji Young Lee, Ja Eun Koo, Jong Soo Lee, Sungwon Park, Hye Won Park, Hye-Sook Chang, Hong-Kyu Kim, Jaewon Choe, Ju Hyun Shim Gut and Liver.2026; 20(5): 880. CrossRef
Vitamin E administration reduces liver enzyme levels in patients with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD): evidence from a systematic review and meta-analysis Mehdi Karimi, Maryam Abidi, Ramak Gholamian, Alireza Ostovan, Negar Zakerolhosseini, Sara Boroomand, Sana Esmaeili, Mohammad Hadi Pourramezan, Sina Mohebi, Abolfazl Javadimoghadam, Farimah Behmaneshnia, Omid Asbaghi Nutrition & Metabolism.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Gut and Liver.2026; 20(5): 728. CrossRef
Nutriomic Technologies for Characterizing, Diagnosing, Clustering and Managing Chronic Liver Diseases: Precision Nutrition Implications Nuria Perez-Diaz-del-Campo, Miguel Lopez-Moreno, Begoña de Cuevillas, Diego Martinez-Urbistondo, J. Alfredo Martínez, Omar Ramos-Lopez International Journal of Molecular Sciences.2026; 27(18): 8106. CrossRef
Application of artificial intelligence in hepatology Zekai Hu, Yajie Lin, Hainv Gao, Leyao Shuai, Zhaowei Tong, Chenqi Nie, Zhe Yang, Junsheng Zhao Frontiers in Digital Health.2026;[Epub] CrossRef
Stéatohépatite associée à un dysfonctionnement métabolique (MASH) : prise en charge M.A. Farrugia, P. Gual, R. Anty EMC - Hépatologie.2026; 41(4): 1. CrossRef
A bioengineered platform reveals progressive impairment of skeletal muscles by metabolic dysfunction-associated steatotic liver disease-derived factors Armando Cortés-Reséndiz, Juan M. Fernández-Costa, Maria Sabater-Arcís, Francesco De Chiara, Javier Ramón-Azcón Disease Models & Mechanisms.2026;[Epub] CrossRef
Licoisoflavone A ameliorates adipose tissue dysfunction in diet‑induced obesity by promoting METTL3 expression Shuangxi Tu, Xiaodan Wang, Zhenbo Wang, Haojun Tang, Kai Yin, Xiao Zhu Molecular Medicine Reports.2026; 34(4): 1. CrossRef
Keratin 8 Destabilization via O-GlcNAcylation Promotes Insulin Resistance in metabolic dysfunction associated steatotic liver disease Long Teng, Ling Luo, Jiaming Lai, Congxiang Shao, Bihui Zhong, Junzhao Ye Metabolism.2026; 185: 156779. CrossRef
Efficacy of efruxifermin in improving liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis/nonalcoholic steatohepatitis: a systematic review and meta-analysis of randomized controlled trials Zain ul Abideen, Muhammad Hassan Waseem, Areeba Shoaib, Muhammad Osama, Tehreem Fatima, Muhammad Hasnain Panjwani, Noor-ul-Huda Ramzan, Pawan Kumar Thada, Prasun Kumar Jalal European Journal of Gastroenterology & Hepatology.2026;[Epub] CrossRef
Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities Yifan Liu, Zihao Xu, Dong-Seon Kim, Hai Xu, Huikun Wu Frontiers in Pharmacology.2026;[Epub] CrossRef
Betaine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms of Action and Therapeutic Potential Tatjana Radosavljevic, Jasmina Djuretic, Milica Brankovic, Janko Samardzic, Ivana Curuvija, Danijela Vucevic Antioxidants.2026; 15(9): 1209. CrossRef
A 5:2 Intermittent Fasting Regimen Ameliorates High‐Fat Diet‐Induced MASLD‐Associated Skeletal Muscle Impairment in Mice Ruohua Wang, Rui Yang, Dan Hu, Tonghe Xin, ZiXin Yang, Yue Guan, Yucun Niu Journal of Cachexia, Sarcopenia and Muscle.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease: pathogenic mechanisms and exercise-induced molecular adaptations Senlin Lei, Jiasheng Tao, Xiaoan Chen, Xianhui Li, Songwei Zhong Lipids in Health and Disease.2026;[Epub] CrossRef
Neue Therapieansätze bei MASH: Mechanismen und klinisches Potenzial Alexander Barton, Jörn M. Schattenberg Zeitschrift für Gastroenterologie.2026; 64(09): 1250. CrossRef
When the Beat and the Bleed Compete: An Opportunity for INTERBLEED Subgroup Analysis in Patients With Liver Cirrhosis Martin S. Mccoy, Kai-Henrik Peiffer, Jan M. Hähner, Michael Praktiknjo, Jonel Trebicka Gastroenterology.2026;[Epub] CrossRef
Metabolic and Bariatric Surgery as a Therapeutic Option for MASLD: Outcome, Mechanism, and Long-Term Implications Christopher Tuffs, Anca Laura Amati, Daniar Amin, Sonali Raj, Thilo Sprenger, Andreas Hecker, Martin Schneider, Martin Reichert, Moritz J. Strowitzki Zeitschrift für Gastroenterologie.2026; 64(09): 1291. CrossRef
Association of metabolic dysfunction-associated steatotic liver disease with colorectal cancer incidence and surgical outcomes Abdulaziz Elemosho, Selamawit Woldesenbet, Arshum Mirzaeifard, Kizuki Yuza, Meher Angez, Odysseas P. Chatzipanagiotou, Charalampos M. Charalampous, Areesh Mevawalla, Qaidar Alizai, Rida Ejaz, Lorenza Arena, Timothy M. Pawlik HPB.2026;[Epub] CrossRef
Low Metabolic Dysfunction–Associated Steatotic Liver Disease Awareness and Missed Screening Opportunities: Results From a United Kingdom Population and Clinician Survey Damien Leith, Paul N. Brennan, Ruairi W. Lynch, John F. Dillon, Christopher J. Byrne Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD Lampros Chrysavgis, Evangelos Cholongitas International Journal of Molecular Sciences.2026; 27(18): 8368. CrossRef
Early-life exposure to tobacco smoke, metabolomic perturbation, and metabolic dysfunction-associated steatotic liver disease incidence risk in later life Yani Xiong, Jiahao Song, Shuhui Wan, Wendi Shi, Qing Liu, Le Hong, Zhiying Huo, Da Shi, Feifei Wang, Pengfei Chen, Wenshan Shi, Jie Liu, Jinqiang Li, Jiamin Xu, Bin Wang Environmental Pollution.2026; 410: 129213. CrossRef
Small-Nerve Fibre Pathology in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Liver Fat/Inflammation and Improves with Weight Loss Alex E. Henney, Azlinda Hamid, Jamie Burgess, David R. Riley, Barbara Fielding, Anne Marshall, Khansa Makawi, Abdel-Naser Elzouki, Einas Elgassim, Graham J. Kemp, Rayaz A. Malik, Uazman Alam, Daniel J. Cuthbertson Nutrients.2026; 18(19): 3242. CrossRef
Genome-wide association and polygenic risk score analyses of MASLD-related hepatic steatosis severity in a Taiwanese Han population Ting-Yuan Liu, Jai-Sing Yang, Yu-Chia Chen, Shih-Chang Tsai, Yu-Jen Chiu, Chi-Chou Liao, Yen‐Ting Chang, Woei-Cheang Shyu, Long-Bin Jeng, Fuu-Jen Tsai Cell & Bioscience.2026;[Epub] CrossRef
Dynamic changes in controlled attenuation parameter (CAP) improve prognostic prediction for CHB patients with significant fibrosis and cirrhosis Xiaowei Ai, Mengyang Zhang, Shuyan Chen, Xinyu Zhao, Jialing Zhou, Tongtong Meng, Bingqiong Wang, Chenglin Sun, Xiao Han, Yankun Gao, Xiaoning Wu, Hong You, Yameng Sun Hepatology International.2026;[Epub] CrossRef
Sex differences in MASLD and fitness improvement during a weight loss intervention for adolescents living with obesity Maarten Buytaert, Kristof Vandekerckhove, Ilse Coomans, Maxine Vangampelaere, Ellen Dupont, Silke Stalpaert, Kevin Caen, Sander Lefere, Ruth De Bruyne JHEP Reports.2026; : 102059. CrossRef
Baseline Liver Metabolic Health in Newly Diagnosed People Living with HIV Compared with HIV-Negative Controls: Cross-Sectional Findings from the Prospective MASHIV-TR Cohort Çiğdem Mermutluoğlu, Yeşim Taşova, Ayşe Özlem Mete, İlkay Karaoğlan, Hüsnü Pullukçu, Meliha Çağla Sönmezer, Dilara İnan, Funda Şimşek, Sıla Akhan, Tuba Damar Çakırca, Nursel Çalık Başaran, Aslıhan Candevir, Yeliz Çiçek, Damla Ertürk, Ahmet Çağkan İnkaya, International Journal of Molecular Sciences.2026; 27(19): 8672. CrossRef
Taurocholic acid attenuates hepatic inflammation in MASH and modulates the PPARγ/NF-κB axis Yue Zhu, Jishuang San, Guangyi Ouyang, Yunheng Liu, Weiwei Li, Jiancheng Yang, Gaofeng Wu European Journal of Pharmacology.2026; 1036: 179395. CrossRef
Sugar-Sweetened Beverages and Childhood Obesity: A Life-Course Perspective Bianca Simionescu, Ancuța Lupu, Alexandra Sidoreac, Vasile Valeriu Lupu, Elena Roxana Buzilă, Raluca Olariu, Bogdan Novac, Ileana Ioniuc, Mihaela Monica Alexoae, Roxana Șerban, Otilia Novac, Emil Anton, Oana Raluca Temneanu Nutrients.2026; 18(19): 3118. CrossRef
Escalating mortality and widening disparities in metabolic dysfunction-associated steatotic liver disease and related hepatocellular carcinoma in the US, 1999–2020 Hongmei Lyu, Ningning Liu, Weifeng Yao, Qiang Wang, Liping Peng, Yi Lu, Xiaoyuan Chen Scientific Reports.2026;[Epub] CrossRef
Bariatric surgery may alleviate MASLD by restoring mitochondria-lipid droplet structural and functional integrity through suppression of the Mitochondrial Fission Factor-Perilipin 5 axis Yuze Sun, Yuxuan Liu, Xiyu Chen, Shizhou Deng, Ning Zhang, Feifei Wu, Dong Fan, Yayun Wang, Yanling Yang Molecular Biomedicine.2026;[Epub] CrossRef
Prospective evaluation of hepatic steatosis and fibrosis after one anastomosis gastric bypass using transient elastography Wissam Ghusn, Shahab Shahabi Shahmiri, Mahsa Soleimani, Seidamir Pasha Tabaeian, Omar M. Ghanem, Mohammad Kermansaravi Scientific Reports.2026;[Epub] CrossRef
Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum Han Ah Lee, Gi-Ae Kim, Won Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0367. CrossRef
Childhood Diet, Gut Microbiota and Early Cardiovascular Risk: A Narrative Review Michał Mazur, Agnieszka Malik, Joanna Popiołek-Kalisz SN Comprehensive Clinical Medicine.2026;[Epub] CrossRef
Therapeutic landscape evolution for steatotic liver disease: from lifestyle interventions to precision pharmacotherapy Shirley Huey Shin Bong, Kevin Kim Jun Teh, Vincent Wai-Sun Wong Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0125. CrossRef
The liver–muscle axis in metabolic dysfunction-associated steatotic liver disease: a narrative review and conceptual framework for body-composition phenotyping Zhendong Ma, Xinri Zhang, Yan Leng, Xingyu Chen Frontiers in Medicine.2026;[Epub] CrossRef
Randomised trial of lifestyle interventions for improving metabolic dysfunction-associated steatotic liver disease Wouter Robaeys, Leen JM. Heyens, Liesbeth Bruckers, Joris Penders, Mathieu Struyve, Ger H. Koek, Sven MA. Francque, Geert KMM. Robaeys Hepatology International.2026;[Epub] CrossRef
Liver disease risk in patients with psoriasis treated with biologics Arjun Mahajan, Maureen Whittelsey, David Westfall Bates, Jeffrey A Sparks, Avery H LaChance, Sheela Reddy, Evan W Piette BMJ Immunology.2026; 1(1): e000026. CrossRef
Blueberry attenuates oxidative stress-associated signals and neutral lipid accumulation in 2D and 3D hepatic cell models Angela Mirarchi, Angelo Galluccio, Rosario Mare, Samantha Maurotti, Francesca Scionti, Francesca Rita Noto, Luana Carmen Mirabello, Martina Rago, Luigi Rotundo, Anna Peta, Bernadette Scopacasa, Yvelise Ferro, Elisa Mazza, Patrizio Candeloro, Luca Tirinato Food Bioscience.2026; 85: 110105. CrossRef
Joint association of body roundness index and HOMA-IR with risk of MASLD in Korean populations Kyo-sun Lee, Sung-Ho Ahn, Da-Hye Son, Yong-Jae Lee BMC Endocrine Disorders.2026;[Epub] CrossRef
Hepatic Overexpression
of a Novel Soluble Endogenous
Transforming Growth Factor β Type II Receptor–Immunoglobulin
G1 Fc Fusion Protein (TβRII-SE/Fc) Attenuates Early Stage Metabolic
Dysfunction-Associated Steatotic Liver Disease in Rats Carolina Anahí Cámara, Anabela La Colla, Tania Melina Rodríguez, Ricardo Alfredo Dewey, Andrea Chisari ACS Pharmacology & Translational
Science.2026; 9(10): 2960. CrossRef
The role of mitochondrial DNA and RNA in promoting liver disease pathogenesis Sanjeevani Raj, Anjali Warhade, Nikkee Kumari, Shweta Pandey, Mrigya Babuta Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
SIRT1-miRNA Regulatory Networks in Liver Diseases: Mechanistic Convergence, Cellular Senescence, and Translational Implications Amr Ali Mohamed Abdelgawwad El-Sehrawy, Safa H. Radhie, Mirza R. Baig, Djaloliddin Mansurov, Rekha M. M, Priya Priyadarshini Nayak, Neeraj Bainsal, Divya Singhal, Aseel Smerat, Mohammed Almajar The Journal of Pharmacology and Experimental Therapeutics.2026; : 105031. CrossRef
Epigenetic antifibrotic effect of expression of long non-coding RNAs GAS5, MEG8, FLRL2 on the development of fibrosis in metabolic dysfunction-associated steatotic liver disease: systematic review A.E. Abaturov, A.O. Nikulina GASTROENTEROLOGY.2026; 60(3): 234. CrossRef
Ultrassonografia com contraste por microbolhas no fígado: atualização clínica sobre agentes, técnica e CEUS LI-RADS Patrícia Henicka Do Amaral, Alessandra Thomé Espada, Camila Lençone, Franciele Leonilda Delgado, Letycia Camargo da Silva Scartezin, Gabriel Machado, Bruno Faleiros De Andrade, Madian Anália Amorim Campos Marcondes, José Geraldo Do Amaral Revista Sociedade Científica.2026; 9(1): 2774. CrossRef
New avenues in metabolic disease treatment: duodenal mucosal resurfacing and gene therapy Christina Dias, Smit Patel, Tanmay Gaglani, Nirav Thosani Exploration of Endocrine and Metabolic Diseases.2026;[Epub] CrossRef
PNPLA3 Is Associated With Hepatocellular Carcinoma, While a Five‐Variant Polygenic Risk Score Shows Limited Discrimination in Korean Patients With MASLD Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Hyun Yang, Mi Young Byun, Seok Keun Cho, Seong Wook Yang, Si Hyun Bae, Seung Up Kim, Su Jong Yu, Pil Soo Sung Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Classification of pre-metabolic syndrome and metabolic syndrome using machine learning and routine clinical variables in Thai adults Metha Yaikwawong, Khanittha Kamdee, Somlak Chuengsamarn, Marwan Salih Al-Nimer PLOS One.2026; 21(9): e0359283. CrossRef
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial Mijra Koning, Artemiy Kovynev, Marcos F. Fondevila, Eliza J. M. Ruhe, Michiel C. Mommersteeg, Christian Ramakers, Barbara A. Hutten, Bart Verwer, Marije Vlug, Teaco Kuiper, Maarten van den Berg, Anne Vrieze, Maurice Bizino, Annewieke van den Beld, Luuk Be Nature Metabolism.2026;[Epub] CrossRef
MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management Hubert Krzewiński, Oliwier Wątroba, Jarosław Koza Journal of Clinical Medicine.2026; 15(19): 7540. CrossRef
The metabolic paradigm shift in gastroenterology and hepatology: Clinical applications of incretin-based co-agonists Abdulrahman Ismaiel, Dan L. Dumitrascu Best Practice & Research Clinical Gastroenterology.2026; : 102146. CrossRef
Machine learning–assisted prediction of obstructive sleep apnea in patients with metabolic dysfunction-associated steatotic liver disease: a multicenter study with external validation Qihang Gao, Yahui Wu, Ke Lei, Tie Zhao, Yixiang Xing, Min Kang, Yun Shen BMC Endocrine Disorders.2026;[Epub] CrossRef
Allostatic load, unhealthy behaviors, and mortality risk among participants with and without metabolic dysfunction–associated steatotic liver disease Dongzhi Hong, Bin Xi, Zuopei Lv, Nannan Li, Xinyu He, Xinyi Zhu, Jianan Zhang, Chenxing Wang, Zhenzhai Cai, Hao Wu, Beilei Fu European Journal of Gastroenterology & Hepatology.2026;[Epub] CrossRef
Clinical trends in hepatocellular carcinoma from 2005 to 2019 with a focus on metabolic diseases: a German nationwide study Josune Cabello, Wenyi Gu, Robert Schierwagen, Maximilian Joseph Brol, Frank Erhard Uschner, Martin Sebastian McCoy, Sabine Klein, Kai-Henrik Peiffer, Dominik Van de Loo, Andreas Pascher, Martina Holstein, Felix Becker, Haluk Morgül, Michael Köhler, Max Ma European Journal of Gastroenterology & Hepatology.2026; 38(11): 1339. CrossRef
Cuproptosis and ferroptosis: signal pathways, diseases and therapeutic targets Yuan-Yuan Li, Franklin R. Tay Signal Transduction and Targeted Therapy.2026;[Epub] CrossRef
Discordance between ICD‐10‐AM coding and confirmed prevalence of MASLD in a quaternary diabetes service Janakan Selvarajah, Maddison Terlato, Weilun Gao, Omar Salehi, Christine Lu, Faris Gondal, Karen Lu, Angela Zhu, Spiros Fourlanos, Ashok S. Raj Internal Medicine Journal.2026;[Epub] CrossRef
Restricted Spectrum Imaging for Diagnosis of High‐Risk Metabolic Dysfunction‐Associated Steatohepatitis Jie Yuan, Huamei Yan, Zhiwei Qin, Liping You, Guangda Liu, Wei Xu, Zheng Tu, Jinghao Zhang, Xuehua Sun, Wenli Tan Journal of Magnetic Resonance Imaging.2026;[Epub] CrossRef
Semaglutide for metabolic dysfunction-associated steatotic liver disease in Asian and lean populations Yeo Wool Kang Kosin Medical Journal.2026; 41(3): 203. CrossRef
Targeting gut dysbiosis: a new frontier in MASLD management Shweta Sharma, Arun Pachauri, Harshal Nagar, Vishwa Thakkar, Kajal Patel Frontiers in Systems Biology.2026;[Epub] CrossRef
siRNA therapeutics for metabolic dysfunction-associated Steatohepatitis: Targets, delivery, clinical evidence, and translational challenges Yanan Guo, Qunyan Yao Biochemistry and Biophysics Reports.2026; 48: 102817. CrossRef
Association of steatotic liver disease with long-term oncological outcomes after hepatic resection for hepatocellular carcinoma Nobuhiro Hasui, Saori Funakoshi, Aya Yamazaki, Takuya Yanase, Shohei Kudo, Hirokazu Momose, Ryota Matsuki, Masaharu Kogure, Akimasa Hayashi, Yutaka Suzuki, Junji Shibahara, Yoshihiro Sakamoto Global Health & Medicine.2026;[Epub] CrossRef
Ovarian tumor domain-containing protein 1 deficiency attenuates metabolic dysfunction-associated steatotic liver disease by promoting the ubiquitination of HSP90α in hepatocytes Mei-Qin Huang, Si-Yi Wei, Meng-Zhe Li, Tian-Yu Chen, Shu-Qin Ou, Meng Gao, Feng Shi, Tao Zhang, Ying-Lan Liu, Meng-Zhuo Qin, Run-Lei Du, Qi Zhang, Bai-Qi Wang, Xiao-Dong Zhang Molecular Biomedicine.2026;[Epub] CrossRef
Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling Ying He, Tianyi Ma, Hanying Xing, Xinming Cao, Fanfan Song, Yongning Pan, Luping Ren European Journal of Pharmacology.2026; : 179418. CrossRef
Klotho Within Cardio-Renal-Hepatic-Metabolic Health: Integrating Mineral Metabolism, Organ Crosstalk, and Therapeutic Opportunities Sanika Taigade, Siddhi Bagwe Parab, Gaurav Doshi Ageing Research Reviews.2026; : 103390. CrossRef
Obesity-induced mesenchymal stem cell dysfunction: from molecular mechanisms to therapeutic strategies Ahmed Elmaraezy, Xiang-Yang Zhu, Alfonso Eirin, Lilach O. Lerman Metabolism and Target Organ Damage.2026;[Epub] CrossRef
Endoscopic Bariatric and Metabolic Therapies for Metabolic Dysfunction-Associated Steatohepatitis: From Weight Loss to Liver Direct Outcomes. Is it possible to include them as a therapeutic option? Cristian Alejandro Bautista-Mondragón, Eva Juárez-Hernández, Adrian López-Pérez-Alférez, Graciela Castro-Narro, Iván López-Méndez Best Practice & Research Clinical Gastroenterology.2026; : 102153. CrossRef
Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults Guannan Zong, Wangjia Mao, Ming Wen, Xiaoyun Cheng, Guanghui Liu Annals of Hepatology.2025; 30(2): 101583. CrossRef
Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang Diabetes & Metabolism.2025; 51(1): 101602. CrossRef
Hepatic Estrogen Receptor Alpha Overexpression Protects Against Hepatic Insulin Resistance and MASLD Ester S. Alves, Jessica D. M. Santos, Alessandra G. Cruz, Felipe N. Camargo, Carlos H. Z. Talarico, Anne R. M. Santos, Carlos A. A. Silva, Henrique J. N. Morgan, Sandro L. Matos, Layanne C. C. Araujo, João Paulo Camporez Pathophysiology.2025; 32(1): 1. CrossRef
Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States Fan Zhang, Longgen Liu, Wenjian Li Nutrition Journal.2025;[Epub] CrossRef
The association between working hours and working type with non-alcoholic fatty liver disease: results from the NHANES 1999-2014 Ruli Wang, Ningxi Wu, Huan Qu, Xiaowei Zheng, Haoyang Zhang, Lihong Zhu, Xiaolei Wang, Xiaodie Yao, Le Zhang Frontiers in Endocrinology.2025;[Epub] CrossRef
Genetic risk amplifies lifestyle effects on hepatic steatosis and its progression: Insights from a population-based cohort Xin Zhang, Haili Wang, Chengnan Guo, Shuzhen Zhao, Yi Li, Zhenqiu Liu, Tiejun Zhang Digestive and Liver Disease.2025;[Epub] CrossRef
Tetrahydrocurcumin Alleviates Metabolic Dysfunction-Associated Steatohepatitis in Mice by Regulating Serum Lipids, Bile Acids, and Gut Microbiota Shang Peng, Moran Meng, Ping Luo, Jiao Liu, Junjun Wang, Yong Chen International Journal of Molecular Sciences.2025; 26(3): 895. CrossRef
Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity Katharina L. Hupa-Breier, Heiko Schenk, Alejandro Campos-Murguia, Freya Wellhöner, Benjamin Heidrich, Janine Dywicki, Björn Hartleben, Clara Böker, Julian Mall, Christoph Terkamp, Ludwig Wilkens, Friedrich Becker, Karl Lenhard Rudolph, Michael Peter Manns Molecular Metabolism.2025; 93: 102104. CrossRef
Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen Cells.2025; 14(3): 221. CrossRef
Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease Yunfei Wu, Guojun Zheng, Fan Zhang, Wenjian Li Frontiers in Immunology.2025;[Epub] CrossRef
Liver fibrosis progression analyzed with AI predicts renal decline Dan-Qin Sun, Jia-Qi Shen, Xiao-Fei Tong, Ya-Yun Ren, Hai-Yang Yuan, Yang-Yang Li, Xin-Lei Wang, Sui-Dan Chen, Pei-Wu Zhu, Xiao-Dong Wang, Christopher D. Byrne, Giovanni Targher, Lai Wei, Vincent W.S. Wong, Dean Tai, Arun J. Sanyal, Hong You, Ming-Hua Zhen JHEP Reports.2025; 7(5): 101358. CrossRef
Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut–Liver Axis Adrian Rotaru, Remus Stafie, Ermina Stratina, Sebastian Zenovia, Robert Nastasa, Horia Minea, Laura Huiban, Tudor Cuciureanu, Cristina Muzica, Stefan Chiriac, Irina Girleanu, Ana-Maria Singeap, Catalin Sfarti, Carol Stanciu, Anca Trifan Life.2025; 15(2): 288. CrossRef
Sex differences in diet-induced MASLD – are female mice naturally protected? Jana Meyer, Ana Mendes Teixeira, Sandy Richter, Dean P. Larner, Asifuddin Syed, Nora Klöting, Madlen Matz-Soja, Susanne Gaul, Anja Barnikol-Oettler, Wieland Kiess, Diana Le Duc, Melanie Penke, Antje Garten Frontiers in Endocrinology.2025;[Epub] CrossRef
Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nak Journal of Gastroenterology.2025; 60(7): 891. CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
A Narrative Review on the Risk Factors and Healthcare Disparities of Type 2 Diabetes Elvira Meni Maria Gkrinia, Andrej Belančić Diabetology.2025; 6(4): 25. CrossRef
Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur Stergios A. Polyzos, Christos S. Mantzoros Metabolism.2025; 168: 156253. CrossRef
Molecular Landscape and Diagnostic Model of MASH: Transcriptomic, Proteomic, Metabolomic, and Lipidomic Perspectives Yilong Chen, Shuixiu Bian, Jiamei Le Genes.2025; 16(4): 399. CrossRef
Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques Pirangi Srikanth, Khaja Moinuddin Shaik, Vijay Patibandla, Deepak Kumar, Sukhendu Nandi Exploration of Endocrine and Metabolic Diseases.2025;[Epub] CrossRef
Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)! Hannah Mohr, Jonathan G. Stine Alimentary Pharmacology & Therapeutics.2025; 61(9): 1565. CrossRef
The socioeconomic and environmental determinants of metabolic dysfunction-associated steatotic liver disease: understanding inequalities in prevalence and outcomes Dominika Lorek, Krzysztof Łupina, Wiktoria Bisaga, Dominik Malicki, Weronika Stępień, Laura Kumor, Jakub Janczura Korean Journal of Family Medicine.2025; 46(2): 61. CrossRef
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho Trends in Endocrinology & Metabolism.2025; 36(11): 1000. CrossRef
Use of Hepatoscope 2DTE for non-invasive assessment of liver stiffness among Mexican immigrant adults in a community-based setting Edgar A. Villavicencio, Cindy Serdjebi, Adriana Maldonado, Estefania Ochoa Mora, Adrien Besson, Naim Alkhouri, David O. Garcia Clinics and Research in Hepatology and Gastroenterology.2025; 49(5): 102581. CrossRef
Potential bidirectional communication between the liver and the central circadian clock in MASLD Frédéric Gachon, Elisabetta Bugianesi, Gabriele Castelnuovo, Henrik Oster, Julie S. Pendergast, Sara Montagnese npj Metabolic Health and Disease.2025;[Epub] CrossRef
Impact of Severity of Metabolism-Related Fatty Liver Disease Based on Pathologic Grading on Outcomes after Sleeve Gastrectomy 云飞 曲 Journal of Clinical Personalized Medicine.2025; 04(02): 826. CrossRef
GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e189. CrossRef
Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease” Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li Clinical and Molecular Hepatology.2025; 31(2): e145. CrossRef
Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy Yun Feng, Bingran Yu, Anxiao Liu, Chongpeng Cai, Changming Zhou, Tong Tong, Lu Wang, Qi Pan Frontiers in Nutrition.2025;[Epub] CrossRef
The Unequal Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease in 204 Countries and Territories From 1990 to 2021 Junqiao Feng, Yudan Fan Liver International.2025;[Epub] CrossRef
Chronic Hepatitis B and MASLD: Growing Awareness and Unmet Clinical Needs Nicola Pugliese, Davide Polverini, Stefano Ciardullo Liver International.2025;[Epub] CrossRef
Multi‐Center, Multi‐Vendor Validation of Simultaneous MRI‐Based Proton Density Fat Fraction and R2* Mapping Using a Combined Proton Density Fat Fraction‐R2* Phantom Jitka Starekova, David Rutkowski, Won C. Bae, Hung Do, Ananth J. Madhuranthakam, Vadim Malis, Sheng Qing Lin, Suraj Serai, Takeshi Yokoo, Scott B. Reeder, Jean H. Brittain, Diego Hernando Journal of Magnetic Resonance Imaging.2025; 62(3): 800. CrossRef
Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease Murali Krishna Moka, Deepalaxmi Rathakrishnan, D.K. Sriram, Melvin George Clinical Nutrition.2025; 49: 52. CrossRef
Targeting Metabolism: Innovative Therapies for MASLD Unveiled Weixin Wang, Xin Gao, Wentong Niu, Jinping Yin, Kan He International Journal of Molecular Sciences.2025; 26(9): 4077. CrossRef
Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease? Luciana Agoglia, Maria Chiara Chindamo, Cristiane Villela-Nogueira World Journal of Hepatology.2025;[Epub] CrossRef
Evaluating the RESET care program: Advancing towards scalable and effective healthcare solutions for metabolic dysfunction-associated liver disease Mariana M Ramírez-Mejía, Froylan D Martínez-Sánchez, Jacqueline Córdova-Gallardo, Nahum Méndez-Sánchez World Journal of Hepatology.2025;[Epub] CrossRef
Association between glucose time-in-range and the severity of metabolic dysfunction-associated steatotic liver disease in Chinese adults with type 2 diabetes mellitus Chun-Hua Wang, Xuan-Yao Ji, Nian Ji, Qing-Feng Yan, Hong-Qing Xu, Xue-Qin Wang, Xiang-Fan Chen, Chun-Feng Lu BMC Endocrine Disorders.2025;[Epub] CrossRef
Gut microbiota in patients with metabolic, dysfunction-associated steatotic liver disease Lissette Duarte, Fabien Magne, Martin Gotteland Current Opinion in Clinical Nutrition & Metabolic Care.2025; 28(4): 307. CrossRef
Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease Sheng Lyu, Jiani Yang, Xin Xin, Qinmei Sun, Beiyu Cai, Xin Wang, Ziming An, Jian Sun, Yiyang Hu, Lei Shi, Qin Feng, Xiaojun Gou BMC Gastroenterology.2025;[Epub] CrossRef
Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies Claudia Reytor-González, Daniel Simancas-Racines, Martín Campuzano-Donoso, Janeth Castano Jimenez, Náthaly Mercedes Román-Galeano, Gerardo Sarno, Evelyn Frias-Toral Food and Agricultural Immunology.2025;[Epub] CrossRef
Association between urinary albumin-to-creatinine ratio and all-cause and cardiovascular-cause mortality among MASLD: NHANES 2001–2018 Zhengjin Wang, Zhangxin Chen, Hanxu Zhuang Frontiers in Nutrition.2025;[Epub] CrossRef
Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study Yee Hui Yeo, Yixuan Zhu, Jingli Gao, Shanghao Liu, Wenjing Ni, Fajuan Rui, Xue Bai, Nan Geng, Rui Jin, Elizabeth K. Speliotes, Chao Wu, Junping Shi, Xiaolong Qi, Vincent L. Chen, Philip N. Newsome, Jie Li Alimentary Pharmacology & Therapeutics.2025; 62(2): 168. CrossRef
Association of gut microbiota dietary index with metabolic dysfunction-associated steatotic liver disease: the mediating roles of inflammation and body mass index Yu Pu, Zongbiao Tan, Yanrui Wu, Suqi Zeng, Haodong He, Jixiang Zhang, Weiguo Dong Frontiers in Nutrition.2025;[Epub] CrossRef
Association of sarcopenia and physical activity on the severity of metabolic dysfunction-associated steatotic liver disease among United States adults: NHANES 2017 - 2018 Xiaodie Wei, Xiaohui Liu, Jinhan Zhao, Yang Zhang, Lixia Qiu, Jing Zhang Frontiers in Aging.2025;[Epub] CrossRef
Low carbohydrate and low-calorie diets reduce liver fat and lower brain glutamate and myo-inositol levels in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Andreana P. Haley, Jack Knight-Scott, Marie Caillaud, Isabelle Gallagher, Jessica Park, Yanrong Li, Tianyu Wang, Hirofumi Tanaka, Jeffrey D. Browning Metabolic Brain Disease.2025;[Epub] CrossRef
FGF21 reverses MASH through coordinated actions on the CNS and liver Jesse P. Rose, Donald A. Morgan, Andrew I. Sullivan, Xiaorong Fu, Melissa Inigo-Vollmer, Shawn C. Burgess, David K. Meyerholz, Kamal Rahmouni, Matthew J. Potthoff Cell Metabolism.2025; 37(7): 1515. CrossRef
Liver cirrhosis in metabolic dysfunction-associated steatohepatitis Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah Gastroenterology Report.2025;[Epub] CrossRef
From liver to limb: Exploring the association between fatty liver disease and peripheral artery disease—A systematic review Vera Ciornolutchii, Abdulrahman Ismaiel, Jennifer Bogdan, Stefan‐Lucian Popa, Teodora Surdea‐Blaga, Dan L. Dumitrascu European Journal of Clinical Investigation.2025;[Epub] CrossRef
Developing and validating a predictive model for all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease Fan Zhang, Longgen Liu, Wenjian Li Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis Zhifa Ge, Qingwei Wu, Chengyu Lv, Qifeng He Immunology.2025; 176(2): 145. CrossRef
Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma Young-Min Jee, Jeong-Yoon Lee, Tom Ryu Biomedicines.2025; 13(5): 1260. CrossRef
Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry Yusuf Yilmaz, Caglayan Keklikkiran, Andrei Racila, Maria Stepanova, Zobair M. Younossi Clinical and Translational Gastroenterology.2025; 16(6): e00844. CrossRef
Impact of Metabolic Dysfunction–associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure Bhavik Bansal, Fannie Lajeunesse-Trempe, Neil Keshvani, Carl J. Lavie, Ambarish Pandey Canadian Journal of Cardiology.2025; 41(9): 1777. CrossRef
Pathogenesis and Treatment of Hepatocellular Carcinoma Associated with Nonalcoholic Steatohepatitis 舒惟 梁 Advances in Clinical Medicine.2025; 15(05): 2063. CrossRef
Prevalence of MASLD, Met-ALD, and ALD and Associated Fibrosis Among US Adults James M. Paik, Kathryn Hobbs, Amolika Gupta, Rand Jamal Alkalbani, Manuel Alexander Reyes, Zobair M. Younossi Journal of Clinical Gastroenterology.2025;[Epub] CrossRef
Association between weight fluctuation and the risk of metabolic dysfunction-associated steatotic liver disease Jin-Ping Wang, Jia-Yang Wang, Pei-Qi Sun, Xue-Wei Wang, Ze-Ting Yuan, Qin Cao, Shu-Ming Pan, Yuan-Ye Jiang World Journal of Hepatology.2025;[Epub] CrossRef
Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease Jonathan Mertens, Jonas Weyler, Eveline Dirinck, Luisa Vonghia, Wilhelmus J. Kwanten, Luc F. Van Gaal, Benedicte Y. De Winter, Sven Francque, Christophe De Block Cardiovascular Diabetology.2025;[Epub] CrossRef
The Significance of the Presence of Gilbert's Syndrome in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Retrospective Cohort Study Arjuna P De Silva, Krishanni Prabagar, Anuradha S Wickramasinghage, Aruni A Wanniarachchi, Dileepa S Ediriweera, Madunil A Niriella, Hithanadura J De Silva Cureus.2025;[Epub] CrossRef
GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD) Laura Pagès, Aina Martí-Carretero, Diego Rojo, Clara Sabiote, Farnaz Faninam, Sophia C. Parks, María Martínez-Gómez, M Serra Cusidó, Neda Akhlaghi, Sergio Muñoz-Martínez, Alba Jiménez-Masip, Juan M. Pericàs Current Hepatology Reports.2025;[Epub] CrossRef
Challenges in applying MASLD risk algorithms in pregnancy: A call for adaptation and inclusion Nina Rodriguez, Cecilia Katzenstein, Marcia Lange, Jeanette Rios, Tatyana Kushner, Rachel Meislin, Emma Rosenbluth, Carin Carroll, Theresa Worthington, Shaelyn O’Hara, Joanne Stone, Sonam Rosberger, Keith Sigel, Rhoda Sperling, Norah A. Terrault Journal of Hepatology.2025; 83(5): e236. CrossRef
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD Yong He, Yingfen Chen, Shengying Qian, Schalk van Der Merwe, Debanjan Dhar, David A. Brenner, Frank Tacke Cellular & Molecular Immunology.2025; 22(10): 1159. CrossRef
Association between trans-palmitoleic acid and metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma: NHANES 1999–2018 Qirui Li, Luqi Zhan, Qian Li, Shuai Zhu, Shuaihui Liu, He Jiang, Jinlin Cheng, Lanjuan Li Frontiers in Nutrition.2025;[Epub] CrossRef
To sleeve or not to sleeve: Validation of liver transplantation with sleeve gastrectomy Linda W. Moore, Elizabeth W. Brombosz, R. Mark Ghobrial Journal of Hepatology.2025; 83(3): 625. CrossRef
Redefining Diagnosis and Management in Hepatology with Multiparametric Ultrasound Yolande Chalmers EMJ Hepatology.2025; : 66. CrossRef
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual Current Obesity Reports.2025;[Epub] CrossRef
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs Daniel Clayton-Chubb, William W. Kemp, Ammar Majeed, Peter W. Lange, Jessica A. Fitzpatrick, Karl Vaz, John S. Lubel, Alexander D. Hodge, Joanne Ryan, John J. McNeil, Alice J. Owen, Robyn L. Woods, Stuart K. Roberts Nutrients.2025; 17(13): 2189. CrossRef
Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric population Wei Li, Lina Jiang, Meiling Li, Chen Lin, Li Zhu, Bokang Zhao, Yisi Liu, Yan Li, Yiyun Jiang, Shuhong Liu, Ping Liang, Junqi Niu, Jingmin Zhao Gastroenterology Report.2025;[Epub] CrossRef
Extracellular Vesicles as Biomarkers in Chronic Hepatobiliary Diseases: An Overview of Their Interplay Eleni Myrto Trifylli, Sotirios P. Fortis, Anastasios G. Kriebardis, Nikolaos Papadopoulos, Evangelos Koustas, Panagiotis Sarantis, Spilios Manolakopoulos, Melanie Deutsch International Journal of Molecular Sciences.2025; 26(13): 6333. CrossRef
Relationship between metabolic dysfunction-associated steatotic liver disease and sarcopenia: A systematic review and meta-analyses Ninglin Xia, Jiwei Wang, Qian Lu, Xue Fan, Zhenzhou Jiang, Qinwei Yu Clinical Nutrition ESPEN.2025; 68: 679. CrossRef
Time trends and health inequalities of cirrhosis caused by metabolic Dysfunction-associated steatotic liver disease from 1990 to 2021: A global burden of disease study Min Wu, Yifeng Li, Dong Liu, Weinong Wen, Yan Min, Qiang Su, Zhenxiang An, Xiaofang Yang Journal of Endocrinological Investigation.2025; 48(11): 2599. CrossRef
Therapeutic horizons in metabolic dysfunction–associated steatohepatitis Philip N. Newsome, Rohit Loomba Journal of Clinical Investigation.2025;[Epub] CrossRef
High Prevalence of Fatty Liver in Bangladeshi Adolescents and Young Adults with Type 2 Diabetes: Key Predictors and Screening Recommendations Kishore Shil, Mashfiqul Hasan, Nusrat Sultana, Sayad Salam, Syeda Mostafa, Muhammad Hasanat Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 2019. CrossRef
Adipose Tissue Dysfunction and Hepatic Steatosis in New-Onset Diabetes Emilia Rusu, Mariana Jinga, Raluca Cursaru, Georgiana Enache, Adrian Costache, Ioana Verde, Andra Nica, Anca Alionescu, Florin Rusu, Gabriela Radulian Diabetology.2025; 6(7): 70. CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi Nutrients.2025; 17(13): 2211. CrossRef
Altered HDL Phospholipid and Fatty Acid Profile in MASLD: A Possible Explanation for the Increased CVD Risk Sofia Kartsoli, Christina E. Kostara, Athanasios Papathanasiou, Vasilis Tsimihodimos, Eleni T. Bairaktari, Dimitrios K. Christodoulou International Journal of Molecular Sciences.2025; 26(13): 6148. CrossRef
Pan-immune-inflammation value and mortality in the US adult MASLD: a nonlinear NHANES analysis Qing Zhou, Jisu Xue, Lu Hao BMC Gastroenterology.2025;[Epub] CrossRef
Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2018 Yanshan Yi, Li Yang Frontiers in Nutrition.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease: Mechanisms, metabolic reprogramming, and therapeutic insights Wan-Qi Yang, Ling-Ling Xue, Jing-Lin Wang World Journal of Gastroenterology.2025;[Epub] CrossRef
Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population Ayesha Sualeheen, Sze-Yen Tan, Robin M. Daly, Ekavi Georgousopoulou, Gavin Abbott, Stuart K. Roberts, Jacob George, Elena S. George Clinics and Research in Hepatology and Gastroenterology.2025; 49(7): 102649. CrossRef
Quantitative US in Metabolic Dysfunction–Associated Steatotic Liver Disease Manjiri Dighe, Manish Dhyani Radiology.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and gastrointestinal cancer risk in youth: is it time to unveil a hidden link? Gianmario Forcina, Vittoria Frattolillo, Maria Grazia Fusco, Emanuele Miraglia Del Giudice, Anna Di Sessa Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef
Metals in the human liver: An underappreciated risk factor of hepatic insulin resistance and associated pathophysiology Rahul Kumar, Ashwin Chinala, Dhruv Grandhe, S. Joseph Endicott, Marcus A. Garcia, Matthew J. Campen, Rama R. Gullapalli Environmental Pollution.2025; 383: 126844. CrossRef
La alimentación es pieza clave en la patogénesis de la enfermedad hepática esteatósica asociada a disfunción metabólica en la población pediátrica R. Vázquez-Frias Revista de Gastroenterología de México.2025; 90(3): 347. CrossRef
Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring Gong Feng, Vincent Wai-Sun Wong, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng Gut.2025; 74(10): 1741. CrossRef
Intestinal TM6SF2 and the gut-liver axis in MASLD: new insights Markos Kalligeros, Linda L. Henry, Zobair M. Younossi Metabolism and Target Organ Damage.2025;[Epub] CrossRef
The role of Bergamot Polyphenolic Fraction (BPF) in MASLD-Induced HFpEF: Mitigate diastolic dysfunction by targeting chronic low-grade inflammation Cristina Carresi, Antonio Cardamone, Vincenzo Musolino, Rocco Mollace, Annamaria Tavernese, Anna Rita Coppoletta, Micaela Gliozzi, Vincenzo Mollace Biomedicine & Pharmacotherapy.2025; 190: 118375. CrossRef
Nonlinear Association Between BMI and Depression Among Nonalcoholic Fatty Liver Disease: NHANES (2017–2018) Hui Peng, Dan Zhou, Yuan Dai, Weifeng Chen, Tauheed Ishrat Behavioural Neurology.2025;[Epub] CrossRef
Analysis of gastric electrical rhythm in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus Xi-Xi Wang, Chun Yan, Su-Juan Wang, Hong Zhu, Chang-Chun Cao, Li Wu, Shuang Wang, Ji Hu, Hong-Hong Zhang World Journal of Hepatology.2025;[Epub] CrossRef
Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration Evelien Van Dijck, Steven Van Laere, Emilie Logie, Steven Timmermans, Erik Fransen, Joe Ibrahim, Timothy J. Kendall, Jonathan A. Fallowfield, Ligia M. Mateiu, Claude Libert, Guy Van Camp, An Verrijken, Luc Van Gaal, Sven Francque, Wim Van Hul, Wim Vanden Clinical Epigenetics.2025;[Epub] CrossRef
Physical Activity and Metabolic Disorders—What Does Gut Microbiota Have to Do with It? Aneta Sokal-Dembowska, Ewelina Polak-Szczybyło, Kacper Helma, Patrycja Musz, Maciej Setlik, Weronika Fic, Dawid Wachowiak, Sara Jarmakiewicz-Czaja Current Issues in Molecular Biology.2025; 47(8): 630. CrossRef
Optimal Vegetable Intake for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) Prevention: Insights from a South Italian Cohort Maria Noemy Pastore, Caterina Bonfiglio, Rossella Tatoli, Rossella Donghia, Pasqua Letizia Pesole, Gianluigi Giannelli Nutrients.2025; 17(15): 2477. CrossRef
Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials Alessandro Mantovani, Riccardo Morandin, Veronica Fiorio, Maria Giovanna Lando, Norbert Stefan, Herbert Tilg, Christopher D. Byrne, Giovanni Targher Liver International.2025;[Epub] CrossRef
Discovery of
Highly Potent, Selective, and Liver-Targeted
THR-β Agonists for the Treatment of Metabolic Dysfunction-Associated
Steatohepatitis Ju Liang, Yipei Gu, Liuyu Hu, Hui Qu, Nana Li, Chaoyue Xia, Lei Feng, Li Qin, Li Hai, Yaxi Yang, Ying Leng, Bing Zhou Journal of Medicinal Chemistry.2025; 68(16): 17457. CrossRef
Adipokine and Hepatokines in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current and Developing Trends Salvatore Pezzino, Stefano Puleo, Tonia Luca, Mariacarla Castorina, Sergio Castorina Biomedicines.2025; 13(8): 1854. CrossRef
Dietary Strategies in the Prevention of MASLD: A Comprehensive Review of Dietary Patterns Against Fatty Liver Barbara Janota, Karolina Janion, Aneta Buzek, Ewa Janczewska Metabolites.2025; 15(8): 528. CrossRef
Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: a cross-sectional study based on NHANES 2017–2020 Ting Xu, Weifang Zhu Diabetes Research and Clinical Practice.2025; 227: 112418. CrossRef
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025) Shikha Patel, Sarfaraz K. Niazi Pharmaceutics.2025; 17(8): 1036. CrossRef
CircDock6 drives metabolic dysfunction–associated steatotic liver disease progression in mice and mouse hepatocytes via mmu-let-7g-5p/insulin-like growth factor 1 receptor regulation Hongpeng Lu, Xiaoyun Ding, Peifei Li Journal of International Medical Research.2025;[Epub] CrossRef
Multi-omics integration reveals the impact of mediterranean diet on hepatic metabolism and gut microbiota in mice with metabolic dysfunction-associated steatotic liver disease Zixuan Wang, Ge Chen, Xutong Sun, Jia Xiao, Lingling Kong, Shunshun Jiang, Tingting Xu, Meijiao Wang, Hong Zhao Frontiers in Nutrition.2025;[Epub] CrossRef
Amaranthus graecizans L. Mitigates Hyperlipidemia-Induced Nonalcoholic Fatty Liver Disease in Experimental Rats: Future Pharmaceuticals Nadiah S. Alzahrani, Bayan Aljahdali, Aeshah Alhosain, Abeer Abdullah Alasmari, Touseef Amna, Soha Mohamed Yousef Pharmaceuticals.2025; 18(8): 1196. CrossRef
Non-invasive biomarkers for monitoring portal hypertension in metabolic dysfunction-associated steatotic liver disease (MASLD) Shreya C. Pal, Mariana M. Ramírez-Mejía, Andrew P. Keaveny, Nahum Méndez-Sánchez Expert Review of Gastroenterology & Hepatology.2025; 19(9): 1021. CrossRef
Controlled Red Blood Cell Apheresis as a Pretreatment of Hepatic Peliosis Resection Surgery for Severe Polycythemia Secondary to Hepatic Peliosis in a Child Chun‐Xi Wu, Rong Fu, Jie Yan, Bin Zhang, Zhong‐Mei Yi, Qiang Zhang Pediatric Blood & Cancer.2025;[Epub] CrossRef
SGLT2 inhibitors and the risk of hepatocellular carcinoma in patients with MASLD and Type 2 diabetes Ruey-Shyang Soong, Wan-Ming Chen, An-Tzu Jao, Ming-Che Lee, Szu-Yuan Wu, Chih-Lang Lin Diabetes & Metabolism.2025; 51(6): 101698. CrossRef
MIND diet score and its association with metabolic dysfunction-associated steatotic liver disease and gut microbiota profiles: a cross-sectional study Shengbo Yang, Litao Zhang, Mingli Hu, Weina He Frontiers in Nutrition.2025;[Epub] CrossRef
Early Insights from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: An Observational Study on Polygenic Risk and Liver Biomarkers Pietro Torre, Benedetta Maria Motta, Tommaso Sarcina, Mariano Festa, Mario Masarone, Marcello Persico International Journal of Molecular Sciences.2025; 26(17): 8426. CrossRef
Higher Food Inflammation Index Is Linearly Associated With Higher Risk of MASLD: A Cross‐Sectional Study Based on the NHANES (1999–2020) Qingwan Yang, Xin Cai, Zhenghua Xiao Food Science & Nutrition.2025;[Epub] CrossRef
Metabolic Divergence Between MASLD and Metabolic Syndrome: Distinct Clinical Phenotypes and Risk Stratification Implications Mariana M. Ramírez‐Mejía, Sandra M. Barbalho, Guadalupe Ponciano‐Rodríguez, Mohammed Eslam, Jacob George, Ming‐Hua Zheng, Nahum Méndez‐Sánchez Liver International.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review Marcelo do Rego Maciel Souto Maior, Nathália de Lacerda Interaminense Ribeiro, Hannah Vicentini Vitoriano Silva, Edmundo Pessoa Lopes, Emilia Chagas Costa Biomedicines.2025; 13(9): 2162. CrossRef
Mediation analysis of the molecular phenotypes in a severe MASH-like liver injury mouse model Zhuolin Song, Volodymyr P Tryndyak, Rose A Willett, Igor P Pogribny, Ivan Rusyn, Fred A Wright Toxicological Sciences.2025; 208(1): 155. CrossRef
Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) rs738409 Variant and Non-Alcoholic Fatty Liver Disease Risk in Vietnamese Working-Age Adults: A Case-Control Study with Metabolic Insights Ha Nguyen, Duong Hoang Huy Le, Thinh Nguyen, Hung Cao Dinh, Tuan Nguyen Clinical and Experimental Gastroenterology.2025; Volume 18: 191. CrossRef
Narrative review of metabolic syndrome and its relationships with non-alcoholic fatty liver disease, gonadal dysfunction and obstructive sleep apnea Doha Reda Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease in patients with prediabetes and type 2 diabetes mellitus Armida N. Sasunova, Alexey A. Goncharov, Sergey V. Morozov, Vladimir I. Pilipenko, Vasily A. Isakov Terapevticheskii arkhiv.2025; 97(8): 689. CrossRef
Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon? Amedeo Lonardo, Ralf Weiskirchen Exploration of Drug Science.2025;[Epub] CrossRef
Fecal Zonulin as a Non-Invasive Marker of Intestinal Permeability: Findings from a Prospective Cohort Study Naomi-Adina Ciurea, Cristina Monica Pantea, Paul Grama, Irina-Bianca Kosovski, Simona Bataga Medicina.2025; 61(9): 1527. CrossRef
Steatotic liver disease and cancer: from pathogenesis to therapeutic targets Zhihong Yang, Zhenjie Liu, Wanqing Liu, Xiaocheng Charlie Dong eGastroenterology.2025; 3(3): e100218. CrossRef
Increasing Acute Coronary Syndrome Mortality in Cirrhosis After a Period of Decline: A National Analysis of Temporal and Demographic Disparities Abdalhakim Shubietah, Ameer Awashra, Fathi Milhem, Mohammed AbuBaha, Maisam Tobeh, Abubakar Nazir, Mohamed S. Elgendy, Mohammad Bdair, Jehad Zeidalkilani, Hosam I. Taha, Anwar Zahran, Ahmed Emara, Suleiman Khreshi, Islam Rajab Catheterization and Cardiovascular Interventions.2025; 106(6): 3136. CrossRef
Prenatal Choline Attenuates the Elevated Adiposity and Glucose Intolerance Caused by Prenatal Alcohol Exposure Susan M. Smith, Carolyn A. Munson, George R. Flentke, Sandra M. Mooney Cells.2025; 14(18): 1429. CrossRef
THE CHANGING LANDSCAPE OF TRANSPLANT ONCOLOGY: OPPORTUNITIES AND CHALLENGES Emanuele Federico Kauffmann, Michael Ginesini, Allegra Ripolli, Paolo De Simone European Journal of Transplantation.2025; 3(1): 3. CrossRef
Clinical and Genetic Predictors of Non‐Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals Karina Sato‐Espinoza, Robert A. Vierkant, Perapa Chotiprasidhi, Filippo Pinto e Vairo, Shulan Tian, Jun Ma, Daniel O'Brien, Konstantinos N. Lazaridis, Carola Dlugosch, Carolin Scheider, Alina M. Allen, Kirk J. Wangensteen Liver International.2025;[Epub] CrossRef
MASLD Under the Microscope: How microRNAs and Microbiota Shape Hepatic Metabolic Disease Progression Clelia Asero, Maria Stella Franzè, Irene Cacciola, Sebastiano Gangemi International Journal of Molecular Sciences.2025; 26(17): 8633. CrossRef
Diet is a key factor in the pathogenesis of metabolic dysfunction-associated steatotic liver disease in the pediatric population R. Vázquez-Frias Revista de Gastroenterología de México (English Edition).2025; 90(3): 347. CrossRef
Exploring the Role of Extra Virgin Olive Oil (EVOO) in MASLD: Evidence from Human Consumption Melvin Bernardino, Claudio Tiribelli, Natalia Rosso Nutrients.2025; 17(18): 2932. CrossRef
Refining the Classification of Steatotic Liver Disease: Beyond Self-Reported Alcohol Intake Won-Mook Choi Gut and Liver.2025; 19(5): 639. CrossRef
Immunonutrition: Another Player on the MASLD Field Iván López-Méndez, Misael Uribe, Eva Juárez-Hernández International Journal of Molecular Sciences.2025; 26(18): 8928. CrossRef
Extracellular RNAs in Liquid Biopsy: Applications in MASLD and MASH Diagnosis and Monitoring Dimitrios Raptis, Shiny Teja Kolli, Sonal Agarwal, Praveen Kumar Komminni, Prashamsha Bhattarai, Prinka Hablani, Rahul Kumar, Petras Das, Martin McIntosh, Michail Kladas, Priyanka Gokulnath, Michail Spanos Diagnostics.2025; 15(18): 2346. CrossRef
Diagnostic Performance of Fibrosis‐4 Index, Nonalcoholic Fatty Liver Disease Fibrosis Score, AST‐To‐Platelet Ratio Index, and BARD Score Among Young and Older Adults for the Diagnosis of Advanced MASLD Fibrosis: A Retrospective Cohort Study Frank Lin, Ayah Obeid, Mehak Sharma, Parampreet Kaur, Kimberly Chaput, Hammad Liaquat JGH Open.2025;[Epub] CrossRef
The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model Oscar René Zambrano-Vásquez, Fernando Cortes-Camacho, Juan Carlos Cabrera-Angeles, Ana Lilia Hernández-Alba, Fernando Enrique García-Arroyo, Jorge Ismael Castañeda-Sánchez, Elena Aréchaga-Ocampo, Omar Emiliano Aparicio-Trejo, Leonardo Del Valle-Mondragón, International Journal of Molecular Sciences.2025; 26(18): 9010. CrossRef
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial Metha Yaikwawong, Khanittha Kamdee, Somlak Chuengsamarn International Journal of Molecular Sciences.2025; 26(19): 9286. CrossRef
A Systematic Review and Meta-Analysis of Cannabis Use Frequency and Metabolic Dysfunction-Associated Steatotic Liver Disease: Scapegoat or Healer? Néstor Israel Quinapanta Castro, Abdel Bermúdez-del Sol Cureus.2025;[Epub] CrossRef
Cumulative Effect of Metabolic Factors on Hepatic Steatosis Anna Egresi, Brigitta Kozma, Márton Karácsony, Aladár Rónaszéki, Klára Werling, Barbara Csongrády, Pál Kaposi Novák, Anikó Folhoffer, Attila Szijártó, Krisztina Hagymási Diagnostics.2025; 15(18): 2406. CrossRef
A non-apoptotic caspase-8–meteorin pathway in hepatocytes promotes MASH fibrosis Xiaobo Wang, Mary P. Moore, Hongxue Shi, Yang Xiao, Jiayu Zhang, Lanuza A. P. Faccioli, Zhiping Hu, Shareef Khalid, Danish Saleheen, Dwayne G. Stupack, Tatiana Kisseleva, Alejandro Soto Gutierrez, Mitchell A. Lazar, Ira Tabas Nature Metabolism.2025; 7(10): 2067. CrossRef
The impact of aging on liver health and the development of liver diseases Sha Neisha Williams, Wen-Xing Ding Hepatology Communications.2025;[Epub] CrossRef
Timosaponin AIII from Anemarrhena asphodeloides binds and inhibits S100A8-mediated neutrophil infiltration and NET formation ameliorates MASH Yunfan Bai, Jingxin Ju, Ruishi Xie, Jing Li, Xinyi Zhao, Xiaoxue Fang, Ming Zhu, Xintian Lan, Haoming Luo International Immunopharmacology.2025; 166: 115539. CrossRef
Clinacanthus nutans leaf extract prevents metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH) progression in western diet-fed C57BL/6 mice Nurina Hasanatuludhhiyah, Arifa Mustika, Viskasari Pintoko Kalanjati, Muhammad Miftahussurur, Hirokazu Wakuda, Naoto Uemura Pharmacia.2025; 72: 1. CrossRef
The role of hypothalamus in the pathophysiological process of MASLD and advances in drug discovery Shizhang Wei, Yuan Dong, Yanping Wang, Guohui Li, Yanling Zhao, Ruimao Zheng Pharmacological Research.2025; 221: 107972. CrossRef
BMI mediates the association of CALLY index with liver steatosis and fibrosis Si-Hua Wen, Tao Tang, Zheng-Rong Ye Scientific Reports.2025;[Epub] CrossRef
Era of metabolic dysfunction-associated steatotic liver disease and impact on the liver donor pool Juanita Pérez-Escobar, Aline Huerta-Álvarez, Graciela Elia Castro-Narro, María Isabel Astudillo-Delgado, Paulina Carpinteyro-Espin World Journal of Gastroenterology.2025;[Epub] CrossRef
Editorial: Metabolic dysfunction-associated steatotic liver disease (MASLD) - pathogenesis, prevention and treatment Stanisław Surma, Łukasz Bułdak Frontiers in Endocrinology.2025;[Epub] CrossRef
Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Advances in understanding the mechanism of noncoding RNA (ncRNA)-mediated regulation of macrophage polarization in NAFLD Chang Ge, Yi Yuan, Xiaoning Li, Jianmin Zhang, Jitao Ling, Xuehong Zheng, Yuting Wu, Xin Huang, Pingping Yang, Xiao Liu, Deju Zhang, Jianping Liu, Jing Zhang, Peng Yu Biochemical Pharmacology.2025; 242: 117372. CrossRef
Association of serum trace elements with non-invasive fibrosis scores in metabolic dysfunction-associated steatotic liver disease Erfan Banisefid, Sahand Karkon Zonouzi, Sina Hamzehzadeh, Zeinab Nikniaz, Seyedehyasmin Moghaddamziabari, Leila Alizadeh Scientific Reports.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease: epidemiological trends, risk factors, and the role of gut microbiota in disease progression (a literature review) А.А. Antoniv, L.V. Kanovska, O.V. Kaushanska, Yu.M. Yarinich INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(6): 656. CrossRef
Preventing false positive imaging diagnosis of HCC: differentiating HCC from mimickers and practical strategies Ijin Joo Journal of Liver Cancer.2025; 25(2): 217. CrossRef
Real-World Lifestyle Interventions are a Practical Model to Improve Liver Stiffness Christopher Kasia, Mary Rinella Journal of Clinical and Experimental Hepatology.2025; 15(6): 103201. CrossRef
The effects of different exercise intensities on body composition and cardiovascular risk indicators in children with metabolic syndrome: a RCT network meta-analysis Yimin Hu, Juan Ouyang, Yi Xia, Yi Sheng BMC Sports Science, Medicine and Rehabilitation.2025;[Epub] CrossRef
Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies Sana Raza, Rukshana Mahamood, Pratik Medhe, Ambuj Shahi, Abhishek Yadav, Archana Tewari, Rohit A. Sinha npj Metabolic Health and Disease.2025;[Epub] CrossRef
Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon International Journal of Molecular Sciences.2025; 26(19): 9715. CrossRef
Immunosenescence and metabolic reprogramming in MASLD: an age-dependent immunometabolic vicious cycle and therapeutic opportunities Yuxin Xu, Qiuxiang Li, Xuehua Jiao Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease Ralf Weiskirchen, Amedeo Lonardo International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis Meng Li, Jianli Hu, Yip Han Chin, Han Shi Jocelyn Chew, Wenru Wang Frontiers in Endocrinology.2025;[Epub] CrossRef
Investigation of the Effect of Isotonic Drinks on Quantitative MRI Markers of the Liver and Spleen Natassa N. Pittas, Michael Pavlides, Ferenc E. Mózes NMR in Biomedicine.2025;[Epub] CrossRef
Physiological roles of phosphoinositides and inositol phosphates: Implications for metabolic dysfunction-associated steatotic liver disease Zhili Cheng, Magdalene K Montgomery Clinical Science.2025; 139(19): 1095. CrossRef
Naringin mitigates liver damage in a tissue-engineered liver of metabolic dysfunction-associated steatotic liver disease model by promoting autophagy via the mTOR-ULK1 pathway Jihui Jia, Yizhi Zhang, Jing Lin, Zhongping Duan, Yu Chen, Xiaohui Zhang Molecular Biology Reports.2025;[Epub] CrossRef
Dietary supplementation with a designer metabolic modulator improves MASLD and associated anxiety in mice Agnese Segala, Gaia Favero, Emanuela Bottani, Alice Vetturi, Emirena Garrafa, Edoardo Parrella, Chiara Ruocco, Maurizio Ragni, Rita Rezzani, Enzo Nisoli, Alessandra Valerio Frontiers in Pharmacology.2025;[Epub] CrossRef
From Steatosis to Immunosenescence: The Impact of Metabolic Dysfunction on Immune Aging in HIV and Non-HIV Populations Carlo Acierno, Maria Frontuto, Giulio Francesco De Stefano, Ana Erezanu, Andrea Limone, Simona Morella, Francesco Picaro, Donatella Palazzo, Michele Gilio Biomedicines.2025; 13(10): 2513. CrossRef
Linear association between the composite dietary antioxidant index and the prevalence of sarcopenia in metabolic dysfunction-associated steatotic liver disease Jue Zhang, Huan Shi Lipids in Health and Disease.2025;[Epub] CrossRef
Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu Frontiers in Nutrition.2025;[Epub] CrossRef
2025 Clinical Practice Guidelines for Diabetes: Management of Metabolic Dysfunction-Associated Steatotic Liver Disease Jaehyun Bae The Journal of Korean Diabetes.2025; 26(3): 172. CrossRef
Pharmacotherapy of the metabolically associated fatty liver disease E.E. Mulyukova, E.L. Novikova, I.A. Skirdov, K.S. Usmanova, N.V. Yusifzade Russian Journal of Preventive Medicine.2025; 28(10): 103. CrossRef
Proton Density Fat Fraction and Its Role in Prediction of Metabolic Dysfunction Scott B. Reeder, Jitka Starekova Radiology.2025;[Epub] CrossRef
Coffee and Tea Intake Is Inversely Associated With Hepatic Fat Deposition, Iron Deposition, and Fibroinflammation in the General Population Zhuoshuai Liang, Xiaoyue Sun, Huizhen Jin, Wenhui Gao, Xinmeng Hu, Yi Cheng, Jikang Shi, Yawen Liu Molecular Nutrition & Food Research.2025;[Epub] CrossRef
Hydroxytyrosol Improves Metabolic Dysfunction-Associated Fatty Liver Disease Dependent on the Modulation of Gut Microbiota Yuji Xiao, Xue Zhang, Bing Shao, Ziyi Wu, Xiao Li, Dongxin Yi, Tao Li, Tao Yang, Jiaxin Zhu, Tiecheng Huang, Yixue Deng, Tianming Qiu, Guang Yang, Xiance Sun, Ningning Wang Journal of Agricultural and Food Chemistry.2025; 73(43): 27450. CrossRef
Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova GASTROENTEROLOGY.2025; 59(3): 206. CrossRef
CT-Based Radiomic Models in Biopsy-Proven Liver Fibrosis Staging: Direct Comparison of Segmentation Types and Organ Inclusion Andreea Mihaela Morariu-Barb, Tudor Drugan, Mihai Adrian Socaciu, Horia Stefanescu, Andrei Demirel Morariu, Monica Lupsor-Platon Diagnostics.2025; 15(21): 2671. CrossRef
Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years Ieva Vanaga, Oksana Kolesova, Aleksandrs Kolesovs, Maija Radzina, Davis Simanis Putrins, Jelena Egle, Sniedze Laivacuma, Jelena Storozenko, Ludmila Viksna Journal of Clinical Medicine.2025; 14(21): 7604. CrossRef
Metabolic dysfunction–associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy Teresa Cardoso Delgado, Celia Martín-Cuevas, Ana C. Sánchez Hidalgo, Antonio Gil Gómez, Claudia M. Rejano Gordillo, Jon Landa, Rocío Gallego Durán, Naroa Goikoetxea-Usandizaga, Irene González-Recio, Clàudia Gil-Pitarch, L. Estefanía Zapata-Pavas, Jon Ande Science Advances.2025;[Epub] CrossRef
Association of Diet Quality, Dietary Acid Load, and Dietary Antioxidant Index With Cardiometabolic and NAFLD Risk Factors Among Patients With Metabolic Syndrome: A Cross‐Sectional Study Bijan Ghobadian, Seyedeh Atiye Shahrokhi, Saman Rezaei Talabon, Vahid Notash, Fatemeh Maleki Sedgi, Mehran Rahimlou Food Science & Nutrition.2025;[Epub] CrossRef
Quantitative Approaches to Accelerate MASH Drug Discovery and Development Yasmeen Abouelhassan, Shailendra Tallapaka, Ramin Mehrani, Scott Q. Siler, Li Qin, Zeyuan Wang, Maria E. Trujillo Clinical Pharmacology & Therapeutics.2025; 118(6): 1378. CrossRef
Mitochondrial transplantation and platelet rich plasma for the treatment of non-alcoholic fatty liver disease Manuel Alejandro Vargas-Vargas, Marcela González-Montoya, Olin Torres-Isidro, Omar Ortiz-Avila, Elizabeth Calderón-Cortés, Christian Cortés-Rojo World Journal of Hepatology.2025;[Epub] CrossRef
Repurposing levothyroxine for managing metabolic dysfunction-associated steatotic liver disease Leonidas H. Duntas, Stergios A. Polyzos, Ulrike Gottwald-Hostalek, Bogumila Urgatz, Paul M. Yen Endocrine.2025; 90(3): 1043. CrossRef
Genetic polymorphisms associated with metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk susceptibility in the Chinese Han population Mingjia Dai, Yan Li, Jing Zhang, Yuhua Ruan, Ye Liu, Jungui Hao, Fang Ji, Xuebing Yan Human Genomics.2025;[Epub] CrossRef
Lipid-lowering mechanism of Swietenia macrophylla king leaves through SREBP-1c/FASN axis and RNA sequencing validation Yingwei Liu, Yunpeng Sun, Ting Zhou, Xiao Huang, Guokai Wang, Lijuan Sun Food Bioscience.2025; 74: 107860. CrossRef
Reconsidering Cardiovascular Risk Assessment in Patients With MASLD Ming Hou Liver International.2025;[Epub] CrossRef
From steatosis to cirrhosis: the role of obesity in the progression of liver disease Klaudia Nowak, Maria Paluch, Maja Cudzik, Klaudia Syska, Wiktoria Gawlikowska, Jakub Janczura Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Triglyceride-cholesterol-body weight index associated with the risk of metabolic dysfunction-associated steatotic liver disease: a population-based cross-sectional study Li Fan, Yongkang Su, Yue Chen, Ling Xu, Hairong Huang, Chunsheng Lu, Jia Peng, Yingbin Sun, Min Jia Frontiers in Nutrition.2025;[Epub] CrossRef
Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism Rosellina M. Mancina, Luca Valenti, Stefano Romeo Nature Metabolism.2025; 7(11): 2199. CrossRef
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano Exploration of Medicine.2025;[Epub] CrossRef
The effects of salvia hispanica (chia seeds) on insulin sensitivity, hematological inflammatory indices and liver function in obese patients with non-alcoholic fatty liver disease (NAFLD) Sara Arefhosseini, Maryam Parimi, Helda Tutunchi, Mehrangiz Ebrahimi-Mameghani Nutrition & Metabolism.2025;[Epub] CrossRef
Prevalence and Risk Factors of Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Type 2 Diabetes Mellitus at a Tertiary Center in Saudi Arabia: Cross-Sectional Questionnaire Study Abdulrahman M Elnasieh, Mohammed Almesned, Akram N Al Hazmi, Atheer Alturki, Faisal I Alhawaidi, Razan K Alhadlq, Maryam Alramadhan, Nasser Alobilan, Yasser Sheikh Qroosh JMIR Diabetes.2025; 10: e77772. CrossRef
Differentiating MASL and MASH: Clinical Insights from Comparative Case Reports in MASLD Chang-Gue Son The Journal of Internal Korean Medicine.2025; 46(4): 954. CrossRef
Multi-omics analysis elucidates the therapeutic mechanisms of the Quzhi formula in metabolic dysfunction-associated steatohepatitis targeting gut microbiota, lipid metabolism, and the role of its metabolite fraxin Jiao-Xiang Wu, Yue-Lan Wu, Mei-Fang Li, Nian Liu, Ying Liu, Yan-Ping Huang, Yuan Gan, Xiao-Yu Wang, Hai-Sheng Chai, Jin Xu, Qian Xi, Xi-Rong Guo, Hui-Ming Sheng, Ting-Ting Shen, Qin Zhang Frontiers in Pharmacology.2025;[Epub] CrossRef
Implications of the Liver-Gut Axis in Liver Disease: From Mechanisms to Therapeutic Targets Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodríguez, Nahum Méndez-Sánchez Archives of Medical Research.2025; 56(8): 103335. CrossRef
Herbal Medicine for Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Effectiveness and Research Trends - A Systematic Review and Meta-Analysis Min-jo Seo, Su-na Park, Ji-won Lee, So-rim Kim, Jin-hyun Kim, Min-ji Sun, Geon-sik Kong, Yo-sup Choi The Journal of Internal Korean Medicine.2025; 46(4): 774. CrossRef
Primary Human Tissue Models for Metabolic Dysfunction‐Associated Liver Disease ‐ toward Streamlining Drug Discovery with Patient‐Derived Assays Sonia Youhanna, Nayere Taebnia, Yingxin Liang, Ningtao Cheng, Yi Wang, Maurice Michel, Volker M. Lauschke Advanced Biology.2025;[Epub] CrossRef
The Impact of Liraglutide on Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease Jae Eun So, Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Hye Won Lee, Seung Up Kim Journal of Gastroenterology and Hepatology.2025; 40(12): 2976. CrossRef
Remnant cholesterol, low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: a cohort study Di Zhou, Mengge Zhou, Shuohua Chen, Chenlu Yang, Yanhong Wang, Yang Zhou, Shutong Wu, Shouling Wu, Li Wang Lipids in Health and Disease.2025;[Epub] CrossRef
Effects of long working hours on metabolic dysfunction-associated steatotic liver disease, with and without increased alcohol intake, in healthy workers: A 10-year cohort study Yesung Lee, Woncheol Lee, Anna Di Sessa PLOS One.2025; 20(11): e0336569. CrossRef
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study Mazen Noureddin, Stephen A Harrison, Rohit Loomba, Naim Alkhouri, Naga Chalasani, Muhammad Y Sheikh, Shaheen Tomah, Julio A Gutierrez, Silvia Urbina, John J Suschak, Randy Brown, Ozioma Odili, Jay Yang, Stephine Keeton, Guy Neff, Edward Mena, M Scot Rober The Lancet.2025; 406(10520): 2644. CrossRef
Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Fatigue and Pruritus in Primary Sclerosing Cholangitis: A U.S. Single-Center Study Natalia Rojas-Amaris, Ana Marenco-Flores, Carmen Lara-Romero, Romelia Barba, Denisse Rubio-Cruz, Ximena Parraga, Daniela Goyes, John Esli Medina-Morales, Leandro Sierra, Manuel Romero-Gomez, Michelle Lai, Behnam Saberi, Vilas Patwardhan, Alan Bonder Journal of Clinical Medicine.2025; 14(22): 8083. CrossRef
Personalized management of metabolic dysfunction-associated steatotic liver disease Zhen Sun, Kui Ming Chan, Haojie Jin iLIVER.2025; 4(4): 100207. CrossRef
Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum Cong Xie, Yulian Yuan, Yunjing Wang, Cong Qi, Wei Wang, Chuan An, Aifeila Aikepaer, Yaofu Zhang, Ge Zhang, Xingzhong Feng, Huijuan Gao Current Obesity Reports.2025;[Epub] CrossRef
Immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: The critical role of subgroup analyses Tingfeng Huang, Jia-Hao Law, Ningqi Pang, Shichuan Tang iLIVER.2025; 4(4): 100208. CrossRef
Plasma Extracellular Vesicles Contain Protein Biomarkers for Capturing Stages of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Preliminary Exploratory Study Yakun Li, Koen C. van Son, Sandra Serna-Salas, Justina C. Wolters, Nienke P. M. Wassenaar, Stan Driessen, Anne Linde Mak, Anne-Marieke van Dijk, Veera A. T. Houttu, Julia J. Witjes, Diona Zwirs, Michail Doukas, Joanne Verheij, Robin P. F. Dullaart, Hans B Biomolecules.2025; 15(11): 1596. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances Dalia M. Miller, Kiana F. McCauley, Kimberly J. Dunham‐Snary Endocrinology, Diabetes & Metabolism.2025;[Epub] CrossRef
Liver Transplantation in the Era of Metabolic Dysfunction–Associated Fatty Liver Disease: Challenges, Ethical Dilemmas, and Future Directions Said A. Al-Busafi, Mohammed Eslam Transplantology.2025; 6(4): 35. CrossRef
The albumin-to-creatinine ratio predicts and explores potential mediation of mortality in metabolic dysfunction-associated steatotic liver disease in U.S. adults: evidence from NHANES 1999–2018 Huanjie Zhou, Hao Huang, Huiliu Zhao, Naiqi Pang, Meifang Huang, Chao Ou, Ming Lao BMC Gastroenterology.2025;[Epub] CrossRef
Signatures of proteomics and glycoproteomics revealed liraglutide ameliorates MASLD by regulating specific metabolic homeostasis in mice Yuxuan Chen, Chendong Liu, Qian Yang, Jingtao Yang, He Zhang, Yong Zhang, Yanruyu Feng, Jiaqi Liu, Lian Li, Dapeng Li Journal of Pharmaceutical Analysis.2025; 15(11): 101273. CrossRef
К эпидемиологии жировой болезни печени, связанной с метаболической дисфункцией (систематический обзор литературы)
Вера Людвиговна Грицинская, Валерия Павловна Новикова Children's medicine of the North-West.2025; 13(3): 108. CrossRef
The shifting burden of gastrointestinal and liver diseases in Southeast Asia and effective control strategies
An umbrella meta-analysis of microbial therapy on hepatic steatosis, fibrosis, and liver stiffness in metabolic dysfunction-associated steatotic liver disease Gvzalnur Kurban, Xiangjun Chen, Xingyi Jin, Hui Xia, Shaokang Wang, Guiju Sun Frontiers in Nutrition.2025;[Epub] CrossRef
Linking bisphenol a exposure to MASLD: insights from network toxicology and machine learning based on NHANES 2005–2012 data Jiaquan Yuan, Haoyang Xu, Junhong Gan, Haiyan Zhao Toxicology Research.2025;[Epub] CrossRef
Curcumin and Tetrahydrocurcumin as Multi-Organ Modulators of the Adipose Tissue–Gut–Liver Axis: Mechanistic Insights, Therapeutic Potential, and Translational Challenges Marina Konaktchieva, Radoslav Stojchevski, Nikola Hadzi-Petrushev, Hristo Gagov, Rositza Konakchieva, Vadim Mitrokhin, Gjoko Kungulovski, Mitko Mladenov, Dimiter Avtanski Pharmaceuticals.2025; 18(12): 1791. CrossRef
Ten-Year Atherosclerotic Cardiovascular Disease Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Separate Analyses from Romanian and Italian Cohorts Integrating Metabolic, Hepatic, and Gut–Liver Axis Markers Naomi-Adina Ciurea, Cristina Monica Pantea, Paul Grama, Irina-Bianca Kosovski, Ilaria Farella, Simona Bataga, Agostino Di Ciaula, Piero Portincasa Journal of Clinical Medicine.2025; 14(23): 8361. CrossRef
Ultra-processed food consumption and the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD): a five-year prospective cohort study in Iranian adults Omid Emami, Ali Nikparast, Matin Sepehrinia, Saeid Hadi, Jalaledin Mirzay Razzaz, Reza Homayounfar Journal of Health, Population and Nutrition.2025;[Epub] CrossRef
MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury Sarmis Marian Săndulescu, Denisa Ștefania Ghiga, Diana Rodica Tudorașcu, Daniela Larisa Săndulescu, Adrian Mită, Marinela Cristiana Urhuț, Citto-Iulian Taisescu Life.2025; 15(12): 1805. CrossRef
NAD + in fatty liver disease: mechanistic insights and associated targets Yaxin Guo, Yuting Wang, Shiran Wu, Yong Wang, Xinde Liu Cell Biology and Toxicology.2025;[Epub] CrossRef
The impact of high fructose corn syrup on liver injury and glucose metabolism: a systematic review Zane Z. Yu, Sneha Varahala, Sean L. C. Lim, Maimuna C. Marenah, Julia Wattacheril Frontiers in Nutrition.2025;[Epub] CrossRef
Association Between Subclinical Hypothyroidism and MASLD: A Systematic Review and Meta‐Analysis Gedion Yilma Amdetsion, Chun-Wei Pan, Hiwot Tebeje, Abhin Sapkota, Shreyas Nandyal, Vikram Kotwal, Fortofoiu Mircea-Catalin International Journal of Hepatology.2025;[Epub] CrossRef
Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis Chun-Ye Zhang, Shuai Liu, Yu-Xiang Sui, Ming Yang World Journal of Hepatology.2025;[Epub] CrossRef
Liver fibrosis index and mortality in metabolic dysfunction–associated steatotic liver disease: a Korean cohort study Yesung Lee, Woncheol Lee Scientific Reports.2025;[Epub] CrossRef
Macrophage-tregs crosstalk: the “hub” of the immune network in MASLD Huihui Zhao, Weili Wang, Pengchao Zhu, Zhaohong Shi Frontiers in Immunology.2025;[Epub] CrossRef
Proteolysis targeting chimera degraders target pseudokinases to treat metabolic dysfunction-associated steatohepatitis and fibrosis: Mechanisms and therapeutic insights Yibing Wang, Jiajing Peng Pharmacological Research.2025; 222: 108054. CrossRef
Metabolic dysfunction-associated steatotic liver disease is associated with androgenetic alopecia in adults with stronger effects in women and unhealthy lifestyles Sina Bazmi, Mohammad Saeed Soleimani-Meigoli, Mohammadreza Fardaei, Zahra Mohammadi, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Mojtaba Farjam Scientific Reports.2025;[Epub] CrossRef
Nutritional and Fasting Strategies for the Management of MASLD/MASH: An Integrative Review Diya Tawk, Ghalia Ghader, Yasmina Khatib, Philippe Attieh, Tya Youssef, Mahmoud Othman, Frederic Harb, Sami Azar, Hilda E. Ghadieh JGH Open.2025;[Epub] CrossRef
Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis Mei-jun Wang, Yu-nuo Jiang, Pei-pei Li, Yuan-jie Wu Systematic Reviews.2025;[Epub] CrossRef
A network meta-analysis of the clinical efficacy of different dietary patterns in the treatment of adult metabolic dysfunction-associated steatotic liver diseases Diwen Yu, Peipei Yu, Wanting Huang, Pengwei Zhang, Li Li Clinical Nutrition Open Science.2025; 64: 357. CrossRef
Synergistic Impact of Sarcopenia and T2DM on Mortality in Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Qi Zhou, Peiyan Liu, Lixiang Li, Tengfei Yin, Hao Bai, Yanqing Li The FASEB Journal.2025;[Epub] CrossRef
Early-Life Nutritional Determinants of Pediatric MASLD Johanna K. DiStefano Nutrients.2025; 17(24): 3871. CrossRef
From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1329. CrossRef
The association of multiple metabolic disorders with the severity of fasting blood glucose and hepatic steatosis in a Chinese population with MAFLD: a cross-sectional study of over 3000 participants Xue Qu, Shanshan Jin, Yuqing Shi, Weisong Zhang, Delong Cong, Yangyang Liu Scientific Reports.2025;[Epub] CrossRef
Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide Husam Albarmawi, Firas Dabbous, Abdalla Aly, Alia Yousif, Samuel Huse, Maximilian Jara, Andres Quintero, Eric Lawitz Current Medical Research and Opinion.2025; 41(11): 2089. CrossRef
Cross-sectional and longitudinal associations between fatty liver index and kidney function using updated MASLD and CKD–EPI 2021 definitions: a population-based study with region-specific cutoffs Sina Bazmi, Mohammadreza Fardaei, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Reza Malekzadeh, Nasrollah Ghahramani, Mojtaba Farjam European Journal of Medical Research.2025;[Epub] CrossRef
The Impact of the Mediterranean Diet, Physical Activity, and Nutrition Education on Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Review Melvin Bernardino, Claudio Tiribelli, Natalia Rosso Nutrients.2025; 18(1): 28. CrossRef
Machine learning-based model for predicting metabolic dysfunction-associated steatotic liver disease using non-invasive parameters in young adults Kyungchul Song, Yu-Jin Kwon, Eunju Lee, Young Hoon Youn, Su Jung Baik, Hye Sun Lee, Hyun Wook Chae Frontiers in Endocrinology.2025;[Epub] CrossRef
Soft drink consumption and liver fibrosis in type 2 diabetes Arianna Ferro, Martina Bollati, Gian Paolo Caviglia, Angelo Armandi, Stefania Bellini, Selene Limoncelli, Giulio Mengozzi, Federica Barutta, Fabio Broglio, Guglielmo Beccuti, Elisabetta Bugianesi, Marilena Durazzo, Gabriella Gruden Frontiers in Nutrition.2025;[Epub] CrossRef
Artificial intelligence applications for managing metabolic dysfunction-associated steatotic liver disease: Current status and future prospects Jian-Jun Lou, Jing Zeng World Journal of Gastroenterology.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of heart failure: a nationwide cohort study Chan Kyeol Kim, Sangyong Jo, Kyupin Ha, Bongjo Kim, Hyeon Ji Kim, Sang Yi Moon, Byoung-Gwon Kim, Kyungil Park, Jong Sung Park, Young Rak Cho, Tae-Ho Park, Kyunghee Lim, Minkook Son Heart.2025; : heartjnl-2025-327102. CrossRef
Association between vitamin D and metabolic-associated steatotic liver disease in type 2 diabetes mellitus patients: a systematic review and meta-analysis Bruno Basil, Winifred Adiri, Ejike Lawrence Ugwu, Ngozi Ijeoma Okoro Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Association between atherosclerosis-related indicators and fatty liver: a population-based observational study Xiaoping Liu, Ping Yuan, Ying Huang European Journal of Medical Research.2025;[Epub] CrossRef
Associations Between Systemic Inflammatory Markers, Metabolic Dysfunction, and Liver Fibrosis Scores in Patients with MASLD Ragaey Ahmad Eid, Ahmed Moheyeldien Hamed, Sara O. Elgendy, Khalid M. Orayj, Ahmed R. N. Ibrahim, Ahmed M. Abdel Hamied, Engy A. Wahsh, Maha Youssif, Hoda Rabea, Yasmin M. Madney, Dina Attia, Shaymaa Nafady Metabolites.2025; 16(1): 25. CrossRef
Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, Javeed Mohammad, Mamatha Reddy Dundigalla, Pavan Kumar Madala, Sanyasirao KSSVV, Althaf Shaik World Journal of Hepatology.2025;[Epub] CrossRef
Interplay between intestinal permeability and metabolic dysfunction-associated steatotic liver disease: Could there be a role for extra virgin olive oil consumption? Lydia Giannitrapani, Marinella Ferraro, Aurelio Seidita, Anna Licata, Maurizio Soresi World Journal of Hepatology.2025;[Epub] CrossRef
Does Continuous Positive Airway Pressure Improve Liver Outcomes in MASLD with Obstructive Sleep Apnea? A Systematic Review Theja V. Channapragada, Clinton R. Brenner, Keven Guruswamy, Rewanth Katamreddy, Alwyn T. Pandian, Vyshnavi Pendala, Jaydon J. Sam, Jonathan G. Stine, Michael J. Brenner, Vinciya Pandian Journal of Clinical Medicine.2025; 15(1): 225. CrossRef
Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction Chae-Been Kim, Jinwoo Sung, Dohyun Ahn, Eun-Ah Jo, Kyung-Wan Baek, Hae-Ri Heo, Ju-Hwan Oh, Fengrui Zhang, Hyoung-Su Park, Hong-Soo Kim, Jung-Jun Park Nutrients.2025; 18(1): 83. CrossRef
SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh Endocrinology and Metabolism.2025; 40(6): 851. CrossRef
Impact of liraglutide and dapagliflozin on steatosis, fibrosis, aminotransferases, and lipid profile in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: results of a 6-month randomized study V.V. Cherniavskyi, A.I. Akimov, V.V. Tishchenko, L.M. Parunian GASTROENTEROLOGY.2025; 59(4): 269. CrossRef
Circulating histones as potential biomarkers of MASLD-MASH-HCC progression Desislava K. Tsoneva, Diana Buzova, Salvatore Daniele Bianco, Maria Rita Braghini, Giulia Andolina, Antonio Liguori, Francesca D’ Ambrosio, Andrea Urbani, Antonio Gasbarrini, Maurizio Pompili, Anna Alisi, Jan Cerveny, Tommaso Mazza, Manlio Vinciguerra, Lu Epigenomics.2025; 17(18): 1435. CrossRef
Modelos Animais de MASLD/NAFLD: uma revisão narrativa do estado atual e perspectivas futuras Gabriel dos Santos, Fabio de Castro Machado, Ana Beatriz Serrato Carmo, Alvaro Ivanski Sabedotti, Laura Moscardi Milléo, Lorenzo Cultz, Mateus Baptista Pizyblski, Leonardo Henrique de Figueiredo Lima, Mário Cláudio Soares Sturzeneker Cuadernos de Educación y Desarrollo.2025; 17(12): e10446. CrossRef
THE EFFECT OF S-ADENOSYLMETHIONINE ON LIPID PROFILE PARAMETERS IN PATIENTS WITH MULTIPLE MYELOMA AND CONCOMITANT METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE DURING CHEMOTHERAPY Y. Stadnik, G. Maslova Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії.2025; 25(4): 76. CrossRef
Serum Biomarkers for Hepatocellular Carcinoma: A Comparative Review of Traditional and Emerging Markers Min Kyung Park Journal of Digestive Cancer Research.2025; 13(3): 242. CrossRef
Risk Factors for Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction–Associated Steatotic Liver Disease in Brazzaville Farel Elilie Mawa Ongoth, Rudel Godrèche Kondo, Philestine Clausina Mikolélé Ahoui Apendi, Nestor Ghislain Andzouana Mbamognoua, Raïssa Laure Mayanda Ohouana, Aymande Okoumou-Moko, Ornella Marline Yvonne Dinghat, Joël Rudy Ekoundzola, Sévérin Nkoua Eloi, Open Journal of Endocrine and Metabolic Diseases.2025; 15(08): 142. CrossRef
Kidney function mediates the association of per- and poly-fluoroalkyl substances (PFAS) and heavy metals with hepatic fibrosis risk Zhengqi Wei, Jincheng Liu, Na Wang, Keke Wei Environmental Research.2024; 263: 120092. CrossRef
Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis Fahad Lakhdhir, Agha Syed Muhammad, Ahmed Nasir Qureshi, Imran A Shaikh, Imran Joher, Jawaria Majeed, Javaria Khan Cureus.2024;[Epub] CrossRef
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2024; 30(4): 982. CrossRef
Understanding the epidemiology of metabolic dysfunction-associated steatotic liver disease is essential for its management: need for attention to accurate diagnostic coding and classification Han Ah Lee The Korean Journal of Internal Medicine.2024; 39(6): 869. CrossRef
AI in Hepatology: Revolutionizing the Diagnosis and Management of Liver Disease Sheza Malik, Rishi Das, Thanita Thongtan, Kathryn Thompson, Nader Dbouk Journal of Clinical Medicine.2024; 13(24): 7833. CrossRef
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.
Citations
Citations to this article as recorded by
Association between goiter and type 2 diabetes in a Chinese population: a cross-sectional study using CHNS data Jiajia Song, Xiaofang Han, Kemei Liu, Fei Zhai, Dechao Yin, Xiaohuan Zhu, Ting Hu Frontiers in Endocrinology.2026;[Epub] CrossRef
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari, Journal of Clinical Medicine.2025; 14(2): 428. CrossRef
Exploring the Mechanism of Action of GLP-1RAs in the Treatment of Non-Alcoholic Fatty Liver Disease Combined with Diabetes Based on Network Pharmacology 高林 齐 Medical Diagnosis.2025; 15(02): 200. CrossRef
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease Roxana Liana Lucaciu, Sorina Cezara Coste, Adriana Corina Hangan, Mihaela Iancu, Olga Hilda Orășan, Angela Cozma, Sidonia Gog Bogdan, Lucia Maria Procopciuc International Journal of Molecular Sciences.2025; 26(12): 5717. CrossRef
High sensitivity C-reactive protein may be a significant predictor of non-alcoholic fatty liver disease in non-obese adults: A four-year retrospective study Changxi Chen, Jiande Gong, Mengting Li, Shiyu Pan, Guitao Xia, Yuemei Xu, Hongliang Li, Qi Lin Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(12): 104224. CrossRef
MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk Alaa M. Mostafa, Ziyan Pan, Ming-Lung Yu, Necati Örmeci, Yasser Fouad, Mohammed Eslam Hepatic Medicine: Evidence and Research.2025; Volume 17: 75. CrossRef
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng Alimentary Pharmacology & Therapeutics.2024; 59(7): 802. CrossRef
Current status and future trends of the global burden of MASLD Lei Miao, Giovanni Targher, Christopher D. Byrne, Ying-Ying Cao, Ming-Hua Zheng Trends in Endocrinology & Metabolism.2024; 35(8): 697. CrossRef
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye, Bihui Zhong Obesity Reviews.2024;[Epub] CrossRef
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research E. V. Biryukova Meditsinskiy sovet = Medical Council.2024; (6): 72. CrossRef
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic Current Issues in Molecular Biology.2024; 46(7): 6300. CrossRef
AI‐based digital pathology provides newer insights into lifestyle intervention‐induced fibrosis regression in MASLD: An exploratory study Hai‐Yang Yuan, Xiao‐Fei Tong, Ya‐Yun Ren, Yang‐Yang Li, Xin‐Lei Wang, Li‐Li Chen, Sui‐Dan Chen, Xiao‐Zhi Jin, Xiao‐Dong Wang, Giovanni Targher, Christopher D. Byrne, Lai Wei, Vincent W.‐S Wong, Dean Tai, Arun J. Sanyal, Hong You, Ming‐Hua Zheng Liver International.2024; 44(10): 2572. CrossRef
Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury Hewei Wei, Ting Zhao, Xinglong Liu, Qiteng Ding, Junran Yang, Xiaoyu Bi, Zhiqiang Cheng, Chuanbo Ding, Wencong Liu Molecules.2024; 29(15): 3537. CrossRef
Protective Effects of Plum on Liver and Gut Injury in Metabolic Dysfunction-Associated Fatty Liver Disease Ji-Su Kim, Sun-Mee Hong, Do-Kyun Kim, Young-Eun Cho Nutrients.2024; 16(21): 3760. CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng Cardiology Plus.2024; 9(4): 275. CrossRef
Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection Tzu-I Chen, Fu-Jen Lee, Wan-Lun Hsu, Yong-Chen Chen, Mingchih Chen Cancers.2023; 15(4): 1148. CrossRef
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different? Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome David S. H. Bell, Terri Jerkins Diabetes, Obesity and Metabolism.2023; 25(11): 3093. CrossRef
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha Cureus.2023;[Epub] CrossRef
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD) Iryna Kostitska, Nadia Protas, Liliia Petrovska Diabetes Obesity Metabolic Syndrome.2023; (5): 8. CrossRef
Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives Lei Miao, Giovanni Targher, Christopher D. Byrne, Luca Valenti, Xiaolong Qi, Ming‐Hua Zheng Portal Hypertension & Cirrhosis.2022; 1(1): 57. CrossRef
The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy Bo Yuan, Jichun Ma, Jing Wang, Jinyong Hao Frontiers in Endocrinology.2022;[Epub] CrossRef
First
Prev
